Proti společnosti GoDaddy (GDDY) byla podána hromadná žaloba kvůli údajnému zkreslování informací o strategii získávání zákazníků; akcie 25. února 2026 po zveřejnění zpomalení růstu objednávek klesly o 14,28 %.
NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against GoDaddy Inc. (NYSE:GDDY) and certain of the company’s senior executives for securities fraud after its significant stock drop resulting from potential violations of the federal securities laws.
If you invested in GoDaddy, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/godaddy-class-action-lawsuit.
Key Details of the GoDaddy ($GDDY) Class Action:
Lead Plaintiff Deadline: October 26, 2026Alleged Misconduct: Securities fraud alleging GoDaddy misrepresented its customer acquisition and go-to-market strategyStock Drop: February 25, 2026 – 14.28% Stock DropCourt: U.S. District Court for the Southern District of New YorkAction: Contact BFA Law to discuss your rights
Investors have until October 26, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in GoDaddy common stock. The class action is pending in the U.S. District Court for the Southern District of New York. It is captioned Johnson v. GoDaddy Inc. et al., No. 26-cv-7144.
Why is GoDaddy Being Sued for Securities Fraud?
GoDaddy is an internet domain registry, domain registrar, and web hosting company that primarily serves small businesses, entrepreneurs, and other customers seeking tools to build and manage an online presence.
According to the complaint, GoDaddy repeatedly told investors that its strategy was focused on attracting “high-intent” customers who were likely to buy more products and spend more money, while allegedly failing to disclose that it had introduced a heavily discounted $4.99 promotional offer for one-year dotcom domain contracts.
As alleged, the promotion contradicted GoDaddy’s public messaging that it had turned off front-end discounting and was not pursuing customer growth for its own sake. The complaint alleges that the promotion encouraged shorter-term, lower-value contracts, reduced upfront bookings, and rendered GoDaddy’s statements about demand, average order size, and bookings growth misleading.
Why did GoDaddy’s Stock Drop?
On February 24, 2026, after the market closed, GoDaddy disclosed that total bookings growth sharply decelerated to 5% in Q4 2025, down from 9% the prior quarter and below analyst expectations. GoDaddy also disclosed that it had expanded its go-to-market approach and introduced a promotional price for dotcom domains with a one-year term. The Company stated that the offer increased new customer volume but that the shift in term mix and promotional pricing reduced upfront bookings and near-term revenue.
On this news, GoDaddy’s stock dropped $13.18 per share, or 14.28%, from a closing price of $92.30 per share on February 24, 2026, to $79.12 per share on February 25, 2026.
Click here for more information: https://www.bfalaw.com/cases/godaddy-class-action-lawsuit.
What Can You Do?
If you invested in GoDaddy, you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Or contact:
Adam McCall
[email protected]
212.789.3619
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “SuperLawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
BFA’s notable successes include a recovery of over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
For more information about BFA and its attorneys, please visit https://www.bfalaw.com.
Proti společnosti Doximity (DOCS) byla podána hromadná žaloba kvůli údajnému nadhodnocení přínosu zpravodajského feedu k růstu tržeb. Akcie 14. května 2026 klesly o 23 %.
New York, New York--(Newsfile Corp. - October 19, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Doximity, Inc. ("Doximity" or the "Company") (NYSE: DOCS) on behalf of investors that purchased or otherwise acquired Doximity common stock between August 8, 2024 and May 13, 2026 (the "Class Period").
CLICK HERE TO JOIN THE CASE
If you are an investor in Doximity and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 16, 2026 for an opportunity to be lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
The complaint alleges that throughout the Class Period, Doximity claimed that the Company's Newsfeed was its "biggest revenue driver." The truth - that Doximity overstated the impact that its Newsfeed would have on its revenue growth, and that the Company was losing market share to its competitors with more favorable pricing and engagement models - was allegedly revealed through a series of disclosures ending on May 13, 2026 when Doximity announced that it missed its already-reduced revenue guidance for the fiscal year ending March 31, 2026. Following this news, the price of Doximity stock declined by $5.38 per share, or 23%, on May 14, 2026.
CLICK HERE TO LEARN MORE
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America-the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act-$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this Notice, your rights, or your interests, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
EU obvinila KKR z poskytnutí zavádějících informací v rámci schvalovacího řízení o akvizici pevné sítě Telecom Italia za 22 miliard eur. KKR může být uložena pokuta až do výše 1 % jejího celosvětového ročního obratu.
KKR (KKR.N) was hit with EU antitrust charges on Monday, alleging it misled regulators during their review of its €22 billion acquisition of Telecom Italia's (TLIT.MI) fixed-line network two years ago, exposing the US buyout group to a potentially hefty fine.
The decision by the European Commission, the EU competition enforcer, followed a year-long investigation. It approved the deal in 2024, but opened an investigation a year later following complaints by other operators.
The rivals argued that prices for them to access TIM's fixed broadband network had been unilaterally increased after the deal, even though KKR had convinced the Commission that it would not have the power to deteriorate conditions for wholesale access.
The EU antitrust watchdog said it sent a charge sheet, known as a statement of objections, to KKR for providing incorrect or misleading information about whether it would keep its existing long-term access agreements under the same terms unless mutually agreed otherwise with the third-party operators.
The Commission had cleared the Telecom Italia deal due in part to the long-term agreements between FiberCop, which is Telecom Italia's last-mile grid unit, and telecoms companies Fastweb and Iliad.
Companies found guilty of misleading regulators during reviews of their deals risk fines of up to 1% of their aggregate annual worldwide turnover.
The Commission has in recent years handed out hefty fines for such violations.
SteelPeak Wealth LLC purchased a new position in shares of Reddit Inc. (NYSE:RDDT – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 13,201 shares of the company’s stock, valued at approximately $1,880,000.
Other institutional investors also recently bought and sold shares of the company. Wellington Management Group LLP grew its position in shares of Reddit by 21.8% in the 2nd quarter. Wellington Management Group LLP now owns 1,564,535 shares of the company’s stock valued at $271,572,000 after buying an additional 280,030 shares during the last quarter. Moore Capital Management LP raised its stake in Reddit by 611.4% during the 2nd quarter. Moore Capital Management LP now owns 12,577 shares of the company’s stock worth $2,183,000 after acquiring an additional 10,809 shares in the last quarter. State Street Corp lifted its position in Reddit by 8.7% in the second quarter. State Street Corp now owns 2,979,587 shares of the company’s stock valued at $517,197,000 after acquiring an additional 237,523 shares during the last quarter. Light Street Capital Management LLC purchased a new stake in Reddit in the second quarter valued at $31,678,000. Finally, PensionDanmark Pensionsforsikringsaktieselskab boosted its stake in Reddit by 102.3% in the second quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 19,120 shares of the company’s stock valued at $3,319,000 after acquiring an additional 9,670 shares in the last quarter.
Reddit News Summary Here are the key news stories impacting Reddit this week:
Positive Sentiment: CNBC’s Jim Cramer recommended buying Reddit, describing the shares as “inexpensive.” The endorsement could improve retail-investor sentiment and draw attention to Reddit’s valuation. Jim Cramer recommends Reddit Neutral Sentiment: Reddit will report third-quarter results on Thursday, October 29. Investors are likely to focus on advertising growth, user trends and management’s outlook following the company’s previous quarterly revenue increase of 61% year over year. Reddit third-quarter earnings announcement Neutral Sentiment: Goldman Sachs maintained its Hold rating on RDDT, indicating that the firm does not see a sufficiently compelling risk-reward profile at current levels. Goldman Sachs maintains Hold rating Negative Sentiment: CEO Steve Huffman sold 17,308 shares for approximately $2.74 million, reducing his direct holdings by 4.89%. COO Jennifer Wong separately sold 60,000 shares for about $9.03 million, reducing her position by 5.60%. Both transactions were made under pre-arranged Rule 10b5-1 plans, which lessens—but does not eliminate—the negative signaling effect of insider selling. Reddit insider sales Insider Activity In other news, Director Robert Sauerberg sold 5,128 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $159.92, for a total transaction of $820,069.76. Following the completion of the sale, the director owned 27,087 shares in the company, valued at approximately $4,331,753.04. This represents a 15.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jennifer Wong sold 60,000 shares of the stock in a transaction dated Wednesday, October 14th. The stock was sold at an average price of $150.55, for a total transaction of $9,033,000.00. Following the sale, the chief operating officer owned 1,012,226 shares of the company’s stock, valued at $152,390,624.30. This trade represents a 5.60% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 306,052 shares of company stock valued at $49,754,523. Insiders own 28.48% of the company’s stock. Analyst Upgrades and Downgrades RDDT has been the topic of several research reports. BNP Paribas Exane initiated coverage on Reddit in a report on Friday, September 18th. They set a “neutral” rating and a $180.00 price objective on the stock. Wells Fargo & Company cut their target price on Reddit from $187.00 to $142.00 and set an “equal weight” rating on the stock in a research report on Friday, July 31st. Guggenheim reissued a “buy” rating on shares of Reddit in a report on Wednesday, September 16th. Zacks Research cut Reddit from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 25th. Finally, UBS Group reissued a “buy” rating on shares of Reddit in a research report on Friday, July 31st. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $219.29.
Read Our Latest Analysis on Reddit
Reddit Price Performance Shares of NYSE:RDDT opened at $155.97 on Monday. The stock has a market cap of $30.01 billion, a P/E ratio of 36.27, a P/E/G ratio of 0.72 and a beta of 2.05. The firm has a fifty day moving average price of $154.22 and a 200 day moving average price of $161.65. Reddit Inc. has a 1-year low of $119.27 and a 1-year high of $263.50.
Reddit (NYSE:RDDT – Get Free Report) last issued its quarterly earnings data on Thursday, July 30th. The company reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.30. The company had revenue of $804.91 million for the quarter, compared to the consensus estimate of $731.00 million. Reddit had a net margin of 31.35% and a return on equity of 29.02%. Reddit’s revenue for the quarter was up 61.0% on a year-over-year basis. During the same period last year, the firm posted $0.45 EPS. Sell-side analysts expect that Reddit Inc. will post 5.27 EPS for the current fiscal year.
About Reddit (Free Report)
Reddit, Inc operates a global online platform where users participate in communities organized around shared interests, topics and activities. Members can submit text posts, links, images and videos, as well as comment on and vote on content. The platform includes thousands of communities, commonly known as subreddits, covering subjects such as news, entertainment, technology, sports, finance and lifestyle.
Reddit generates revenue primarily through digital advertising, offering advertisers access to audiences based on community interests and user engagement.
Featured Stories Five stocks we like better than Reddit These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom Want to see what other hedge funds are holding RDDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Reddit Inc. (NYSE:RDDT – Free Report).
Receive News & Ratings for Reddit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reddit and related companies with MarketBeat.com's FREE daily email newsletter.
Christopher Bohrson, zasvěcená osoba ve společnosti Cohu, prodal ve čtvrtek 15. října v rámci předem sjednaného plánu 10b5-1 1 000 akcií Cohu za průměrnou cenu 55,31 USD za akcii, celkem za 55 310 USD.
Cohu, Inc. (NASDAQ:COHU – Get Free Report) insider Christopher Bohrson sold 1,000 shares of the firm’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $55.31, for a total transaction of $55,310.00. Following the transaction, the insider directly owned 157,702 shares in the company, valued at $8,722,497.62. The trade was a 0.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Christopher Bohrson also recently made the following trade(s):
On Wednesday, August 19th, Christopher Bohrson sold 10,000 shares of Cohu stock. The shares were sold at an average price of $55.82, for a total transaction of $558,200.00. On Monday, August 17th, Christopher Bohrson sold 1,000 shares of Cohu stock. The shares were sold at an average price of $61.90, for a total transaction of $61,900.00. Cohu Price Performance Shares of NASDAQ:COHU opened at $50.81 on Monday. The company has a 50-day simple moving average of $57.87 and a 200-day simple moving average of $53.21. Cohu, Inc. has a one year low of $21.10 and a one year high of $75.72. The company has a debt-to-equity ratio of 0.37, a quick ratio of 4.72 and a current ratio of 5.74. The stock has a market capitalization of $2.41 billion, a price-to-earnings ratio of -61.22 and a beta of 1.51.
Cohu (NASDAQ:COHU – Get Free Report) last announced its earnings results on Thursday, July 30th. The semiconductor company reported $0.26 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.12. Cohu had a negative net margin of 7.43% and a negative return on equity of 1.96%. The business had revenue of $149.00 million during the quarter, compared to the consensus estimate of $144.20 million. During the same quarter in the prior year, the firm earned $0.02 earnings per share. The business’s quarterly revenue was up 38.3% compared to the same quarter last year. On average, analysts predict that Cohu, Inc. will post 0.47 EPS for the current year. Analyst Ratings Changes A number of analysts have weighed in on the company. Jefferies Financial Group reaffirmed a “buy” rating and set a $74.00 price objective on shares of Cohu in a research report on Friday, July 31st. Needham & Company LLC lifted their target price on Cohu from $54.00 to $65.00 and gave the company a “buy” rating in a research note on Friday, July 31st. Stifel Nicolaus boosted their target price on Cohu from $50.00 to $70.00 and gave the company a “buy” rating in a report on Friday, July 10th. Robert W. Baird initiated coverage on Cohu in a report on Wednesday, July 8th. They issued an “outperform” rating and a $65.00 target price on the stock. Finally, Zacks Research cut Cohu from a “strong-buy” rating to a “hold” rating in a research note on Friday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Cohu currently has a consensus rating of “Moderate Buy” and an average target price of $68.75.
Get Our Latest Report on Cohu
Institutional Inflows and Outflows A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vontobel Holding Ltd. increased its holdings in Cohu by 23.3% in the third quarter. Vontobel Holding Ltd. now owns 14,380 shares of the semiconductor company’s stock valued at $980,000 after buying an additional 2,722 shares in the last quarter. Assenagon Asset Management S.A. lifted its position in shares of Cohu by 6,968.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 340,767 shares of the semiconductor company’s stock valued at $23,220,000 after acquiring an additional 335,946 shares during the period. Fortitude Family Office LLC boosted its stake in shares of Cohu by 147.9% during the 3rd quarter. Fortitude Family Office LLC now owns 528 shares of the semiconductor company’s stock worth $36,000 after acquiring an additional 315 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Cohu by 8.3% during the 3rd quarter. GAMMA Investing LLC now owns 8,366 shares of the semiconductor company’s stock worth $570,000 after acquiring an additional 641 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its stake in shares of Cohu by 148.7% during the 3rd quarter. Farther Finance Advisors LLC now owns 2,972 shares of the semiconductor company’s stock worth $203,000 after acquiring an additional 1,777 shares in the last quarter. Institutional investors and hedge funds own 94.67% of the company’s stock.
About Cohu (Get Free Report)
Cohu, Inc provides semiconductor test and inspection equipment, consumables and related services used by semiconductor manufacturers and outsourced semiconductor assembly and test providers. Its solutions support the testing and handling of integrated circuits throughout the manufacturing process, helping customers evaluate device performance, reliability and quality.
The company’s product portfolio includes semiconductor test handlers, inspection and metrology systems, thermal-management equipment, test contactors and other interface products.
Read More Five stocks we like better than Cohu These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom
Receive News & Ratings for Cohu Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cohu and related companies with MarketBeat.com's FREE daily email newsletter.
Insider Stash Ptak prodal celkem 2 000 akcií společnosti Signet Jewelers (SIG) za 240 000 USD v rámci předem sjednaného obchodního plánu podle pravidla 10b5-1.
Signet Jewelers Limited (NYSE:SIG – Get Free Report) insider Stash Ptak sold 1,595 shares of the business’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $120.00, for a total value of $191,400.00. Following the completion of the transaction, the insider directly owned 20,833 shares of the company’s stock, valued at approximately $2,499,960. This trade represents a 7.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Stash Ptak also recently made the following trade(s):
On Friday, October 16th, Stash Ptak sold 405 shares of Signet Jewelers stock. The shares were sold at an average price of $120.00, for a total value of $48,600.00. Signet Jewelers Stock Down 0.3% SIG opened at $118.18 on Monday. The firm has a market cap of $4.53 billion, a P/E ratio of 13.61, a PEG ratio of 0.65 and a beta of 1.10. The business’s fifty day simple moving average is $95.58 and its 200 day simple moving average is $90.36. Signet Jewelers Limited has a 52 week low of $71.61 and a 52 week high of $122.64.
Signet Jewelers (NYSE:SIG – Get Free Report) last announced its earnings results on Wednesday, September 9th. The company reported $2.19 earnings per share for the quarter, beating the consensus estimate of $1.69 by $0.50. The firm had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.53 billion. Signet Jewelers had a net margin of 5.19% and a return on equity of 23.28%. The firm’s revenue for the quarter was down .5% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.61 EPS. Signet Jewelers has set its FY 2027 guidance at 10.450-12.150 EPS. As a group, equities analysts expect that Signet Jewelers Limited will post 11.70 EPS for the current fiscal year. Signet Jewelers Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 20th. Stockholders of record on Friday, October 23rd will be given a $0.35 dividend. This represents a $1.40 dividend on an annualized basis and a dividend yield of 1.2%. The ex-dividend date of this dividend is Friday, October 23rd. Signet Jewelers’s payout ratio is currently 16.13%.
Institutional Inflows and Outflows A number of institutional investors and hedge funds have recently modified their holdings of SIG. Ameritas Advisory Services LLC acquired a new stake in shares of Signet Jewelers in the second quarter worth approximately $32,000. Parallel Advisors LLC grew its holdings in Signet Jewelers by 101.0% in the first quarter. Parallel Advisors LLC now owns 394 shares of the company’s stock valued at $33,000 after purchasing an additional 198 shares during the period. Farther Finance Advisors LLC grew its holdings in Signet Jewelers by 46.2% in the third quarter. Farther Finance Advisors LLC now owns 842 shares of the company’s stock valued at $86,000 after purchasing an additional 266 shares during the period. Central Pacific Bank Trust Division acquired a new position in Signet Jewelers during the second quarter worth approximately $139,000. Finally, Leonteq Securities AG increased its position in Signet Jewelers by 747.8% during the first quarter. Leonteq Securities AG now owns 1,721 shares of the company’s stock worth $146,000 after purchasing an additional 1,518 shares during the last quarter.
More Signet Jewelers News Here are the key news stories impacting Signet Jewelers this week:
Positive Sentiment: Signet is reportedly considering joining a bidder group with Richemont to acquire a small stake in De Beers. Such a move could strengthen Signet’s access to the diamond supply chain and provide strategic influence during a difficult period for the diamond industry. Richemont and Signet reportedly interested in acquiring De Beers Positive Sentiment: Analysts’ value-focused coverage highlights Signet’s relatively attractive valuation, including a trailing price-to-earnings ratio around 13.6 and a PEG ratio near 0.6. The company also recently exceeded quarterly EPS expectations, supporting the recent increase in its shares. Are Investors Undervaluing Signet Jewelers? Neutral Sentiment: Signet has reached a fresh 52-week high following a 9.5% prior-session surge on above-average volume, indicating strong momentum. Nonetheless, the analysis notes that recent earnings-estimate revisions do not clearly support continued strength. Signet surges 9.5 percent Negative Sentiment: Insider Stash Ptak sold a combined 2,000 Signet shares for approximately $240,000. The transactions were conducted under a pre-arranged Rule 10b5-1 plan, reducing their negative signaling, but the sales could still weigh modestly on sentiment after the stock’s strong run. Signet insider transaction filing Analysts Set New Price Targets A number of analysts recently issued reports on the stock. Stephens restated an “overweight” rating and set a $130.00 target price on shares of Signet Jewelers in a research report on Tuesday, September 8th. Citigroup lifted their target price on shares of Signet Jewelers from $120.00 to $140.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Bank of America boosted their price target on Signet Jewelers from $102.00 to $115.00 and gave the company a “neutral” rating in a report on Thursday, September 10th. Raymond James Financial boosted their price target on Signet Jewelers from $100.00 to $120.00 and gave the company an “outperform” rating in a report on Thursday, September 10th. Finally, Jefferies Financial Group increased their price target on Signet Jewelers from $150.00 to $175.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $125.56.
Read Our Latest Research Report on Signet Jewelers
(Get Free Report)
Signet Jewelers Limited (NYSE:SIG) is a specialty jewelry retailer that operates through a portfolio of branded stores and online platforms. Its businesses sell diamond, bridal and fashion jewelry, watches, gifts and related accessories, while also providing services such as jewelry repair, customization and financing.
The company’s principal retail brands include Kay Jewelers, Zales, Jared, Diamonds Direct, James Allen, Peoples and Banter by Piercing Pagoda. These brands serve customers through a combination of mall-based and off-mall stores, standalone locations, digital commerce platforms and specialty formats, with offerings positioned across a range of price points and shopping occasions.
Signet primarily serves customers in the United States, Canada and the United Kingdom.
Featured Articles Five stocks we like better than Signet Jewelers These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom Receive News & Ratings for Signet Jewelers Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Signet Jewelers and related companies with MarketBeat.com's FREE daily email newsletter.
Nebius Group N.V. (NASDAQ:NBIS – Get Free Report) Director Arne Grimme bought 148 shares of the firm’s stock in a transaction that occurred on Thursday, October 15th. The stock was bought at an average price of $169.99 per share, with a total value of $25,158.52. Following the transaction, the director directly owned 6,033 shares in the company, valued at $1,025,549.67. This represents a 2.51% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Nebius Group Price Performance Nebius Group stock opened at $165.47 on Monday. The stock has a market cap of $41.87 billion, a price-to-earnings ratio of -5,513.83 and a beta of 4.18. The company has a current ratio of 4.03, a quick ratio of 4.03 and a debt-to-equity ratio of 0.82. The company’s 50-day moving average price is $223.57 and its two-hundred day moving average price is $207.47. Nebius Group N.V. has a 52 week low of $73.52 and a 52 week high of $299.86.
Nebius Group (NASDAQ:NBIS – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.55. The company had revenue of $582.30 million for the quarter, compared to the consensus estimate of $567.91 million. Nebius Group had a net margin of 4.55% and a negative return on equity of 6.03%. Nebius Group’s revenue was up 454% on a year-over-year basis. During the same period in the previous year, the firm earned $2.38 EPS. On average, analysts expect that Nebius Group N.V. will post -3.00 EPS for the current fiscal year.
Institutional Investors Weigh In On Nebius Group A number of institutional investors and hedge funds have recently modified their holdings of NBIS. BlackRock Inc. boosted its stake in shares of Nebius Group by 16.0% during the 2nd quarter. BlackRock Inc. now owns 11,531,270 shares of the company’s stock worth $3,184,591,000 after acquiring an additional 1,593,684 shares in the last quarter. Situational Awareness LP acquired a new stake in shares of Nebius Group during the second quarter worth $1,232,895,000. State Street Corp raised its position in shares of Nebius Group by 16.2% during the second quarter. State Street Corp now owns 4,069,875 shares of the company’s stock worth $1,123,977,000 after purchasing an additional 568,415 shares during the period. Jennison Associates LLC raised its position in shares of Nebius Group by 134.3% during the second quarter. Jennison Associates LLC now owns 3,983,899 shares of the company’s stock worth $1,100,233,000 after purchasing an additional 2,283,676 shares during the period. Finally, Accel Leaders 4 Associates L.P. acquired a new stake in shares of Nebius Group during the second quarter worth $1,012,097,322. Institutional investors and hedge funds own 21.90% of the company’s stock. Analyst Ratings Changes NBIS has been the topic of several research reports. Piper Sandler assumed coverage on shares of Nebius Group in a research report on Monday, August 3rd. They issued a “neutral” rating and a $224.00 price target on the stock. Wall Street Zen raised shares of Nebius Group from a “strong sell” rating to a “sell” rating in a report on Sunday, August 16th. Robert W. Baird raised their price objective on shares of Nebius Group from $250.00 to $340.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. Citigroup lifted their price objective on shares of Nebius Group from $278.00 to $324.00 and gave the stock a “buy” rating in a research note on Friday, August 14th. Finally, William Blair initiated coverage on shares of Nebius Group in a report on Wednesday, September 30th. They issued an “outperform” rating on the stock. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $245.69.
View Our Latest Report on NBIS
Key Headlines Impacting Nebius Group Here are the key news stories impacting Nebius Group this week:
Positive Sentiment: Director bought shares: Director Arne Grimme purchased 148 shares at an average price of $169.99, increasing his direct ownership by 2.51%. The transaction was made under a pre-arranged Rule 10b5-1 plan, providing a modest insider-confidence signal, although the purchase was relatively small. SEC insider purchase filing Positive Sentiment: Revenue growth remains a strength: A comparison with Innodata found that Nebius generated more revenue in five of the eight reported quarters and posted larger quarter-over-quarter gains. This supports the growth case for its AI infrastructure business. Innodata versus Nebius revenue comparison Neutral Sentiment: Analysts and commentators remain divided: some identify Nebius as a potential dip-buying opportunity because of strong AI demand, while others have downgraded the stock after the selloff. Reported customer capacity requests reportedly extend into 2028, and a $775 million secured facility could help fund expansion, but execution and financing remain important risks. AI stocks and potential buying opportunities Negative Sentiment: Debt and funding fears pressured the shares: CoreWeave’s debt-related concerns spread across the AI-cloud sector, raising questions about how GPU providers can finance rapid expansion. Investors are increasingly worried that high capital requirements and falling compute prices could weaken returns. Nebius stock selloff and CoreWeave debt concerns Negative Sentiment: Industry outlook deteriorated: A Gartner warning that most “neocloud” companies may not survive independently triggered additional selling in Nebius and peers. The market’s Fear & Greed reading also moved sharply toward “Extreme Fear,” amplifying risk aversion. AI cloud stocks and Gartner neocloud warning Negative Sentiment: Broader technology weakness, inflation concerns and reports referencing insider selling added to the pressure. With Nebius trading well below its moving averages and carrying a highly volatile profile, investors appear to be prioritizing balance-sheet risk over its strong revenue growth. Nebius stock decline and insider selling report About Nebius Group (Get Free Report)
Nebius Group N.V. is a technology company focused on providing cloud infrastructure and services for artificial intelligence and machine learning applications. Through its Nebius AI division, the company offers access to high-performance computing, graphics processing units (GPUs), storage, networking, and related tools designed to help businesses and developers train, deploy, and operate AI models.
The company also operates or supports other technology businesses, including Toloka, an AI data and evaluation platform; TripleTen, an online education provider focused on technology careers; and Avride, a developer of autonomous driving and delivery technologies.
See Also Five stocks we like better than Nebius Group These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom
Receive News & Ratings for Nebius Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nebius Group and related companies with MarketBeat.com's FREE daily email newsletter.
Ředitelka Planet Labs PBC Kristen Robinson prodala 40 000 akcií za průměrnou cenu 14,14 USD za akcii, celkem za 565 600 USD, čímž snížila svůj podíl o 17,95 %.
Planet Labs PBC (NYSE:PL – Get Free Report) Director Kristen Robinson sold 40,000 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $14.14, for a total value of $565,600.00. Following the completion of the sale, the director directly owned 182,897 shares of the company’s stock, valued at approximately $2,586,163.58. This represents a 17.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Planet Labs PBC Stock Down 0.0% Shares of NYSE PL opened at $13.55 on Monday. Planet Labs PBC has a one year low of $10.52 and a one year high of $51.76. The company has a debt-to-equity ratio of 0.79, a current ratio of 2.84 and a quick ratio of 2.82. The firm’s 50 day simple moving average is $18.69 and its two-hundred day simple moving average is $27.95. The stock has a market capitalization of $4.93 billion, a P/E ratio of -12.32 and a beta of 2.17.
Planet Labs PBC (NYSE:PL – Get Free Report) last posted its quarterly earnings results on Thursday, September 3rd. The company reported $0.02 EPS for the quarter, topping the consensus estimate of ($0.02) by $0.04. The firm had revenue of $116.05 million for the quarter, compared to the consensus estimate of $104.53 million. Planet Labs PBC had a negative net margin of 95.13% and a negative return on equity of 93.11%. The business’s revenue was up 58.2% compared to the same quarter last year. During the same period last year, the firm posted ($0.07) earnings per share. As a group, analysts expect that Planet Labs PBC will post -0.63 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth Several research firms have recently commented on PL. Morgan Stanley set a $19.00 price objective on Planet Labs PBC in a report on Friday. Citizens Jmp reissued a “market perform” rating on shares of Planet Labs PBC in a research note on Friday, September 4th. Zacks Research upgraded Planet Labs PBC from a “strong sell” rating to a “hold” rating in a report on Thursday, July 2nd. New Street Research upgraded Planet Labs PBC from a “sell” rating to a “neutral” rating in a research report on Friday, September 4th. Finally, Citigroup lowered Planet Labs PBC from a “market perform” rating to a “hold” rating in a research report on Friday, September 4th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $30.33. View Our Latest Analysis on Planet Labs PBC
Institutional Investors Weigh In On Planet Labs PBC Large investors have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP raised its stake in Planet Labs PBC by 1.8% in the first quarter. Dimensional Fund Advisors LP now owns 4,013,187 shares of the company’s stock worth $112,167,000 after buying an additional 70,986 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its holdings in Planet Labs PBC by 80.4% in the first quarter. Arrowstreet Capital Limited Partnership now owns 1,932,381 shares of the company’s stock worth $54,010,000 after buying an additional 861,306 shares during the period. Tidal Investments LLC lifted its holdings in Planet Labs PBC by 5,339.2% in the second quarter. Tidal Investments LLC now owns 1,591,020 shares of the company’s stock worth $52,710,000 after buying an additional 1,561,769 shares during the period. Tema ETFs LLC lifted its holdings in Planet Labs PBC by 75,804.6% in the second quarter. Tema ETFs LLC now owns 1,590,960 shares of the company’s stock worth $52,709,000 after buying an additional 1,588,864 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Planet Labs PBC by 36.5% during the 1st quarter. Renaissance Technologies LLC now owns 1,021,180 shares of the company’s stock valued at $28,542,000 after acquiring an additional 273,300 shares in the last quarter. Institutional investors own 41.71% of the company’s stock.
(Get Free Report)
Planet Labs PBC is an Earth-imaging and geospatial data company that operates a constellation of satellites designed to provide frequent, high-resolution imagery of the planet. Its data is used to monitor changes in land, infrastructure, agriculture, forests, oceans and other environments.
The company’s products include PlanetScope, a satellite imagery service intended to provide frequent coverage of large areas; SkySat, which offers higher-resolution imagery and video capabilities; and other satellite and data products, including hyperspectral imaging initiatives.
See Also Five stocks we like better than Planet Labs PBC These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom
Receive News & Ratings for Planet Labs PBC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Planet Labs PBC and related companies with MarketBeat.com's FREE daily email newsletter.
SteelPeak Wealth LLC increased its holdings in Healthpeak Properties, Inc. (NYSE:DOC – Free Report) by 62.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 91,979 shares of the real estate investment trust’s stock after purchasing an additional 35,251 shares during the quarter. SteelPeak Wealth LLC’s holdings in Healthpeak Properties were worth $1,837,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new position in shares of Healthpeak Properties in the second quarter worth about $3,837,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of Healthpeak Properties by 20,832.8% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,217,474 shares of the real estate investment trust’s stock valued at $133,054,000 after acquiring an additional 6,187,772 shares in the last quarter. NewEdge Advisors LLC lifted its position in shares of Healthpeak Properties by 23.1% in the 2nd quarter. NewEdge Advisors LLC now owns 146,336 shares of the real estate investment trust’s stock valued at $3,132,000 after acquiring an additional 27,508 shares in the last quarter. Concurrent Investment Advisors LLC lifted its position in shares of Healthpeak Properties by 70.7% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 63,838 shares of the real estate investment trust’s stock valued at $1,366,000 after acquiring an additional 26,447 shares in the last quarter. Finally, Vontobel Holding Ltd. boosted its stake in Healthpeak Properties by 3,163.9% in the 2nd quarter. Vontobel Holding Ltd. now owns 804,137 shares of the real estate investment trust’s stock worth $17,209,000 after purchasing an additional 779,500 shares during the period. 93.57% of the stock is owned by institutional investors and hedge funds.
Healthpeak Properties Stock Down 0.1% Healthpeak Properties stock opened at $18.96 on Monday. The firm has a market cap of $13.07 billion, a PE ratio of 54.16, a P/E/G ratio of 2.35 and a beta of 1.01. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.02 and a current ratio of 3.02. The firm’s 50 day moving average price is $20.26 and its two-hundred day moving average price is $19.89. Healthpeak Properties, Inc. has a twelve month low of $15.70 and a twelve month high of $22.95.
Healthpeak Properties (NYSE:DOC – Get Free Report) last released its earnings results on Tuesday, August 4th. The real estate investment trust reported $0.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.03 by $0.05. Healthpeak Properties had a net margin of 8.24% and a return on equity of 2.79%. The company had revenue of $771.58 million during the quarter, compared to the consensus estimate of $725.64 million. During the same quarter in the prior year, the firm earned $0.46 EPS. The company’s revenue was up 11.1% compared to the same quarter last year. Healthpeak Properties has set its FY 2026 guidance at 1.730-1.770 EPS. On average, research analysts predict that Healthpeak Properties, Inc. will post 1.77 EPS for the current fiscal year. Healthpeak Properties Dividend Announcement The company also recently disclosed a monthly dividend, which will be paid on Wednesday, December 30th. Investors of record on Friday, December 18th will be issued a dividend of $0.1017 per share. This represents a $1.22 annualized dividend and a dividend yield of 6.4%. The ex-dividend date is Friday, December 18th. Healthpeak Properties’s dividend payout ratio (DPR) is currently 348.57%.
Analysts Set New Price Targets A number of analysts have recently issued reports on the company. Cantor Fitzgerald increased their target price on Healthpeak Properties from $20.00 to $23.00 and gave the company a “neutral” rating in a report on Thursday, August 6th. Wells Fargo & Company lifted their price target on Healthpeak Properties from $20.00 to $22.00 and gave the company an “equal weight” rating in a report on Wednesday, July 15th. Robert W. Baird upped their price target on Healthpeak Properties from $21.00 to $24.00 and gave the company an “outperform” rating in a research report on Thursday, August 13th. UBS Group reduced their price objective on Healthpeak Properties from $21.50 to $20.00 and set a “neutral” rating for the company in a research note on Tuesday, October 13th. Finally, Weiss Ratings lowered Healthpeak Properties from a “hold (c+)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. Four analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $21.80.
Get Our Latest Analysis on Healthpeak Properties
(Free Report)
Healthpeak Properties, Inc (NYSE:DOC) is a real estate investment trust that owns, operates and develops healthcare-related real estate in the United States. The company primarily serves healthcare providers, research organizations and senior-care operators through a portfolio of specialized properties.
Its main activities include the ownership and leasing of outpatient medical office buildings, life science facilities and senior housing properties. These assets support services such as physician practices, ambulatory care, medical research and senior living.
Further Reading Five stocks we like better than Healthpeak Properties These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom Want to see what other hedge funds are holding DOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Healthpeak Properties, Inc. (NYSE:DOC – Free Report).
Receive News & Ratings for Healthpeak Properties Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Healthpeak Properties and related companies with MarketBeat.com's FREE daily email newsletter.
Iren (IREN -11.19%) is the one artificial intelligence (AI) stock I would buy through the next bubble scare. I'm doing it right now, and if Iren stays at such a low price, I will intensify my buying. The company has several bullish catalysts, and certain "bearish" claims about Iren and the neocloud industry are actually quite bullish for Iren on closer inspection.
Image source: Getty Images.
Addressing recent concerns Almost all the bearish concerns people bring up about Iren are actually bullish. First, Gartner released research that projected 80% of neoclouds ceasing independent operations by 2030 while casting doubts about AI infrastructure spending.
IREN Iren$26.99-$3.40 (-11.19%)
NASDAQ · As of 4:00 PM ET 10/16/26
However, Iren remains one of the top neocloud providers and has a pristine balance sheet. If 80% of neocloud providers are out of business by 2030, Iren's capacity will become much more valuable due to supply constraints.
Second, CoreWeave's (CRWV -11.91%) corporate bonds reached yields of 15%, causing investors to worry about how expensive it would be for neoclouds to borrow money in the future. However, CoreWeave has an elevated rate because its balance sheet is under duress. CoreWeave has a current ratio of 0.46 and will need to refinance some of its debt. Iren has a much more favorable current ratio of 3.55.
Their balance sheets are in different leagues. If costs rise for neoclouds, it's yet another barrier that delays or shuts down competitors. That scenario would let Iren charge higher prices for its megawatts. Less supply also gives Iren more negotiating power, which can translate into higher prepayments that reduce dilution or make it unnecessary in the near future. Iren can also obtain low-APR capital through GPU financing and by using its constructed data centers as collateral.
The frustration of zero news is great for investors who can wait Iren hasn't offered investors much material since it reported fiscal 2026 fourth-quarter earnings at the end of August. Since then, the company has only issued one press release at the start of September detailing that its 2-gigawatt Sweetwater Hub was included as Base Load in ERCOT Batch Zero. It's a useful milestone that moves Iren a little closer to energizing the site, but nothing groundbreaking.
The lack of news also means nothing about the stock has changed. Iren still has a 5.8-gigawatt pipeline, and AI demand is still surging. The company is leading discussions for approximately $25 million per megawatt, and customer prepayments have been covering 45% to 55% of GPU capital expenditures.
Iren still expects to deliver 300 megawatts by 2026 and to have a total of 800 megawatts delivered by the end of 2027. The company also has undisclosed sites that it is not counting toward its publicly announced multi-gigawatt pipeline. Iren only includes sites in its portfolio after securing "relevant grid connection agreements."
The long-term catalysts are still intact. Iren is still targeting $4 billion in annual recurring revenue by the end of the year, and its November earnings report will offer more updates.
Tech companies will report earnings soon A few key earnings reports will arrive before the end of October, indicating the overall shape of AI spending. Meta Platforms and Tesla will report on the 21st, while Alphabet, Microsoft, and Amazon report their results one week after.
While those earnings haven't come out yet, chipmakers offer some clues. Micron delivered exceptional results in its fiscal 2026 fourth quarter while telling investors that it expects an even stronger fiscal 2027. Taiwan Semiconductor cited "extremely robust demand" continuing for its chips after announcing 41.2% year-over-year revenue growth in its third quarter.
These results suggest that tech companies are still spending heavily on artificial intelligence and may ramp up capex in 2027. A shortage of AI data centers has been a major bottleneck, and as spending continues to increase, more capital should flow into Iren's coffers. Investors will receive the verdict from these hyperscalers by the end of the month, while Iren will report its earnings shortly after.
Marc Guberti has positions in Iren. The Motley Fool has positions in and recommends Alphabet, Amazon, Meta Platforms, Micron Technology, Microsoft, Taiwan Semiconductor Manufacturing, and Tesla. The Motley Fool recommends Gartner. The Motley Fool has a disclosure policy.
IFP Advisors Inc increased its position in Camden Property Trust (NYSE:CPT – Free Report) by 80,855.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 62,336 shares of the real estate investment trust’s stock after purchasing an additional 62,259 shares during the period. IFP Advisors Inc owned 0.06% of Camden Property Trust worth $6,030,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also made changes to their positions in the company. Squarepoint Ops LLC increased its position in Camden Property Trust by 3,804.2% during the second quarter. Squarepoint Ops LLC now owns 107,327 shares of the real estate investment trust’s stock worth $12,288,000 after buying an additional 104,578 shares during the period. CORDA Investment Management LLC. lifted its stake in Camden Property Trust by 90.8% in the first quarter. CORDA Investment Management LLC. now owns 426,913 shares of the real estate investment trust’s stock valued at $41,692,000 after buying an additional 203,131 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of Camden Property Trust by 100.2% in the first quarter. Jennison Associates LLC now owns 1,206,854 shares of the real estate investment trust’s stock valued at $117,861,000 after acquiring an additional 603,997 shares during the period. Corient Private Wealth LP boosted its holdings in shares of Camden Property Trust by 38.2% in the second quarter. Corient Private Wealth LP now owns 120,014 shares of the real estate investment trust’s stock valued at $13,740,000 after acquiring an additional 33,175 shares during the period. Finally, Empyrean Capital Partners LP acquired a new stake in shares of Camden Property Trust in the first quarter valued at approximately $9,180,000. 97.22% of the stock is owned by hedge funds and other institutional investors.
Shares of Camden Property Trust stock opened at $98.56 on Monday. The company has a market cap of $9.91 billion, a P/E ratio of 32.64, a PEG ratio of 7.34 and a beta of 0.79. The company has a debt-to-equity ratio of 1.25, a quick ratio of 0.18 and a current ratio of 0.18. Camden Property Trust has a one year low of $95.30 and a one year high of $119.81. The firm has a fifty day moving average of $102.65 and a two-hundred day moving average of $106.53.
Camden Property Trust (NYSE:CPT – Get Free Report) last released its earnings results on Thursday, July 30th. The real estate investment trust reported $0.18 EPS for the quarter, missing the consensus estimate of $1.67 by ($1.49). The firm had revenue of $396.07 million during the quarter, compared to analyst estimates of $392.88 million. Camden Property Trust had a return on equity of 7.66% and a net margin of 20.80%. The firm’s revenue was up 7.4% on a year-over-year basis. During the same quarter last year, the business posted $1.70 EPS. Camden Property Trust has set its FY 2026 guidance at 6.680-6.820 EPS and its Q3 2026 guidance at 1.670-1.710 EPS. On average, analysts forecast that Camden Property Trust will post 6.75 earnings per share for the current year. Camden Property Trust Announces Dividend The firm also recently announced a quarterly dividend, which was paid on Friday, October 16th. Shareholders of record on Wednesday, September 30th were given a dividend of $1.06 per share. The ex-dividend date was Wednesday, September 30th. This represents a $4.24 annualized dividend and a yield of 4.3%. Camden Property Trust’s payout ratio is presently 140.40%.
Wall Street Analysts Forecast Growth A number of equities analysts have recently commented on CPT shares. Cantor Fitzgerald lifted their target price on shares of Camden Property Trust from $102.00 to $111.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Piper Sandler decreased their price target on shares of Camden Property Trust from $119.00 to $102.00 and set a “neutral” rating for the company in a research note on Monday, October 12th. Morgan Stanley decreased their price target on shares of Camden Property Trust from $120.00 to $118.00 and set an “equal weight” rating for the company in a research note on Wednesday, August 12th. Jefferies Financial Group raised shares of Camden Property Trust to a “hold” rating in a research report on Wednesday, July 22nd. Finally, Mizuho dropped their price objective on shares of Camden Property Trust from $125.00 to $116.00 and set an “outperform” rating on the stock in a research note on Tuesday, September 8th. Three equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Camden Property Trust has an average rating of “Hold” and an average target price of $112.08.
Check Out Our Latest Analysis on Camden Property Trust
Camden Property Trust Company Profile (Free Report)
Camden Property Trust (NYSE:CPT) is a real estate investment trust that owns, develops, acquires, and manages multifamily apartment communities. The company provides residential rental housing and related property-management services, with properties designed to serve a range of residents in major metropolitan areas.
Camden focuses primarily on high-growth markets in the Sun Belt, including communities in Texas, Florida, Georgia, North Carolina, Colorado, Arizona, Nevada, and Tennessee.
Further Reading Five stocks we like better than Camden Property Trust These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom Want to see what other hedge funds are holding CPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Camden Property Trust (NYSE:CPT – Free Report).
Receive News & Ratings for Camden Property Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Camden Property Trust and related companies with MarketBeat.com's FREE daily email newsletter.
Generální ředitel společnosti Hippo Torben Ostergaard prodal 1 169 akcií HIPO za průměrnou cenu 35,03 USD, přičemž celková hodnota transakce činila 40 950,07 USD.
Hippo Holdings Inc. (NYSE:HIPO – Get Free Report) CEO Torben Ostergaard sold 1,169 shares of the business’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $35.03, for a total value of $40,950.07. Following the completion of the transaction, the chief executive officer directly owned 60,655 shares of the company’s stock, valued at approximately $2,124,744.65. The trade was a 1.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.
Torben Ostergaard also recently made the following trade(s):
On Monday, August 17th, Torben Ostergaard sold 1,169 shares of Hippo stock. The stock was sold at an average price of $33.00, for a total transaction of $38,577.00. Hippo Stock Up 0.1% NYSE:HIPO opened at $35.30 on Monday. The company’s 50-day simple moving average is $32.65 and its 200-day simple moving average is $29.30. The company has a debt-to-equity ratio of 0.10, a quick ratio of 0.95 and a current ratio of 0.95. Hippo Holdings Inc. has a fifty-two week low of $24.08 and a fifty-two week high of $38.72. The stock has a market capitalization of $931.57 million, a P/E ratio of 7.59 and a beta of 1.55.
Hippo (NYSE:HIPO – Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.79 EPS for the quarter, topping the consensus estimate of ($0.17) by $0.96. Hippo had a net margin of 23.92% and a return on equity of 10.68%. The firm had revenue of $144.70 million during the quarter, compared to analyst estimates of $137.44 million. On average, equities analysts anticipate that Hippo Holdings Inc. will post 1.50 earnings per share for the current fiscal year. Institutional Trading of Hippo Large investors have recently added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Hippo during the fourth quarter worth about $26,000. State of Alaska Department of Revenue acquired a new position in Hippo in the 3rd quarter worth approximately $31,000. Public Employees Retirement System of Ohio acquired a new position in Hippo in the 2nd quarter worth approximately $178,000. State of Wyoming raised its position in Hippo by 22.9% during the 2nd quarter. State of Wyoming now owns 8,666 shares of the company’s stock worth $245,000 after buying an additional 1,612 shares during the last quarter. Finally, R Squared Ltd purchased a new position in Hippo during the 1st quarter worth approximately $253,000. Hedge funds and other institutional investors own 43.01% of the company’s stock.
Analyst Upgrades and Downgrades HIPO has been the topic of a number of recent analyst reports. Keefe, Bruyette & Woods upped their price target on Hippo from $33.00 to $35.00 and gave the stock a “market perform” rating in a research report on Thursday, August 6th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hippo in a research report on Friday, July 31st. B. Riley Financial reaffirmed a “buy” rating and set a $41.50 target price (up from $38.00) on shares of Hippo in a research report on Monday, August 3rd. Finally, Zacks Research cut Hippo from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 2nd. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $38.25.
Read Our Latest Report on Hippo
About Hippo (Get Free Report)
Hippo Holdings Inc is a technology-focused property and casualty insurance company that provides homeowners insurance and related services in the United States. The company combines digital insurance tools, data analytics and home-monitoring technology to simplify the process of obtaining coverage and managing a policy.
Hippo’s offerings are centered on homeowners insurance, including coverage for residential property, personal belongings, liability and additional living expenses. Through its home protection platform, the company also provides resources and services intended to help customers identify and address potential risks before they lead to costly losses, such as water leaks, fire hazards and other property-related issues.
Founded in 2015 by Assaf Wand and Eyal Navon, Hippo became a publicly traded company in 2021 through a business combination with Reinvent Technology Partners Z.
See Also Five stocks we like better than Hippo These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom
Receive News & Ratings for Hippo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hippo and related companies with MarketBeat.com's FREE daily email newsletter.
Bernstein doubled down on its SpaceX’s (NASDAQ: SPCX) outlook on October 19, confirming both the “Buy” rating and the $248 SpaceX stock price target.
The price target, which represents a 70% upside potential from the last closing price of $146, was first set in late September, when analyst Douglas S. Harned argued Starlink’s residential broadband business would generate approximately $64 billion in revenues in 2031.
Moreover, the affirmation comes just one day ahead of the space company’s next earnings report, scheduled for tomorrow, October 20, which investors hope can answer the question of whether SpaceX’s expanding AI efforts can justify substantial capital investments.
SpaceX stock price six-month chart. Source: Finbold Wall Street is confident SpaceX spending concerns As of press time, analysts expect third-quarter revenue of $12.89 billion tomorrow, up 65% from the same period last year. At the same time, the consensus earnings estimate stands at $0.14 per share, compared with a loss of $0.09 in the previous quarter.
In the second quarter, SpaceX reported revenue of $7.81 billion, marking a 92% increase year over year. However, the company also recorded $18.4 billion in capital expenditures, with $15.83 billion allocated to AI infrastructure alone, generating a lot of discussion among shareholders.
Despite concerns about elevated spending, Wall Street analysts see considerable potential for the stock. Notably, the average price target of $217.5 represents nearly 50% upside from the current levels, per TipRanks data.
SPCX stock 12-month forecast. Source: TipRanks Analysts set SpaceX stock price target ahead of Q3 earnings report All of the recent analyst calls have been bullish. For example, on October 16, Evercore ISI analyst Kutgun Maral raised his price target on SpaceX by approximately 20%, from $230 to $275, while maintaining an “Outperform” rating.
Maral expects SpaceX to exceed Wall Street’s third-quarter revenue forecasts and projects the company will reach an annualized revenue run rate of $104 billion by year-end, surpassing its $100 billion target.
Similarly, Pivotal Research analyst Jeffrey Wlodarczak reiterated his “Buy” rating on October 12 and raised his price target from $220 to $230. The analyst expects third-quarter revenue to reach $13.2 billion, compared with $7.81 billion in the second quarter, and forecasts earnings of $0.21 per share.
On the same day, Stifel analyst Jonathan Siegmann maintained his “Buy” rating on SpaceX, with a price target of $190. In his report, Siegmann covered SpaceX’s plan to acquire wireless spectrum from Grain Management for approximately $8 billion, which he noted could help Starlink Mobile improve connectivity for users inside buildings and act as an important step toward expanding SpaceX’s mobile network capabilities.
Elon Musk chce příští rok darovat každému dítěti v USA jednu akcii SpaceX; při páteční ceně akcie 146 USD by dar pro zhruba 72 milionů dětí měl hodnotu 10,5 miliardy USD.
By and Theron Mohamed You're currently following this author! Click to unsubscribe from email alerts.
Elon Musk announced on X that he intends to give every child in America a SpaceX share. Finn Gomez/Getty Images Elon Musk says he'll give every child in the US a piece of his space company, a gift worth around $10.5 billion today.
"Next year, I will give one of my SpaceX shares to every kid in America," Musk wrote in an early Monday post on X. "This will be the first of many."
There are roughly 72 million children in the US based on 2025 census data, and SpaceX stock closed at $146 on Friday. If Musk donated 72 million shares today they would be worth around $10.5 billion.
Musk didn't provide any further details on how the giveaway would work, such as eligibility criteria or specific timing, or whether the shares will be transferred to Trump Accounts.
The Tesla and SpaceX CEO is the world's richest person with an estimated $904 billion net worth as of Friday's close, per the Bloomberg Billionaires Index.
Elon Musk's $1 million giveaways
SpaceX — the company behind Falcon rockets, Starship launch vehicles, Starlink satellites, AI chatbot Grok, and X — went public this summer and has about a $2 trillion market capitalization.
Excluding restricted shares and options, Musk owns 4.77 billion SpaceX shares for about a 36% stake, worth just under $700 billion at Friday's close. The rest of his fortune largely comprises his stakes in his other companies, including Tesla, Neuralink, and The Boring Company.
Donating 72 million shares would reduce Musk's number of SpaceX shares by 1.5%. If, as indicated in his X post, he follows that up with further giveaways, his stake could shrink significantly.
Musk's pledge is part of a broader trend of gifting shares to America's children, aimed at ensuring they all own a piece of the stock market and reap its gains over time, and benefit from a lifetime of compounding wealth.
The Trump administration launched Trump Accounts — tax-advantaged investment accounts — for eligible children this summer, with those born between 2025 and 2028 receiving a $1,000 federal seed deposit. Numerous companies have agreed to contribute to them as well.
Michael and Susan Dell contributed $250 to 25 million American children's Trump Accounts earlier this month, a gift totaling $6.25 billion that was allocated first to those in the lowest-income ZIP codes.
SpaceX President Gwynne Shotwell and her husband pledged in July to give SpaceX shares to more than 2 million children.
Correction: October 19, 2026 — An earlier version of this story incorrectly described SpaceX as a private company. It went public in June 2026.
Read next
Business Insider tells the innovative stories you want to know
Business Insider tells the innovative stories you want to know
Business Insider tells the innovative stories you want to know
Business Insider tells the innovative stories you want to know
Georgia Hennessy You're currently following this author! Click to unsubscribe from email alerts.
Georgia is a Business News Fellow at Business Insider's London office.Before joining Business Insider, she worked at Japan's largest newspaper, The Yomiuri Shimbun, and interned at the Financial Times. She is an NCTJ-qualified journalist with a degree in Philosophy from the University of Birmingham.
Theron Mohamed You're currently following this author! Click to unsubscribe from email alerts.
Theron Mohamed is a London-based correspondent on the International team at Business Insider. His coverage spans finance, investing, wealth, markets, and the economy.Theron joined BI in 2019 as a reporter at Markets Insider and rose to the rank of correspondent before moving to the Trending team then the broader International team. He previously covered tech, media, and telecom stocks for Investors Chronicle magazine and had a brief stint on the Financial Times' Data team. He interned at the Wall Street Journal in New York where he primarily wrote for Heard on the Street.Theron has freelanced for The Independent, The Telegraph, WIRED, and several smaller publications. He holds an undergraduate degree in geography from the London School of Economics, and a master's degree in journalism from Columbia University.Theron often covers Warren Buffett, Michael Burry, and other elite investors. He also writes about the world's wealthiest people and shares financial advice from all manner of rich and successful people.Email Theron at [email protected] and follow him on X @theron_mohamed.
Elon Musk Wealth Stocks More Investing Billionaires
In June, Elon Musk's space industrial giant, SpaceX (SPCX -1.74%), broke records with an initial public offering (IPO) that valued it at $1.77 trillion. This was the largest corporate debut in history, and it netted SpaceX $75 billion in capital that will be used to accelerate its burgeoning artificial intelligence (AI) and satellite internet businesses.
But SpaceX's blockbuster IPO is a double-edged sword. The larger a company is, the harder it is for management to move the needle and deliver impressive stock returns. Let's dig into the pros and cons of SpaceX to decide what the shares might be worth by the end of 2027.
SPCX Space Exploration Technologies$146.03-$2.59 (-1.74%)
NASDAQ · As of 4:00 PM ET 10/16/26
A private-sector NASA?
When people thought about space exploration a few decades ago, they were almost exclusively envisioning large state-owned entities like the U.S. National Aeronautics and Space Administration (NASA). SpaceX has helped to change this narrative, achieving milestones like becoming the first private company to return a rocket from low Earth orbit and the first to send astronauts to the International Space Station (in 2020).
As a profit-driven entity, SpaceX offers key advantages over the old government-led model of space exploration. For starters, it has a huge incentive to boost efficiency and reduce costs, which leads to innovation (especially in things like rocket size and reusability). SpaceX has also unlocked impressive levels of vertical integration.
SpaceX's different segments simply mesh well together. The launch services business provides a reliable platform for its Starlink broadband internet service to transport large numbers of satellites to space more cost-effectively than rivals. On the flip side, this also boosts cargo capacity utilization on its vessels to improve economies of scale.
SpaceX is also attempting to control as much of its supply chain as possible by manufacturing everything from its own rocket components to satellites, power infrastructure, and computer chips.
Business is booming
While SpaceX's huge market cap of $1.9 trillion may make it look like a mature company, second-quarter earnings suggest there is still plenty of room for growth. Revenue rose 92% year-over-year to $7.8 billion. And while the strong showing was driven by strength across all the company's business segments, AI stood out with a jump of 213% to $2.56 billion.
SpaceX's AI business is largely comprised of assets acquired through its combination with xAI, another Musk-controlled company known for its ownership of the X.com social media platform, the Grok large language model (LLM), and stockpiles of advanced compute hardware.
Image source: Getty Images.
SpaceX's Grok has fallen behind the industry-leading LLM providers like Anthropic and OpenAI in terms of enterprise and consumer adoption. But the company has shifted its strategy to serve the potentially more lucrative infrastructure side of the AI industry by renting out computing power to its former rivals. This includes high-profile deals with Google and Anthropic, which will pay SpaceX a whopping $920 million and $1.25 billion per month, respectively, for access to its AI infrastructure.
Over the longer term, SpaceX plans to better integrate its AI business with its existing space business through space-based data centers. Musk believes this technology could eventually become an ideal way to handle AI workloads because of its access to virtually limitless solar energy and easier cooling. All this remains highly speculative. But if it works, it could boost SpaceX's vertical integration and create a huge economic moat against other data center companies.
As time goes on, SpaceX's stock is starting to look more and more attractive. But with a price-to-sales (P/S) multiple of 68, it is still too expensive for comfort -- especially for investors who fear the generative AI boom might be a bubble. With this in mind, the shares will probably remain around their current level by the end of 2027. And investors should continue waiting on the sidelines until more information becomes available.
JPMorgan u společnosti Apple potvrdila doporučení „Overweight“ a cílovou cenu akcií na 360 USD díky silné poptávce po iPhonech, včetně rychle vyprodaného skládacího iPhonu Duo.
JPMorgan reiterated its “Overweight” rating on Apple (NASDAQ: AAPL) on October 19 and kept its $360 Apple stock price target, both due to positive demand trends across the iPhone lineup.
In the note, the bank specifically highlighted strong early demand for Apple’s new foldable iPhone Duo, with pre-orders opening on Friday and selling out virtually immediately, pushing delivery estimates into next year.
However, while current delivery timelines suggest demand may already exceed the revised shipment forecast, JPMorgan cautioned that it remains too early to draw definitive conclusions about the foldable iPhone’s long-term performance.
Apple shares last $343.46, after gaining approximately 27% over the past six months, meaning JPMorgan’s forecast implies roughly 5% upside from the current levels.
AAPL share price six-month chart. Source: Finbold iPhone demand is constructive, JPMorgan says After some recent iPhone Pro demand concerns in China, delivery estimates have largely normalized over the past week. Notably, lead times for the lineup now remain unchanged in the U.S., Germany, and the United Kingdom.
JPMorgan believes the situation supports its constructive outlook for the iPhone 18 cycle in fiscal 2027. That is, the firm expects demand volumes to remain resilient, with revenue growth benefiting from pricing changes and a varied product mix.
However, Jefferies maintained its “Sell” rating on Apple on October 19 as well, with a price target of $263, which implies a downside of 23% from the last closing price. The bearish take focused primarily on the fact that the latest iPhone generation is experiencing an increasingly weak launch in China.
Wall Street divided on Apple stock price targets Recent analyst calls also highlight some different perspectives on Apple’s demand outlook, profitability, and upcoming product cycle.
For example, UBS reiterated its “Neutral” rating on Apple on October 16, citing concerns about iPhone demand and noting that Pro model delivery times were shorter than at the same point last year.
On the same day, Evercore ISI maintained an “Outperform” rating, highlighting changes in iPhone 18 delivery estimates, including, again, reductions in lead times in China.
Overall, Wall Street sees a modest 2.5% downside potential for the iPhone maker over the next 12 months, with the average AAPL share price target of $334, judging by the analyst data collected by TipRanks over the past three months.
AAPL stock 12-month forecast. Source: TipRanks The consensus is the combined result of 31 analyst ratings in the aforementioned time period, with 16 of them being “Buys,” 11 “Holds,” and four “Sells.”
Prasad Kalyanaraman, vice president of infrastructure services at Amazon Web Services BASTIEN INZAURRALDE/AFP via Getty Images At an internal staff meeting in September, AWS CFO John Felton had a joke for Prasad Kalyanaraman, the executive overseeing much of Amazon's AI infrastructure expansion.
"You've taken us free cash flow negative as a company, so congratulations," Felton said, according to a recording of the meeting obtained by Business Insider.
The remark was lighthearted. But it captured a stunning reversal.
Just two years ago, Wall Street was debating what Amazon would do with its growing cash hoard. Now, cash flow has evaporated as Amazon embarks on its biggest bet ever, spending $220 billion this year alone to build the physical backbone for AI.
At the meeting, Kalyanaraman did not dispute Felton's premise. Amazon's machine-learning and AI business is "hugely free cash flow negative," he said, adding that he expects the company's free cash flow to remain negative for "the next couple of years or so."
What are the real-life consequences of AI?
Amazon has made big bets before. It spent heavily on cloud computing, fulfillment centers, and its delivery network long before they became some of the company's most valuable assets. Investors questioned those investments at the time, but Amazon ultimately built enormous, profitable businesses from them.
AI is testing this playbook at a far larger scale. Amazon is committing hundreds of billions of dollars to data centers, servers, and power before investors know how quickly those investments will generate revenue.
The company is the best, or among the best, at building data centers, with decades of experience. But the size and complexity of these projects, and the bottlenecks holding progress back, are challenging — even for such a respected cloud pioneer.
Internal documents reviewed by Business Insider and people familiar with the matter show the company trying to coordinate a sprawling industrial system whose parts move on different schedules. A delay in power, equipment, or construction can leave billions of dollars in hardware waiting — and Amazon's cash tied up — while forecasts and costs keep shifting.
Why Amazon thinks it will workAmazon says it has strong evidence that the capacity will be needed. AWS revenue grew 37% in the second quarter, its fastest pace in 18 quarters, while its backlog reached $496 billion.
CEO Andy Jassy thinks the company has a "clear line of sight" to strong financial returns from this record investment cycle. In his latest annual shareholder letter, he called AI a "once in a lifetime opportunity" and said Amazon would not be conservative in its investments.
"We've been through this cycle with the first big AWS growth wave, and liked the results," Jassy wrote. "We expect to feel similarly about this next wave."
Investors are concerned by the scale of the industry's expansion, especially as AI data centers are costing more to build and taking longer to complete.
The market is "repricing anything that funds multi-year builds against revenue that arrives later," Dan Ives, an analyst at Yorkville Ives, wrote in a recent report. Growing uncertainty around data center permitting and the political fight over electricity prices have given investors another reason to question how quickly these investments will pay off, he added.
Racks, but not enough powerOne major industry challenge is securing enough power to run the equipment that goes inside data centers. This includes expensive racks of servers that contain GPUs and other chips that train and run AI models and services such as ChatGPT.
Internal emails from August show Amazon preparing a new "Early Rack Receipt" process for an expected wave of server racks carrying Nvidia's GB300 chips at US facilities before final deployment.
One Amazon email projected the company would take delivery of about $5 billion of Nvidia GB300 racks in August, followed by another roughly $3 billion each month "for the foreseeable future."
Some AWS data center sites had room for more racks but not enough available power to turn them on, people familiar with the effort said, leaving the equipment to be staged at intermediary warehouses until the facilities were ready. These people asked not to be identified discussing sensitive matters.
Timing and coordinationUsually, Amazon doesn't pay for racks until the gear is put into a data center, leaving suppliers to carry the cost of the equipment in transit, according to the internal documents obtained by Business Insider. This helps the company conserve cash.
However, the intensity of the AI data center building boom has made this type of coordination harder. Amazon has to compete more for scarce resources as it jockeys with rivals for access to Nvidia GPUs and other AI components.
Under the new "Early Rack Receipt" process, Amazon now takes ownership of these racks earlier in the supply chain, rather than waiting until the equipment reaches a data center.
The means spending cash sooner. And any delays getting the racks installed and plugged into a reliable power source potentially pushes back the moment when revenue starts flowing from these assets.
At least one AWS supply chain team did not have "a clear forecasted path" for getting racks into data centers, according to one of the emails reviewed by Business Insider.
An Amazon spokesperson said the company routinely stages finished hardware near deployment sites so it can be installed once power capacity is available, calling that approach "best business practice."
The spokesperson added that AWS has "long-established systems" to track infrastructure assets and disputed that the broader company lacks a forecasted path for getting racks into data centers.
This problem is not unique to Amazon.
Bernstein analysts wrote in a recent note that power permits, cooling systems, electrical equipment, construction, and hardware all move on separate schedules.
"Timing is imperfect," the analysts said.
"Inherently uncertain"
John Felton, Chief Financial Officer of Amazon Web Services Chris Jung/NurPhoto via Getty Images During the internal staff meeting in September, Felton, the AWS CFO, described the broader problem eloquently: "How do you work in the future when the future is inherently uncertain?"
Kalyanaraman, the AI infrastructure leader, said Amazon's internal outlook for the return on its AI investments had improved. But the assumptions behind those returns keep shifting.
"The forecast is changing on a daily basis," Kalyanaraman said. "The world that we live in is extremely dynamic."
Those shifting assumptions include when data centers will be ready and how much equipment AWS needs to keep on hand, he explained.
An eight-week supply buffer might be routine for a smaller company. But at Amazon's scale, Kalyanaraman said, this could mean holding "billions and billions of dollars" worth of additional equipment inventory — tying up precious cash.
Frugality meets the AI boomSuch tensions are especially striking for Kalyanaraman, a 21-year Amazon veteran who earlier this year was promoted to the elite S-team that reports directly to Jassy.
Amazon's founding story is defined by frugality. It famously used cheap doors as desks when founder Jeff Bezos started in Seattle in the mid-90s.
Kalyanaraman has absorbed this lore into bones. In late 2023, as AWS faced slower growth and layoffs, he urged employees to do more with less. "Frugality breeds innovation," he said back then.
That instinct still shapes his approach. In the September meeting this year, Kalyanaraman told Felton that AWS tries to make major investments at the "last responsible moment," when it has the clearest possible view of demand.
"If we can wait to spend the capital as late as possible, it's better for us," he said.
Amazon CEO Andy Jassy Bloomberg/Getty Images But the frenetic pace of the AI boom makes this principle difficult to follow. By the time demand is fully visible, the servers, power, and construction capabilities that AWS needs may no longer be available. That puts pressure on the company to commit more money sooner to secure supply and meet its data center capacity goals.
Kalyanaraman recalled telling Jassy in 2023 that AWS would "surely" be out of its capacity crunch by 2027. Instead, Amazon still expects demand to exceed its available capacity in 2027, the AI infrastructure chief said during the meeting this September.
Secured Power at RiskGetting enough electricity may be the biggest challenge for an industry leader like Amazon.
The company has 44 gigawatts of data center capacity under development across 16 states, more than double Google, Meta, and Microsoft, according to Cleanview Research estimates.
An internal AWS dashboard called "Secured Power at Risk" tracks utility and regulatory constraints affecting electricity capacity AWS has lined up for its data centers.
The risks include transmission bottlenecks, requirements to reduce use during grid stress, and "use it or lose it" provisions that can jeopardize capacity if a data center project misses usage or construction milestones.
In other words, AWS is not simply waiting for electricity to arrive. It is managing a portfolio of commitments that can become more costly if a data center project is delayed.
Maryland proposalsA submission to Maryland's utility regulator last year, obtained through a public records request, illustrates the kind of exposure that can accompany massive data center buildouts.
Amazon told the Maryland Public Service Commission that large data center customers could help pay for grid upgrades or bring new power capacity to market without burdening other electricity ratepayers.
The company also proposed setting aside collateral to help utilities get more comfortable with the large investments needed to generate more electricity for data centers. Amazon proposed three years of collateral so that if a large electricity customer abandoned unused capacity, the utility would have time to re-sell the power.
The proposal is not evidence that AWS has made such a payment or posted collateral. It does, however, show that large data centers can face extra financial obligations, beyond their own electricity bills, if projects are delayed or cancelled.
The Amazon spokesperson said such utility rules are not unique to AWS. The company has not disclosed how much cash it has paid upfront to secure power.
New constraints 'keep popping up'The AI buildout also incurs expenses that are harder to model than a conventional capex plan.
In the September meeting this year, Kalyanaraman said that while reviewing plans for gigawatts of capacity in West Texas, AWS confronted a labor problem: There weren't enough nearby pipefitters, electricians, and other skilled workers to build the facilities.
The company's response, he said, was to pay to construct housing complexes near its data centers so workers could live there for the two or three years needed to complete the projects.
Even the crates used to ship servers have become a planning issue. It may seem absurd to worry about the price of a container when servers cost hundreds of thousands of dollars, Kalyanaraman said. But at AWS's scale, where the company needs so many crates, even trivial items can become a material expense.
"We have new constraints that keep popping up," Kalyanaraman said.
Have a tip? Contact this reporter via email at [email protected] or Signal, Telegram, or WhatsApp at 650-942-3061. Use a personal email address, a nonwork WiFi network, and a nonwork device; here's our guide to sharing information securely.
Read next
Business Insider tells the innovative stories you want to know
Business Insider tells the innovative stories you want to know
Business Insider tells the innovative stories you want to know
Business Insider tells the innovative stories you want to know
Eugene Kim You're currently following this author! Click to unsubscribe from email alerts.
Eugene is Business Insider’s Chief Tech Correspondent, where he leads coverage of Amazon. His reporting spans the company’s retail and logistics operations to AWS, Alexa, and its internal culture.Previously, he worked at CNBC, Fortune Magazine Korea, and Japan's Yomiuri Shimbun. He holds degrees from NYU and Columbia University’s Graduate School of Journalism.In 2022, Eugene reported on internal documents indicating that Amazon allegedly used deceptive tactics to enroll customers in Prime and made cancellation difficult. The Federal Trade Commission sued Amazon the following year, citing his reporting. The case ended in a record $2.5 billion settlement in 2025.His work has received multiple honors, including the SF Press Club’s Bay Area Journalism Award and SPJ NorCal’s Excellence in Journalism Award.Eugene lives in the Bay Area. Contact him via email at [email protected], or Signal, Telegram, or WhatsApp at 650-942-3061. Use a personal email address, a nonwork WiFi network, and a nonwork device; here's our guide to sharing information securely.
Amazon Big Tech AWS More Artificial Intelligence Exclusive Data Centers AI Insider
Cetera Trust Company N.A bought a new position in shares of Microsoft Corporation (NASDAQ:MSFT – Free Report) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 13,170 shares of the software giant’s stock, valued at approximately $4,913,000. Microsoft accounts for about 2.5% of Cetera Trust Company N.A’s portfolio, making the stock its 5th biggest holding.
Other large investors have also recently bought and sold shares of the company. Auto Owners Insurance Co lifted its position in Microsoft by 56,160.8% in the fourth quarter. Auto Owners Insurance Co now owns 60,116,384 shares of the software giant’s stock worth $29,073,486,000 after purchasing an additional 60,009,531 shares during the period. Amundi raised its stake in shares of Microsoft by 30.8% in the 1st quarter. Amundi now owns 41,675,076 shares of the software giant’s stock valued at $15,426,862,000 after buying an additional 9,814,598 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Microsoft by 10.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 29,323,744 shares of the software giant’s stock valued at $10,852,884,000 after buying an additional 2,784,809 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Microsoft by 64.3% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 24,264,779 shares of the software giant’s stock valued at $8,982,083,000 after buying an additional 9,493,778 shares in the last quarter. Finally, Hsbc Holdings PLC lifted its holdings in shares of Microsoft by 7.8% during the 4th quarter. Hsbc Holdings PLC now owns 22,138,798 shares of the software giant’s stock worth $10,715,379,000 after acquiring an additional 1,599,412 shares during the period. 71.13% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth Several brokerages have recently weighed in on MSFT. Guggenheim reiterated a “buy” rating and set a $586.00 target price on shares of Microsoft in a research report on Monday, July 27th. BMO Capital Markets started coverage on shares of Microsoft in a research note on Monday, October 5th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. reissued a “buy” rating on shares of Microsoft in a research report on Monday, September 28th. Cantor Fitzgerald raised their price target on shares of Microsoft from $522.00 to $608.00 and gave the stock an “overweight” rating in a research note on Monday, September 21st. Finally, DA Davidson restated a “buy” rating and set a $550.00 price target on shares of Microsoft in a research note on Thursday, July 30th. Forty-two equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, Microsoft presently has an average rating of “Moderate Buy” and an average price target of $589.71.
Get Our Latest Research Report on MSFT Insider Activity In other Microsoft news, EVP Takeshi Numoto sold 4,810 shares of the business’s stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $496.48, for a total value of $2,388,068.80. Following the transaction, the executive vice president directly owned 42,677 shares in the company, valued at $21,188,276.96. The trade was a 10.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Satya Nadella sold 86,525 shares of the company’s stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $501.46, for a total transaction of $43,388,826.50. Following the sale, the chief executive officer directly owned 486,763 shares in the company, valued at $244,092,173.98. This represents a 15.09% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 150,314 shares of company stock valued at $75,404,992 in the last ninety days. 0.03% of the stock is currently owned by corporate insiders.
Key Stories Impacting Microsoft Here are the key news stories impacting Microsoft this week:
Positive Sentiment: Analysts expect Microsoft to remain the only major hyperscaler with positive free cash flow over the next year despite heavy AI investment. This reinforces confidence that the company can fund data-center expansion without substantial external financing. Microsoft Free Cash Flow Expected to Remain Positive Positive Sentiment: Microsoft signed a 20-year agreement with NiSource for approximately 1,100 megawatts of power for an Indiana data-center campus beginning in 2028. Securing electricity supports future Azure capacity as grid constraints become a bottleneck for AI expansion. Microsoft Signs Power Deal With NiSource Positive Sentiment: Microsoft’s custom Maia AI chips and reports that a new model achieved comparable or better performance than OpenAI’s system using a fraction of the computing power could eventually reduce reliance on expensive third-party GPUs and improve AI economics. Microsoft Wants to Make AI Cheaper Neutral Sentiment: Investors are focused on Azure growth, Copilot adoption, AI monetization and capital expenditures ahead of earnings. Strong demand could support the shares, but the market wants evidence that revenue growth is translating into sustainable margins. Negative Sentiment: The U.K. Competition and Markets Authority is investigating Microsoft’s grip on business software and says Microsoft and Amazon Web Services may need to do more to address cloud-service barriers. Potential remedies could increase compliance costs or weaken customer-lock-in advantages. UK Regulator Targets Microsoft’s Business Software Grip Negative Sentiment: Questions remain over whether custom chips will deliver meaningful savings: AI infrastructure, power and data-center commitments are rising rapidly, while Microsoft is reportedly seeking substantial cost reductions in Azure. That creates concern about near-term free-cash-flow and margin pressure. Microsoft Price Performance Shares of NASDAQ MSFT opened at $529.05 on Monday. The stock has a market cap of $3.93 trillion, a PE ratio of 29.46, a PEG ratio of 1.70 and a beta of 1.10. The business has a fifty day moving average of $505.53 and a two-hundred day moving average of $441.16. Microsoft Corporation has a 52-week low of $349.20 and a 52-week high of $553.72. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.22 and a current ratio of 1.23.
Microsoft (NASDAQ:MSFT – Get Free Report) last issued its earnings results on Wednesday, July 29th. The software giant reported $4.74 EPS for the quarter, beating the consensus estimate of $4.24 by $0.50. Microsoft had a net margin of 40.31% and a return on equity of 31.98%. The company had revenue of $90.01 billion for the quarter, compared to the consensus estimate of $87.62 billion. During the same quarter in the previous year, the company earned $3.65 EPS. The firm’s revenue for the quarter was up 17.7% compared to the same quarter last year. As a group, equities research analysts expect that Microsoft Corporation will post 19.65 earnings per share for the current fiscal year.
Microsoft Increases Dividend The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Thursday, November 19th will be issued a dividend of $0.98 per share. The ex-dividend date of this dividend is Thursday, November 19th. This represents a $3.92 annualized dividend and a yield of 0.7%. This is an increase from Microsoft’s previous quarterly dividend of $0.91. Microsoft’s payout ratio is 20.27%.
Microsoft Profile (Free Report)
Microsoft Corporation (NASDAQ:MSFT) is a global technology company that develops software, cloud services, devices and digital platforms. Its products and services are used by consumers, businesses, governments and educational institutions worldwide.
The company’s principal offerings include the Windows operating system; Microsoft 365 productivity applications such as Word, Excel, Teams and Outlook; Azure cloud computing and infrastructure services; Dynamics business applications; and enterprise security solutions.
Recommended Stories Five stocks we like better than Microsoft These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom Want to see what other hedge funds are holding MSFT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Microsoft Corporation (NASDAQ:MSFT – Free Report).
Receive News & Ratings for Microsoft Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microsoft and related companies with MarketBeat.com's FREE daily email newsletter.
Microsoft 28. října zveřejní výsledky za první čtvrtletí fiskálního roku 2027; klíčové budou růst Azure a rozšiřování Copilotu, který měl k 30. červnu 30 milionů placených licencí.
Volatility gripped the stock market last week amid concerns about the sustainability of the artificial intelligence (AI) infrastructure spending boom. The S&P 500 experienced a modest decline, but it continues to trade at a historically expensive valuation, so strong corporate earnings will be necessary to keep this bull market going.
As a result, all eyes are on the current reporting season. Microsoft (MSFT -1.93%) will release its operating results for its fiscal 2027 first quarter (ended Sept. 30) on Oct. 28, and Wall Street will be squarely focused on the Azure cloud platform and Copilot virtual assistant, which are central to the company's AI strategy.
Microsoft stock is attractively valued heading into the report, so here's why I predict it will climb in the weeks and months that follow.
Image source: Getty Images.
Positioned to lead the enterprise AI race
AI is a powerful tool in an enterprise because it can dramatically improve productivity by automating tasks, analyzing large volumes of data, and even generating content like images and computer code. Microsoft is helping businesses tap into the power of AI through Copilot and Azure, and both represent enormous opportunities for the company.
The Copilot assistant is embedded in Microsoft's legacy software products like Windows and Edge for free. But enterprises can also add it to the 365 productivity suite (which includes Word and Excel) for an additional monthly subscription fee. As of June 30, organizations worldwide were paying for 30 million Copilot licenses for 365, a staggering 50% increase from just three months earlier.
However, organizations pay for more than 400 million 365 licenses for their employees, so Copilot adoption is still in the very early stages. Investors should keep an eye out for some updated numbers on Oct. 28.
MSFT Microsoft$529.05-$10.39 (-1.93%)
NASDAQ · As of 4:00 PM ET 10/16/26
Then there is the Azure cloud platform, which provides every tool enterprises need to deploy AI software applications. That includes computing capacity from specialized data centers, more than 11,000 ready-made foundation models, and a platform called Foundry where they can design and manage custom AI agents.
Microsoft built 88 new data centers during fiscal 2026 as part of a two-year plan to double its global infrastructure footprint. This will help Azure convert its enormous $678 billion in remaining performance obligations (RPO) into revenue, which effectively represents the platform's order backlog from customers who are waiting for more infrastructure to come online.
Azure's revenue growth accelerated to 43% in the final quarter of fiscal 2026, so the platform was carrying significant momentum into the fiscal 2027 first-quarter earnings report. A further acceleration will be very bullish for Microsoft stock, but so will growth in the company's RPO, because it can be a good indicator of future revenue.
Microsoft stock could soar after Oct. 28, but there is one caveat
Based on Microsoft's fiscal 2026 earnings of $17.95 per share, its stock is trading at a price-to-earnings (P/E) ratio of 30.1, which is a discount to its five-year average of 32. Plus, the stock has a forward P/E of 27.3 based on Wall Street's average fiscal 2027 earnings estimate of $19.78 per share (provided by Yahoo! Finance), leaving even more room for potential upside.
MSFT PE Ratio data by YCharts
Nevertheless, the AI industry faces increasing doubts right now that could jeopardize Microsoft's ability to actually deliver on Wall Street's fiscal 2027 earnings estimate. Labs like OpenAI and Anthropic are facing questions about their valuations and growth rates, which could reduce their ability to raise more money from investors. Moreover, neocloud companies like CoreWeave are dealing with a surge in borrowing costs on concerns they won't be able to deliver on their lofty future projections, which could weigh on the stock market overall.
OpenAI has committed to spend more than $300 billion on Microsoft Azure's cloud services during the next few years, but it doesn't actually have that money today. OpenAI will have to increase its revenue significantly and also raise more money to meet all of its commitments, so if it fails on either front, Microsoft's RPO could take a hit.
For all of those reasons, the first-quarter earnings report is likely to set the tone for Microsoft stock for at least the next few months. I think there could be upside ahead based on its attractive valuation, and the sheer size of its RPO –- even if we exclude OpenAI's contribution entirely, Azure is still likely to be backlogged for the next couple of years. However, investors might want to manage their risk by using a small position size given the uncertain environment.
AMD očekává ve třetím čtvrtletí tržby ve výši 12,7 až 13,3 miliardy USD, což představuje meziroční růst zhruba o 41 %; klíčový bude výhled růstu systému Helios ve čtvrtém čtvrtletí.
Advanced Micro Devices (AMD -5.96%) shareholders have had a remarkable 2026. As of this writing, the stock is around $530, up more than 140% since the year started.
The last two weeks have been tougher. On Oct. 6, the stock closed at a record $649.42. Since then, it's dropped around 19%. And the pullback comes about two weeks before AMD reports third-quarter results on Tuesday, Nov. 3.
Is the stock worth buying before that report, or is it better to wait for management's update? I lean toward buying. Most of what the report has to show is already in AMD's own guidance.
Image source: AMD.
AMD keeps topping its own guidanceWhen AMD posted second-quarter results on Aug. 4, management guided for third-quarter revenue between $12.7 billion and $13.3 billion. The $13 billion midpoint is around 41% above the year-ago period and about 13% above the second quarter's record $11.5 billion. Management also sees a non-GAAP (adjusted) gross margin of around 56%, matching the second quarter.
AMD has given investors reason to trust these ranges. First-quarter revenue of $10.3 billion was above the top of the company's guidance range of $9.5 billion to $10.1 billion. Second-quarter revenue then edged just over the top of its range.
Profits are keeping up, too. Adjusted earnings per share hit $1.66 for the second quarter, up 21% sequentially. Against a year-ago quarter dragged down by $800 million of inventory and related charges linked to U.S. export controls, it more than tripled.
But a strong report hasn't guaranteed a strong reaction. Shares lost 7% the day after the second-quarter report, and the two reports before that brought a 17% slide in February and a 19% rise in May.
Will data center growth slow in Q3?Showing how much AMD now leans on it, the data center segment, which sells server processors and artificial intelligence (AI) accelerators, made up 58% of second-quarter revenue. Sales there climbed from $5.4 billion in the fourth quarter of 2025 to $5.8 billion and then $6.7 billion in the first two quarters of 2026. Year-over-year growth picked up every time: 39%, then 57%, then 107%.
But the run will probably end in the third quarter, at least on paper. The segment pulled in $4.3 billion in the year-ago quarter, so even 100% growth would mean around $8.7 billion in data center revenue -- about $2 billion over its second-quarter total. AMD's guidance adds only about $1.5 billion in revenue for the whole company, and management expects gaming sales to fall.
Chief financial officer Jean Hu said on the second-quarter earnings call that the data center acceleration AMD expects compares the second half of 2026 to the first half, not one quarter to the last. And management still sees strong double-digit sequential growth in data center revenue in the third quarter.
So, a slower year-over-year rate would mainly reflect a far tougher comparison, not a slowing business.
Helios is the bigger testMuch of AMD's growth from here rides on Helios, its rack-scale AI server system. On that same call, CEO Lisa Su spelled out the timing.
"We've said Q3 is the very beginning of the ramp, Q4 is a step-up, and then Q1 will be a further step-up and we'll ramp as we go through 2027," she said.
So the third-quarter results probably won't show much of Helios. The fourth-quarter revenue guidance AMD gives on Nov. 3 is likely where Su's step-up first shows up.
AMD Advanced Micro Devices$528.75-$33.48 (-5.96%)
NASDAQ · As of 4:00 PM ET 10/16/26
That outlook is also where the stock is most exposed. Going by analysts' average estimate, shares trade at around 34 times 2027 earnings, down from about 41 times 2027 earnings at the Oct. 6 record close. True, that's a lower valuation than the stock had at its high. But it still assumes Helios ramps on schedule. A fourth-quarter outlook with a smaller step-up than Su described could push shares down, even if third-quarter revenue tops its range again.
Investors who'd rather see that guidance before paying 34 times expected 2027 earnings have a reasonable case for waiting. After all, the stock has swung at least 7% the day after each of its past three reports.
Still, I think the pullback and AMD's record against its own guidance make the stock attractive at this price. I'd consider buying a starter position before the report and leave room to add if the price comes down.
Barlow Wealth Partners LLC raised its stake in shares of NVIDIA Corporation (NASDAQ:NVDA – Free Report) by 1.4% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 225,776 shares of the computer hardware maker’s stock after buying an additional 3,028 shares during the quarter. NVIDIA comprises approximately 4.8% of Barlow Wealth Partners LLC’s holdings, making the stock its 3rd largest position. Barlow Wealth Partners LLC’s holdings in NVIDIA were worth $46,085,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also recently modified their holdings of NVDA. Boyd Wealth Management LLC increased its holdings in NVIDIA by 273.4% in the 2nd quarter. Boyd Wealth Management LLC now owns 9,145 shares of the computer hardware maker’s stock worth $1,830,000 after buying an additional 6,696 shares during the period. Ally Financial Inc. raised its position in NVIDIA by 10.3% during the 2nd quarter. Ally Financial Inc. now owns 172,000 shares of the computer hardware maker’s stock worth $34,415,000 after buying an additional 16,000 shares during the last quarter. Altshuler Shaham Ltd lifted its stake in NVIDIA by 6,451.9% during the 1st quarter. Altshuler Shaham Ltd now owns 637,236 shares of the computer hardware maker’s stock valued at $111,134,000 after acquiring an additional 627,510 shares during the period. Storen Legacy Partners LLC acquired a new stake in NVIDIA during the 4th quarter valued at approximately $1,350,000. Finally, Baker Tilly Wealth Management LLC boosted its holdings in shares of NVIDIA by 7.4% in the 2nd quarter. Baker Tilly Wealth Management LLC now owns 71,898 shares of the computer hardware maker’s stock valued at $14,386,000 after acquiring an additional 4,958 shares during the last quarter. Institutional investors own 65.27% of the company’s stock.
Key NVIDIA News Here are the key news stories impacting NVIDIA this week:
Positive Sentiment: New RTX Spark laptops expand NVIDIA’s addressable market. Systems from ASUS, Dell, HP, Lenovo, Microsoft and MSI are now available starting at $2,599, combining Blackwell graphics, up to 128GB of memory and local AI capabilities. The launch could create a new consumer and developer revenue stream beyond data centers. NVIDIA RTX Spark PCs Available Today Positive Sentiment: Automotive and enterprise adoption continues. Volvo expanded its partnership with NVIDIA for automated-driving systems, while Adobe is integrating NVIDIA technology across Photoshop, Premiere and other creative tools. These agreements support longer-term demand for NVIDIA hardware and software. Volvo Cars expands automated driving partnership Positive Sentiment: Supply-chain investment and customer deployments remain strong. Taiwan is reportedly considering as much as $4 billion for Texas industrial parks serving NVIDIA suppliers, and customers continue deploying Blackwell systems. The developments reinforce demand, although they may take time to affect revenue. Taiwan Texas industrial parks Neutral Sentiment: NVIDIA is broadening its software and AI-model ecosystem. Paid offerings such as AI Enterprise and Mission Control, along with Nemotron open models and partnerships with AI startups, could make earnings less dependent on hardware. However, the articles provide no near-term financial contribution. Negative Sentiment: AI financing concerns are the main pressure. CoreWeave’s debt has reportedly traded at distressed yields, raising questions about whether highly leveraged customers can continue funding data-center expansion. Higher Treasury yields and inflation concerns are also making large AI projects more expensive. CoreWeave financing worries Negative Sentiment: Investors are questioning AI growth expectations. OpenAI’s reported $50 billion revenue run rate was below the roughly $68 billion previously anticipated, prompting concern that AI demand may mature more slowly. Microsoft’s development of custom Maia chips also highlights the risk of customers developing alternatives to NVIDIA GPUs. OpenAI revenue expectations Negative Sentiment: Reported insider selling adds a sentiment overhang. Recent data showed NVIDIA insiders made numerous sales and no open-market purchases over the past six months, though such transactions may reflect planned diversification rather than a change in business outlook. Insider Buying and Selling at NVIDIA In other news, Director Mark A. Stevens sold 622,239 shares of the business’s stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $231.62, for a total transaction of $144,122,997.18. Following the completion of the sale, the director owned 2,336,531 shares of the company’s stock, valued at $541,187,310.22. The trade was a 21.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Colette Kress sold 34,918 shares of the business’s stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $219.05, for a total transaction of $7,648,787.90. Following the sale, the chief financial officer directly owned 765,103 shares of the company’s stock, valued at $167,595,812.15. This represents a 4.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 1,766,118 shares of company stock valued at $399,450,353 over the last ninety days. Corporate insiders own 3.94% of the company’s stock. Analyst Ratings Changes A number of analysts have recently weighed in on NVDA shares. KGI Securities increased their price objective on shares of NVIDIA from $335.00 to $345.00 in a research note on Thursday, August 27th. Mizuho set a $315.00 target price on shares of NVIDIA and gave the stock an “outperform” rating in a report on Thursday, August 27th. Sanford C. Bernstein restated a “buy” rating on shares of NVIDIA in a research report on Monday, September 21st. Evercore set a $465.00 target price on shares of NVIDIA and gave the company an “outperform” rating in a research report on Thursday, August 27th. Finally, DZ Bank reaffirmed a “buy” rating on shares of NVIDIA in a report on Wednesday, August 26th. Five analysts have rated the stock with a Strong Buy rating, forty-nine have given a Buy rating and one has issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $321.89.
Read Our Latest Report on NVDA
NVIDIA Stock Performance Shares of NVDA stock opened at $214.13 on Monday. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.59 and a quick ratio of 3.85. The company has a market cap of $5.16 trillion, a price-to-earnings ratio of 27.07, a PEG ratio of 1.65 and a beta of 2.22. The stock has a 50 day simple moving average of $223.20 and a 200-day simple moving average of $211.42. NVIDIA Corporation has a 1-year low of $164.27 and a 1-year high of $243.37.
NVIDIA (NASDAQ:NVDA – Get Free Report) last announced its earnings results on Wednesday, August 26th. The computer hardware maker reported $2.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.09 by $0.13. NVIDIA had a return on equity of 96.04% and a net margin of 63.66%. The firm had revenue of $96.22 billion for the quarter, compared to analyst estimates of $92.27 billion. During the same quarter last year, the firm posted $1.05 EPS. The business’s revenue was up 105.9% on a year-over-year basis. On average, equities research analysts expect that NVIDIA Corporation will post 9.30 EPS for the current fiscal year.
NVIDIA declared that its Board of Directors has approved a share repurchase plan on Monday, September 28th that permits the company to repurchase $150.00 billion in outstanding shares. This buyback authorization permits the computer hardware maker to purchase up to 2.8% of its shares through open market purchases. Share buyback plans are usually a sign that the company’s board believes its shares are undervalued.
NVIDIA Dividend Announcement The business also recently disclosed a quarterly dividend, which was paid on Thursday, October 1st. Shareholders of record on Thursday, September 10th were given a dividend of $0.25 per share. The ex-dividend date was Thursday, September 10th. This represents a $1.00 dividend on an annualized basis and a yield of 0.5%. NVIDIA’s dividend payout ratio is currently 12.64%.
NVIDIA Profile (Free Report)
NVIDIA Corporation (NASDAQ: NVDA) is a technology company that designs graphics processing units (GPUs), accelerated computing platforms, networking products and related software. Its technologies support artificial intelligence, machine learning, scientific computing, data analytics, professional visualization and computer graphics.
The company’s products include GeForce GPUs for gaming and personal computing, data center GPUs and systems for AI and high-performance computing, and networking solutions used to connect and manage large-scale computing infrastructure.
Featured Articles Five stocks we like better than NVIDIA These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom Want to see what other hedge funds are holding NVDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NVIDIA Corporation (NASDAQ:NVDA – Free Report).
Receive News & Ratings for NVIDIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NVIDIA and related companies with MarketBeat.com's FREE daily email newsletter.
Visa (V +0.71%) stock is trading at an all-time high, thanks to a major price surge over the past two weeks.
The payment processor ended September at $359 per share, and in the two weeks since, it has climbed about 12% to $401 per share, an all-time high.
Visa stock is up 14% year to date, with pretty much all of the gains coming in the past two weeks. There have been a few catalysts for Visa; most notably, it got approval from the People's Bank of China to establish a bankcard clearing institution in China. This opens up one of the biggest markets in the world for Visa.
Image source: Getty Images.
Also, on Oct. 15, the company's Visa Direct stablecoin officially moved from the pilot stage to commercial deployment. Now, businesses can use the Visa stablecoin platform, marking a key milestone in bringing stablecoin-enabled money movement into commercial operations.
With these new developments, Visa stock got price target upgrades from both Baird and BMO Capital, perhaps providing a further boost.
A buy heading into earnings?
Visa reports its fiscal fourth-quarter earnings on Oct. 27, and it typically raises its dividend in Q4. It has done that every year since 2009, and it's usually a substantial raise.
Last year, it bumped up the dividend 14% to $0.67 per share, and the year before that it was 13%. The two years previous to that, the raises were 15% and 20%, respectively.
$402.61+$2.86 (+0.71%)
NYSE · As of 4:00 PM ET 10/16/26
Investors should expect a sizable dividend bump on Oct. 27, given that Visa anticipates Q4 revenue gains at the high end of low double digits, similar to the 14% gain in Q3. For the full fiscal year, it anticipates revenue growth in the low-teens and earnings per share (EPS) growth in the low- to mid-teens.
I still like it as a buy heading into earnings, with its forward P/E at a reasonable 24. Visa is durable across markets, which is why I like it as a long-term buy at this valuation.
JPMorgan Chase has made $5 billion in startup investments in the first year of its U.S. security and resiliency initiative, the company said Monday, a faster-than-expected pace that indicates the bank is finding plentiful opportunities in emerging defense, manufacturing and supply chain firms.
The bank, which last year said it would deploy $10 billion into startups over a decade, may expand the program beyond that initial dollar amount, JPMorgan co-president Doug Petno told CNBC in an interview.
Todd Combs, the former Berkshire Hathaway executive who leads the JPMorgan group in charge of making startup investments, has "hit the ground running," Petno said. "He's done a great job and put us in some really interesting companies," he added.
Most of those investments have yet to be disclosed, but two known stakes seem emblematic of the project's mission to bolster companies that are needed for a more dangerous and chaotic era of geopolitics. JPMorgan, the biggest U.S. bank by assets, has taken direct stakes in defense-related startups Hadrian and Castelion.
Wars in Ukraine and the Middle East, as well as trade disputes with China, have threatened the flow of energy and key components needed for U.S. industries and defense, which spurred JPMorgan CEO Jamie Dimon into creating the initiative a year ago.
He put Petno, widely seen as one of two key possible successors, in charge of the overall investment project. Combs, a former board member of the bank, reports directly to Dimon.
The scope of the project extends beyond supply chain, defense and manufacturing to include frontier technologies and the pharmaceutical and health-tech industries.
"There's a lot of really interesting companies that have been working to solve some of these problems," Petno said.
These "early venture-stage, advanced manufacturing companies have found ways to build these capabilities in the U.S." rather than relying on overseas trading partners, he said.
In August, the bank helped lead a $1.4 billion funding round in Hadrian, which builds automated factories that make parts for the defense, aerospace and maritime sectors. A California factory run by Hadrian has 10 robots for every human employee, according to the startup's founder.
That month, JPMorgan was also involved in a $1 billion funding round for Castelion, whose flagship product is a relatively low-cost hypersonic missile called Blackbeard. Castelion was founded in late 2022 by a group of former SpaceX engineers.
"Our approach is to find generational companies and partner with them for the long term," Combs said in a statement Monday.
"Putting more than $5 billion to work in our first year shows how many exceptional businesses are building in industries that strengthen critical supply chains," Combs said.
Risky business? That JPMorgan would make billions of dollars of direct investments in nascent companies is a departure from its usual role as a lender and advisor.
Before the defense initiative, the bank had moved away from taking startup stakes, which can be relatively risky bets on unproven technologies. JPMorgan spun off its private equity business, One Equity Partners, more than a decade ago.
In its more traditional role, JPMorgan has also financed and facilitated more than $230 billion for industries that support American national interests, according to the bank.
That part of its security and resiliency project, meant to hit $1.5 trillion over 10 years, is led by Jay Horine, a former co-head of investment banking.
JPMorgan built a team of about three dozen bankers for the project, who are aided by hundreds more across the firm, as it expanded the initiative to Europe and Canada.
Its bankers are mapping distribution lines for key products, from submarines and missiles to aircraft, to identify suppliers that may lack the capital or capacity to meet rising demand, according to Petno.
JPMorgan is also in regular communication with the U.S. Department of Defense and Department of Commerce about the government's needs, he said.
TD Waterhouse Canada ve třetím čtvrtletí zvýšila svůj podíl ve společnosti Johnson & Johnson o 22,6 % nákupem 227 243 akcií, čímž její celkový počet akcií vzrostl na 1 232 683.
TD Waterhouse Canada Inc. increased its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 22.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,232,683 shares of the company’s stock after purchasing an additional 227,243 shares during the period. Johnson & Johnson accounts for about 0.8% of TD Waterhouse Canada Inc.’s holdings, making the stock its 28th biggest holding. TD Waterhouse Canada Inc. owned approximately 0.05% of Johnson & Johnson worth $319,176,000 as of its most recent filing with the Securities and Exchange Commission.
Several other large investors have also recently added to or reduced their stakes in the stock. Wellington Management Group LLP lifted its stake in shares of Johnson & Johnson by 12.5% during the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after purchasing an additional 2,513,321 shares in the last quarter. Deutsche Bank AG boosted its position in shares of Johnson & Johnson by 8.5% in the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock worth $3,977,506,000 after buying an additional 1,225,676 shares during the period. Amundi grew its stake in shares of Johnson & Johnson by 17.5% in the first quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after buying an additional 2,001,139 shares in the last quarter. Jupiter Topco LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at about $1,967,399,000. Finally, Janus Henderson Group PLC grew its stake in shares of Johnson & Johnson by 1.9% in the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock valued at $1,924,323,000 after buying an additional 148,497 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.
Johnson & Johnson Stock Performance Shares of JNJ stock opened at $255.54 on Monday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The company’s fifty day moving average price is $265.66 and its two-hundred day moving average price is $249.66. The firm has a market capitalization of $615.82 billion, a P/E ratio of 38.72, a P/E/G ratio of 2.53 and a beta of 0.21. Johnson & Johnson has a 12 month low of $184.66 and a 12 month high of $281.07.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.54% and a net margin of 16.20%. The company had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same period last year, the firm earned $2.80 earnings per share. The company’s revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. On average, research analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current fiscal year. Johnson & Johnson Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. Johnson & Johnson’s dividend payout ratio is currently 81.21%.
Johnson & Johnson News Roundup Here are the key news stories impacting Johnson & Johnson this week:
Positive Sentiment: Raised 2026 outlook: Third-quarter operational sales grew 6%, reaching $25.4 billion, and management increased full-year operational sales guidance to approximately $100.7 billion at the midpoint. Adjusted EPS also exceeded analysts’ expectations. Johnson & Johnson: 3 Key Takeaways for Long-Term Investors Positive Sentiment: Pharmaceutical momentum and pipeline potential: Strong demand for TREMFYA, early momentum for ICOTYDE and oncology investments helped offset weakness elsewhere. Investors are also watching J&J’s newly approved surgical robot as a potential long-term MedTech growth driver. Does Raised 2026 Outlook Change the Bull Case for Johnson & Johnson? Positive Sentiment: Defensive appeal and income support: Investors rotating away from technology stocks amid inflation and interest-rate concerns are favoring dividend-paying healthcare companies. J&J also affirmed its $1.34-per-share fourth-quarter dividend, payable in December 2026. Morgan Stanley maintained an “overweight” rating with a $292 price target. Neutral Sentiment: Institutional demand: ETFs recorded approximately $107.4 million of net buying in JNJ, suggesting some portfolio managers continue to view the company as a defensive holding. However, this flow is not necessarily evidence of a change in operating fundamentals. Johnson & Johnson Sees $107.4 Million in Net ETF Buying Negative Sentiment: MedTech weakness remains the main overhang: Medical-device sales missed Wall Street forecasts, while international pricing pressure and acquisition-related costs weighed on results. Analysts described the quarter as setting a negative tone for the broader pharmaceutical sector. Johnson & Johnson Stock Falls on MedTech Miss Negative Sentiment: Valuation and analyst caution: JNJ trades at a premium earnings multiple, increasing the risk of further pressure if growth disappoints. Erste Group expressed a negative view on fiscal 2027 earnings, while RBC lowered its price expectations. Analyst Ratings Changes Several equities research analysts recently commented on the company. Bank of America reiterated a “neutral” rating and set a $278.00 target price on shares of Johnson & Johnson in a report on Tuesday, September 29th. Scotiabank restated an “outperform” rating and issued a $305.00 price target on shares of Johnson & Johnson in a report on Thursday, July 16th. Sanford C. Bernstein set a $270.00 price target on Johnson & Johnson in a report on Thursday. Johnson Rice reaffirmed a “buy” rating on shares of Johnson & Johnson in a research report on Monday, August 3rd. Finally, Raymond James Financial set a $280.00 price objective on shares of Johnson & Johnson in a research note on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $274.87.
Check Out Our Latest Stock Report on Johnson & Johnson
Insider Activity at Johnson & Johnson In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Elizabeth Forminard sold 15,918 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $257.00, for a total value of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares of the company’s stock, valued at approximately $4,367,458. This trade represents a 48.37% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 64,515 shares of company stock valued at $17,271,766. Insiders own 0.16% of the company’s stock.
(Free Report)
Johnson & Johnson (NYSE: JNJ) is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.
Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.
Recommended Stories Five stocks we like better than Johnson & Johnson These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
Altria nabízí očekávaný dividendový výnos 5,9 % a zvyšuje dividendu již 57 let v řadě. Pravidelná investice 100 USD měsíčně po dobu deseti let přinesla zhruba 4 800 USD na dividendách.
Altria (MO +1.72%), the largest tobacco company in the U.S., pays a forward dividend yield of 5.9%. It's raised its dividend annually for 57 consecutive years, making it a Dividend King that has increased its payout for at least 50 straight years.
If you had invested $100 per month over the past ten years into Altria, your principal would have grown from $12,000 to $13,800. But you would also have received about $4,800 in dividends.
Image source: Getty Images.
Is Altria still a reliable dividend stock?
Altria's future might seem murky because adult smoking rates in the U.S. have dropped from over 40% in the 1960s to less than 10% today. But to offset that pressure, it constantly raises its cigarette prices, cuts costs, and repurchases more shares to boost its EPS. It's also expanding its smokeless portfolio with e-cigarettes, nicotine pouches, snus, and other products.
MO Altria Group$75.11+$1.27 (+1.72%)
NYSE · As of 4:00 PM ET 10/16/26
By 2028, Altria expects to generate at least $5 billion in smoke-free revenue, equivalent to nearly a quarter of its projected sales. From 2025 to 2028, analysts expect its EPS to grow at a 13% CAGR even as its revenue barely grows. Over the past 12 months, Altria spent 78% of its free cash flow on its dividends -- so it has plenty of room for future hikes. It's also a cheap stock in this frothy market: at $75 per share, it trades at just 13 times forward earnings.
Leo Sun has positions in Altria Group. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Goldman Sachs ve třetím čtvrtletí meziročně zvýšila tržby o 23 % na 18,68 miliardy USD a vykázala zisk na akcii (EPS) ve výši 17,01 USD, což překonalo odhad analytiků ve výši 12,86 USD.
IFP Advisors Inc lessened its position in shares of The Goldman Sachs Group, Inc. (NYSE:GS – Free Report) by 14.5% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 7,843 shares of the investment management company’s stock after selling 1,329 shares during the quarter. IFP Advisors Inc’s holdings in The Goldman Sachs Group were worth $7,062,000 as of its most recent SEC filing.
Several other institutional investors also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of The Goldman Sachs Group in the second quarter valued at approximately $24,172,123,000. Bank of America Corp DE acquired a new position in shares of The Goldman Sachs Group in the 2nd quarter valued at $6,756,772,000. Orange County Employees Retirement System purchased a new stake in The Goldman Sachs Group in the 2nd quarter valued at $69,537,544,000. Bank of New York Mellon Corp purchased a new stake in The Goldman Sachs Group in the 2nd quarter valued at $2,560,028,000. Finally, International Assets Investment Management LLC purchased a new stake in The Goldman Sachs Group in the 1st quarter valued at $2,024,921,000. Institutional investors and hedge funds own 71.21% of the company’s stock.
The Goldman Sachs Group Stock Performance NYSE GS opened at $880.48 on Monday. The stock has a market capitalization of $256.37 billion, a price-to-earnings ratio of 12.66, a PEG ratio of 0.85 and a beta of 1.29. The business’s 50 day moving average is $974.71 and its two-hundred day moving average is $990.62. The Goldman Sachs Group, Inc. has a 12-month low of $740.01 and a 12-month high of $1,153.99. The company has a current ratio of 1.10, a quick ratio of 0.63 and a debt-to-equity ratio of 2.82.
The Goldman Sachs Group (NYSE:GS – Get Free Report) last issued its earnings results on Tuesday, October 13th. The investment management company reported $17.01 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $12.86 by $4.15. The business had revenue of $18.68 billion during the quarter, compared to the consensus estimate of $16.83 billion. The Goldman Sachs Group had a return on equity of 19.55% and a net margin of 15.77%. The company’s revenue for the quarter was up 23.0% on a year-over-year basis. During the same period in the prior year, the business posted $12.25 EPS. Research analysts expect that The Goldman Sachs Group, Inc. will post 69.57 EPS for the current year. The Goldman Sachs Group Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Wednesday, December 2nd will be issued a dividend of $5.00 per share. This represents a $20.00 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Wednesday, December 2nd. The Goldman Sachs Group’s dividend payout ratio is currently 28.76%.
Key The Goldman Sachs Group News Here are the key news stories impacting The Goldman Sachs Group this week:
Positive Sentiment: Goldman Sachs reported third-quarter net revenue of approximately $18.7 billion, its second-highest quarterly total, while earnings increased 39% year over year. Strong equities trading and investment-banking fees supported the results, and financing activities accounted for more than 40% of trading revenue year to date. Zacks Analyst Blog Highlights Goldman Sachs Positive Sentiment: TD Cowen initiated coverage of Goldman Sachs with a Buy rating, adding a new bullish view after the company’s strong earnings report. TD Cowen Initiates Coverage Positive Sentiment: JPMorgan raised its Goldman Sachs price target from $955 to $970, implying meaningful potential upside from recent levels, although it retained a Neutral rating. JPMorgan Price Target Update Neutral Sentiment: Goldman CEO David Solomon said the underlying economy remains solid and capital-markets activity is strong, but abrupt interest-rate movements are creating headwinds. That suggests favorable deal activity may be offset by macroeconomic volatility. Goldman CEO David Solomon Interest Rate Warning Negative Sentiment: Analyst actions from RBC and Citigroup lowered expectations for Goldman Sachs, reinforcing concerns that the stock’s strong earnings are already reflected in its valuation. RBC Goldman Sachs Price Target Cut Citigroup Goldman Sachs Expectations Negative Sentiment: Goldman Sachs and other banks delivered earnings beats but saw their shares weaken as investors focused on mixed guidance, interest-rate uncertainty and a broader “sell-the-news” reaction. Why Bank Shares Are Falling Negative Sentiment: Goldman Sachs data showed hedge funds suffering losses as investors unwound AI-related trades amid inflation concerns and expectations for higher rates, adding to the risk-off environment affecting financial stocks. AI Trade Unwind Hurts Hedge Funds Analyst Ratings Changes Several brokerages have issued reports on GS. Oppenheimer downgraded shares of The Goldman Sachs Group from a “market perform” rating to an “underperform” rating in a research report on Tuesday, June 30th. BMO Capital Markets decreased their price objective on The Goldman Sachs Group from $972.00 to $970.00 and set a “market perform” rating for the company in a research report on Tuesday, October 6th. Royal Bank Of Canada lowered their target price on The Goldman Sachs Group from $1,220.00 to $1,010.00 and set a “sector perform” rating on the stock in a research note on Wednesday, October 14th. Keefe, Bruyette & Woods lowered their price objective on shares of The Goldman Sachs Group from $1,130.00 to $1,100.00 and set a “market perform” rating on the stock in a research report on Wednesday. Finally, Rothschild & Co Redburn boosted their price objective on shares of The Goldman Sachs Group from $870.00 to $920.00 and gave the company a “neutral” rating in a research note on Thursday, June 25th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $1,051.23.
Check Out Our Latest Report on The Goldman Sachs Group
The Goldman Sachs Group Company Profile (Free Report)
The Goldman Sachs Group, Inc is a global financial services company that provides investment banking, securities, asset management and wealth management services to corporations, financial institutions, governments and individual investors. Its investment banking activities include advising on mergers and acquisitions, public and private offerings, restructurings and other strategic transactions.
Through its global markets businesses, Goldman Sachs helps clients buy and sell securities and other financial instruments and provides financing, risk management and market-making services.
See Also Five stocks we like better than The Goldman Sachs Group These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom Want to see what other hedge funds are holding GS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Goldman Sachs Group, Inc. (NYSE:GS – Free Report).
Receive News & Ratings for The Goldman Sachs Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Goldman Sachs Group and related companies with MarketBeat.com's FREE daily email newsletter.
Qualcomm Incorporated (NASDAQ:QCOM – Get Free Report) EVP Ann Chaplin sold 1,827 shares of the stock in a transaction dated Friday, October 16th. The stock was sold at an average price of $174.75, for a total transaction of $319,268.25. Following the sale, the executive vice president owned 25,770 shares in the company, valued at approximately $4,503,307.50. This trade represents a 6.62% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Qualcomm Stock Performance Shares of NASDAQ QCOM opened at $172.11 on Monday. The company has a quick ratio of 1.28, a current ratio of 2.02 and a debt-to-equity ratio of 0.46. The firm’s 50-day moving average price is $175.02 and its two-hundred day moving average price is $179.70. Qualcomm Incorporated has a 52-week low of $121.99 and a 52-week high of $259.92. The stock has a market capitalization of $183.79 billion, a P/E ratio of 19.92, a P/E/G ratio of 3.88 and a beta of 1.65.
Qualcomm (NASDAQ:QCOM – Get Free Report) last issued its earnings results on Wednesday, July 29th. The wireless technology company reported $2.21 EPS for the quarter, missing analysts’ consensus estimates of $2.23 by ($0.02). The company had revenue of $9.95 billion during the quarter, compared to analyst estimates of $9.69 billion. Qualcomm had a net margin of 21.01% and a return on equity of 38.36%. The business’s revenue was down 4.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.77 earnings per share. Qualcomm has set its Q4 2026 guidance at 2.050-2.250 EPS. As a group, sell-side analysts forecast that Qualcomm Incorporated will post 7.74 earnings per share for the current year.
Analyst Upgrades and Downgrades A number of research analysts recently commented on the company. DZ Bank upgraded Qualcomm from a “hold” rating to a “buy” rating and set a $265.00 price objective for the company in a research note on Friday, June 26th. Mizuho raised their target price on Qualcomm from $170.00 to $210.00 and gave the company a “neutral” rating in a research note on Monday, June 29th. Barclays reiterated an “underweight” rating on shares of Qualcomm in a research note on Wednesday, September 9th. Dbs Bank raised shares of Qualcomm to a “moderate buy” rating in a report on Tuesday, July 7th. Finally, Bank of America upped their price target on shares of Qualcomm from $165.00 to $195.00 and gave the stock an “underperform” rating in a research report on Tuesday, June 23rd. Two analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, twenty-one have issued a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, Qualcomm presently has a consensus rating of “Hold” and a consensus target price of $204.10. View Our Latest Stock Analysis on QCOM
Key Qualcomm News Here are the key news stories impacting Qualcomm this week:
Positive Sentiment: Qualcomm appears to have prevailed in its licensing dispute with Arm. A Delaware jury found that Arm breached its license agreement with Qualcomm, supporting Qualcomm’s position in a dispute that could have affected the company’s ability to use Arm-based designs. The verdict is a potential legal and strategic win, although further proceedings may still be required. Jury finds Arm breached license agreement with Qualcomm Positive Sentiment: A renewed Apple licensing agreement improves revenue visibility. Qualcomm’s continued licensing relationship with Apple helps support its high-margin patent-licensing business, even as Apple works to develop more of its own modem technology. Qualcomm renews Apple license Positive Sentiment: Qualcomm expanded its 5G licensing coverage with Transsion through 2031. The extended agreement provides longer-term royalty visibility in emerging smartphone markets. Qualcomm, Transsion Extend 5G Patent License Deal Positive Sentiment: The company launched an AI-native Wi-Fi 8 gateway. The product combines next-generation connectivity with edge AI computing, supporting Qualcomm’s strategy to diversify beyond smartphones into home broadband and AI-enabled devices. Qualcomm unveils AI-native Wi-Fi 8 gateway Neutral Sentiment: Analysts continue to view Qualcomm as a cash-generative wireless technology company with growth opportunities in automotive, AI and other markets, but investors remain focused on the pace of its transition away from handset dependence. Qualcomm: Navigating the shift from handsets to AI Negative Sentiment: Sector-wide chip selling is pressuring QCOM. Qualcomm’s legal win has not prevented broader weakness across semiconductor stocks, with investors reducing exposure to chipmakers. Chip selloff following Qualcomm verdict Negative Sentiment: Reports that Samsung could replace Qualcomm’s chip in the Galaxy S27 Ultra if thermal issues persist raise concerns about flagship handset share and Qualcomm’s near-term mobile revenue. Samsung may swap Galaxy S27 Ultra chip Negative Sentiment: MediaTek’s reported progress toward an AI data-center chip pact with ByteDance highlights increasing competition in Qualcomm’s effort to build an AI and data-center business. ByteDance and MediaTek AI chip pact Hedge Funds Weigh In On Qualcomm Hedge funds and other institutional investors have recently made changes to their positions in the business. Your Advocates Ltd. LLP bought a new position in Qualcomm in the 1st quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Qualcomm by 17,000.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 171 shares of the wireless technology company’s stock worth $29,000 after buying an additional 170 shares during the last quarter. ABS Investment Management LLC bought a new stake in shares of Qualcomm in the second quarter valued at approximately $34,000. ABS Direct Equity Fund LLC bought a new stake in shares of Qualcomm in the second quarter valued at approximately $34,000. Finally, Burk Holdings LLC grew its stake in shares of Qualcomm by 191.7% in the second quarter. Burk Holdings LLC now owns 210 shares of the wireless technology company’s stock worth $39,000 after acquiring an additional 138 shares during the last quarter. 74.35% of the stock is currently owned by institutional investors and hedge funds.
Qualcomm Company Profile (Get Free Report)
Qualcomm Incorporated is a technology company that develops and commercializes wireless communications and semiconductor technologies. Through Qualcomm Technologies, Inc, the company designs integrated circuits, system software and related platforms used in smartphones, personal computers, automobiles, industrial equipment, consumer devices and other connected products. Its Snapdragon platforms support mobile computing, connectivity, artificial intelligence and multimedia applications, while its broader portfolio includes radio-frequency systems, networking and edge-computing technologies.
Qualcomm also operates a significant technology-licensing business through its Qualcomm Technology Licensing segment.
Featured Articles Five stocks we like better than Qualcomm These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom
Receive News & Ratings for Qualcomm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualcomm and related companies with MarketBeat.com's FREE daily email newsletter.
Preferenční akcie Series A společnosti Innovative Industrial Properties nabízejí výnos kolem 9,3 % a kumulativní dividendu; tento REIT vlastní 108 nemovitostí v 19 státech.
Many income investors wouldn't go near a pot stock with a 10-foot pole -- and for good reason. For one thing, most cannabis stocks don't pay dividends. The ones that do operate in a highly volatile industry.
However, it's important to remember the adage "don't throw the baby out with the bath water." Sure, most cannabis stocks aren't good picks if you're seeking reliable income. There's one, though, that I think is hands-down the best cannabis stock for dividend investors. If you want cannabis exposure without cannabis-company risk, along with an exceptionally juicy yield, check out Innovative Industrial Properties 9.00% Series A Cumulative Redeemable Preferred Stock (NYSE: IIPR-PA).
The preferred pickLet's get one thing straight right out of the gate: Innovative Industrial Properties (IIPR -1.52%) is emphatically not a pure-play cannabis company. However, it is a key player in the cannabis industry.
The company is the top real estate investment trust (REIT) that specializes in owning and leasing facilities to licensed U.S. cannabis operators. It collects rents from cannabis operators under long-term triple-net leases, in which the tenants pay property taxes, insurance, and standard maintenance expenses. Innovative Industrial Properties currently owns 108 properties in 19 states.
Buying Innovative Industrial Properties' common stock gives you a staggering forward dividend yield of 14.5%. Is that lofty yield sustainable? Probably not. The REIT's dividend payout ratio is roughly 172%, meaning it's paying out far more in dividends than it's earning. Even worse, Innovative Industrial Properties doesn't generate enough free cash flow to cover its dividends.
But the Innovative Industrial Properties' Series A preferred stock is a different animal altogether. Its yield hovers around 9.3%, close to the 9% in its name. And those standard payout ratios don't matter for this preferred stock.
The investment case and the honest risksBuying a preferred stock is similar to buying a bond in some respects. Both pay a predetermined, fixed rate (9% for the Innovative Industrial Properties 9.00% Series A Cumulative Redeemable Preferred Stock). Unlike common dividends, these fixed returns reflect a contractual obligation.
The word "cumulative" in this preferred stock's name is important. It means that if Innovative Industrial Properties ever missed a preferred dividend payment, the missed amount would accrue. The REIT would have to pay the full amount of preferred dividends owed before it could resume paying common dividends.
This makes Innovative Industrial Properties' preferred dividends inherently safer than its common dividends. The company's balance sheet should make income investors feel even better. Innovative has manageable debt levels.
That said, there are some risks associated with investing in this preferred stock. Innovative Industrial Properties could still experience financial problems and be unable to pay its preferred dividends. The REIT depends on its tenants paying their rents. Several large cannabis operators have previously missed payments to Innovative.
Tenant concentration is a valid concern, too. Innovative Industrial Properties has 37 tenants, but only five of them pay half of its total rental revenue.
Who this preferred stock could be right forIf you're a conservative, highly risk-averse investor, buying Innovative Industrial Properties 9.00% Series A Cumulative Redeemable Preferred Stock probably won't be up your alley. The risks associated with the cannabis industry will likely eliminate this stock from consideration.
On the other hand, I think this preferred stock could be a good fit for aggressive income investors. Most states have legalized medical cannabis, with a growing number allowing legal recreational cannabis as well. Cannabis regulations at the federal level are loosening. In some ways, the cannabis industry is in its best regulatory position ever.
Innovative Industrial Properties remains the leading provider of real estate capital to the industry. Its tenants include some of the biggest cannabis operators. The REIT seems likely to continue meeting its obligations to pay preferred dividends.
In an industry that's historically been a danger zone for income investors, Innovative Industrial Properties' preferred stock is a rare opportunity. It offers a high yield and places preferred shareholders second only to bondholders in the order of payment. It's the hands-down best cannabis stock for dividend investors.
Costco ve čtvrtletí vykázalo tržby ve výši 95,72 miliardy USD, což představuje meziroční nárůst o 11,1 %, a EPS ve výši 6,75 USD, čímž překonalo odhad EPS ve výši 6,54 USD.
IFP Advisors Inc raised its stake in Costco Wholesale Corporation (NASDAQ:COST – Free Report) by 43.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,484 shares of the retailer’s stock after purchasing an additional 12,856 shares during the period. Costco Wholesale comprises 0.6% of IFP Advisors Inc’s investment portfolio, making the stock its 19th biggest position. IFP Advisors Inc’s holdings in Costco Wholesale were worth $38,675,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Bank of America Corp DE purchased a new stake in shares of Costco Wholesale during the second quarter worth approximately $6,781,946,000. Diamant Asset Management Inc. raised its holdings in Costco Wholesale by 99,278.0% in the first quarter. Diamant Asset Management Inc. now owns 6,726,899 shares of the retailer’s stock valued at $672,690,000 after acquiring an additional 6,720,130 shares in the last quarter. State Street Corp raised its holdings in Costco Wholesale by 31.7% in the second quarter. State Street Corp now owns 23,901,594 shares of the retailer’s stock valued at $22,359,224,000 after acquiring an additional 5,749,362 shares in the last quarter. Legal & General Group Plc purchased a new position in Costco Wholesale in the second quarter worth approximately $2,362,188,000. Finally, Ascentis Wealth Management LLC lifted its stake in Costco Wholesale by 103,637.0% in the second quarter. Ascentis Wealth Management LLC now owns 2,500,062 shares of the retailer’s stock worth $2,549,616,000 after acquiring an additional 2,497,652 shares during the last quarter. Hedge funds and other institutional investors own 68.48% of the company’s stock.
More Costco Wholesale News Here are the key news stories impacting Costco Wholesale this week:
Positive Sentiment: September sales accelerated: Costco reported September net sales of $30.02 billion, up 13% year over year, while digitally enabled sales increased 19%. The results reinforce the strength of Costco’s membership model, e-commerce business and value-focused offering. September Sales Growth Positive Sentiment: Analyst support remains strong: Tigress Financial reiterated a Buy rating while setting a $1,065 price target after previously publicizing a higher $1,250 target. Other coverage highlights Costco’s sales growth, membership loyalty and digital gains, supporting the recent recovery above key moving averages. Tigress Financial Price Target Positive Sentiment: Dividend maintained: Costco declared a quarterly dividend of $1.47 per share, payable November 13 to shareholders of record October 30. While the approximately 0.6% yield is modest, the payment signals continued cash-flow strength. Costco Dividend Announcement Positive Sentiment: Expansion pipeline: Proposed warehouse projects in Macon and Oakland, along with a planned Merced County relocation, point to continued investment in Costco’s store network. Infrastructure financing of up to $30 million could support the Macon development. Macon Costco Project Neutral Sentiment: Costco’s fiscal 2027 executive bonus plan adds sustainability-related measures. The change may support long-term operational goals, but it is unlikely to materially affect near-term earnings. Costco Executive Bonus Update Negative Sentiment: Valuation and macro risks remain: Costco trades at a high earnings multiple, leaving the stock vulnerable if growth or membership trends slow. Persistent inflation and potentially higher interest rates could also pressure consumer spending and market valuations. Negative Sentiment: An executive sold 1,100 shares worth approximately $1.05 million. The transaction is relatively small compared with Costco’s market value, but it may add a modest cautionary signal for investors. Costco Insider Sale Costco Wholesale Price Performance COST stock opened at $989.11 on Monday. The business has a 50 day moving average price of $933.15 and a 200 day moving average price of $963.04. The stock has a market cap of $438.30 billion, a price-to-earnings ratio of 47.64, a PEG ratio of 4.23 and a beta of 0.88. Costco Wholesale Corporation has a fifty-two week low of $844.06 and a fifty-two week high of $1,096.50. The company has a quick ratio of 0.62, a current ratio of 1.06 and a debt-to-equity ratio of 0.11. Costco Wholesale (NASDAQ:COST – Get Free Report) last announced its quarterly earnings results on Thursday, September 24th. The retailer reported $6.75 EPS for the quarter, beating the consensus estimate of $6.54 by $0.21. The company had revenue of $95.72 billion for the quarter, compared to analyst estimates of $94.97 billion. Costco Wholesale had a net margin of 3.04% and a return on equity of 27.60%. The firm’s revenue was up 11.1% on a year-over-year basis. During the same period in the prior year, the firm posted $5.87 earnings per share. Equities research analysts anticipate that Costco Wholesale Corporation will post 22.70 earnings per share for the current fiscal year.
Costco Wholesale Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 30th will be given a dividend of $1.47 per share. This represents a $5.88 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, October 30th. Costco Wholesale’s payout ratio is currently 28.32%.
Insider Buying and Selling at Costco Wholesale In other news, EVP Claudine Adamo sold 2,200 shares of the company’s stock in a transaction on Tuesday, September 29th. The shares were sold at an average price of $915.93, for a total value of $2,015,046.00. Following the completion of the transaction, the executive vice president owned 7,134 shares in the company, valued at approximately $6,534,244.62. This represents a 23.57% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP William Richard Wilcox sold 1,100 shares of the stock in a transaction on Tuesday, October 13th. The shares were sold at an average price of $958.21, for a total transaction of $1,054,031.00. Following the completion of the transaction, the executive vice president directly owned 3,094 shares in the company, valued at $2,964,701.74. This trade represents a 26.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.10% of the company’s stock.
Analyst Upgrades and Downgrades COST has been the subject of several analyst reports. Roth Capital reiterated a “sell” rating and set a $781.00 price target on shares of Costco Wholesale in a report on Friday, September 25th. UBS Group reissued a “buy” rating on shares of Costco Wholesale in a research report on Thursday, September 17th. Argus restated a “buy” rating and issued a $1,230.00 price objective on shares of Costco Wholesale in a report on Monday, September 28th. Evercore reaffirmed an “outperform” rating on shares of Costco Wholesale in a research report on Tuesday, September 22nd. Finally, Raymond James Financial decreased their price objective on shares of Costco Wholesale from $1,100.00 to $1,050.00 and set an “outperform” rating for the company in a research report on Friday, September 25th. Twenty-four equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $1,087.40.
View Our Latest Stock Report on Costco Wholesale
(Free Report)
Costco Wholesale Corporation operates a membership-based warehouse retail business under the Costco name. The company sells merchandise in bulk and at competitive prices through warehouse clubs and e-commerce platforms, serving individual consumers, businesses and other organizations.
Its product selection includes groceries and fresh foods, household supplies, appliances, electronics, furniture, apparel, health and beauty products, jewelry, automotive products and prescription drugs. Costco also provides services such as optical care, pharmacy services, hearing-aid sales, travel offerings and fuel sales, depending on location.
The company traces its roots to Price Club, which opened in San Diego in 1976.
Featured Articles Five stocks we like better than Costco Wholesale These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom Want to see what other hedge funds are holding COST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Costco Wholesale Corporation (NASDAQ:COST – Free Report).
Receive News & Ratings for Costco Wholesale Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Costco Wholesale and related companies with MarketBeat.com's FREE daily email newsletter.
Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) CFO Andrew Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the transaction, the chief financial officer owned 161,096 shares of the company’s stock, valued at $25,166,417.12. This represents a 1.83% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Gilead Sciences Price Performance NASDAQ:GILD opened at $156.19 on Monday. Gilead Sciences, Inc. has a one year low of $114.02 and a one year high of $160.51. The company has a debt-to-equity ratio of 2.03, a quick ratio of 1.09 and a current ratio of 1.27. The firm has a market cap of $193.67 billion, a price-to-earnings ratio of -58.50 and a beta of 0.31. The firm’s fifty day moving average is $147.19 and its two-hundred day moving average is $137.29.
Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share for the quarter, topping the consensus estimate of ($7.25) by $0.50. The company had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same period last year, the firm earned $2.01 EPS. Research analysts expect that Gilead Sciences, Inc. will post -0.47 EPS for the current year.
Gilead Sciences Dividend Announcement The business also recently announced a quarterly dividend, which was paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th were paid a $0.82 dividend. The ex-dividend date was Tuesday, September 15th. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.1%. Gilead Sciences’s dividend payout ratio is presently -122.85%. Institutional Investors Weigh In On Gilead Sciences Several hedge funds have recently modified their holdings of the company. Onyx Bridge Wealth Group LLC increased its position in shares of Gilead Sciences by 2.2% in the third quarter. Onyx Bridge Wealth Group LLC now owns 5,039 shares of the biopharmaceutical company’s stock valued at $751,000 after buying an additional 108 shares in the last quarter. IFP Advisors Inc raised its stake in shares of Gilead Sciences by 33.4% during the 3rd quarter. IFP Advisors Inc now owns 11,135 shares of the biopharmaceutical company’s stock worth $1,660,000 after buying an additional 2,788 shares during the period. Founders Grove Wealth Partners LLC lifted its position in shares of Gilead Sciences by 3.9% during the 3rd quarter. Founders Grove Wealth Partners LLC now owns 2,437 shares of the biopharmaceutical company’s stock valued at $363,000 after buying an additional 91 shares in the last quarter. Frank Rimerman Advisors LLC lifted its position in shares of Gilead Sciences by 1.2% during the 3rd quarter. Frank Rimerman Advisors LLC now owns 35,698 shares of the biopharmaceutical company’s stock valued at $5,321,000 after buying an additional 412 shares in the last quarter. Finally, Encompass More Asset Management lifted its position in shares of Gilead Sciences by 4.2% during the 3rd quarter. Encompass More Asset Management now owns 3,057 shares of the biopharmaceutical company’s stock valued at $456,000 after buying an additional 122 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes Several analysts recently commented on GILD shares. Weiss Ratings raised Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. HSBC boosted their price target on Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Bank of America restated a “buy” rating and issued a $164.00 price objective on shares of Gilead Sciences in a research report on Monday, October 12th. Barclays lowered their price objective on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 29th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price objective on shares of Gilead Sciences in a research note on Thursday, October 8th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $159.33.
View Our Latest Stock Analysis on GILD
Key Stories Impacting Gilead Sciences Here are the key news stories impacting Gilead Sciences this week:
Positive Sentiment: Vir oncology collaboration expands Gilead’s pipeline. Gilead and Vir Biotechnology agreed to develop three novel cancer therapies, including next-generation T-cell engagers. The deal could provide Vir with up to approximately $1.74 billion in additional milestone payments, giving Gilead access to potential long-term oncology growth while diversifying its pipeline. Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers Positive Sentiment: Investors are rotating toward defensive healthcare stocks. As investors reduce exposure to technology and chip stocks, major pharmaceutical companies—including Gilead—have traded near record highs. This rotation may be supporting demand for GILD because of the sector’s defensive characteristics and potential earnings support. Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets Neutral Sentiment: Recent momentum has increased investor attention. GILD gained 2.57% in the prior session and closed at $157.48, while shares remain close to their 52-week high. Market commentary notes heightened investor interest, although analysts have expressed mixed views on the company’s prospects. Gilead Sciences rises higher than market: Key facts Negative Sentiment: Two senior executives reported planned stock sales. CFO Andrew Dickinson and insider Johanna Mercier each sold 3,000 shares at an average price of $156.22. Both transactions were executed under pre-arranged Rule 10b5-1 plans, limiting their significance as a bearish signal; each executive continues to hold a substantial position. Gilead CFO Form 4 filing (Get Free Report)
Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.
Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.
Recommended Stories Five stocks we like better than Gilead Sciences These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
Workers at Micron Technology (MU -5.63%) in Taiwan have come a step closer to a strike. On Oct. 7, the union at the memory maker's Taoyuan site said 1,994 members voted to authorize a strike over how Micron splits its profits. This was 99% of the ballots cast. Just 14 voted against.
No strike date has been set. The union asked members to take Monday, Oct. 19, off for a rally in Taipei, which it said wouldn't be a strike. But the union's chair has said a surprise walkout, announced to members by text on short notice, is on the table.
When I covered the dispute in early September, I thought a deal was the likelier ending. As of this writing, the growth stock trades near $879, off about 28% from its record close of $1,213.56 in late June.
Image source: Micron.
A tougher lineIn an August poll, over 80% of participating union members backed strike action. Then mediation between Micron and the Taoyuan union ended without a deal in September.
In prepared remarks for its Sept. 30 earnings call, CEO Sanjay Mehrotra said the firm had raised fiscal 2026 incentive pay for all employees worldwide.
But that didn't settle the dispute. The union wants a permanent system that gives 15% of Micron's operating profit to workers.
Pressure on the tech firm is coming from outside, too. Taiwan's labor ministry urged Micron to offer "concrete, feasible proposals."
And on Oct. 15, President Lai Ching-te called on both sides to negotiate sincerely at the opening of Micron's new Taichung plant, which packages and tests high-bandwidth memory (HBM) for AI systems.
How much output is at risk?Taiwan arguably matters more to Micron than any other country. A majority of the company's DRAM output in fiscal 2026 came from its fabs there, according to its annual report.
And DRAM is most of the business. Showing how fast it's grown, Micron's DRAM revenue hit a record $39.8 billion in the fiscal fourth quarter, up 27% from the previous quarter and 343% year over year. That was 73% of total revenue. Taiwan also had $27.6 billion of Micron's long-lived assets (mostly plants and equipment) at the end of fiscal 2026, versus $19 billion a year before -- around 43% of the company's total.
But the strike vote so far covers the smaller of Micron's two big Taiwan sites. Taoyuan's union has 2,258 registered members, and the fab there mainly makes DRAM.
Taichung is Micron's largest base in Taiwan, and its union, which represents around 10,000 workers there and in Tainan, hasn't voted. It holds a second mediation session with the company on Oct. 22, and a failed one might lead to a strike vote there, too.
Micron has already sold much of its supplyDelays might cost Micron more than usual, because much of what its fabs make is already spoken for. On its Sept. 30 earnings call, management said over 75% of Micron's fiscal 2027 shipments were already committed.
"We have already sold out all the capacity for 2027 that this factory will build," Micron President and Chief Operating Officer Manish Bhatia said at the Taichung opening.
MU Micron Technology$878.84-$52.40 (-5.63%)
NASDAQ · As of 4:00 PM ET 10/16/26
A long strike, then, might leave Micron short on deliveries it's already promised. Micron's latest annual report warns that labor disruptions "could also impair our ability to meet delivery schedules under strategic customer agreements, which could result in contractual liability, loss of customer confidence, or diversion of customer demand to competing suppliers."
Of course, I think the more likely cost is a richer pay plan. Notably, Micron's annual report now names new profit-sharing or bonus programs among the ways a labor dispute might get settled.
Under the union's 15% formula, Micron's fiscal 2026 operating income of $99.3 billion (up from $9.8 billion in fiscal 2025) would have meant around $14.9 billion for employees. The payout would be around a third of the $43.8 billion in operating income Micron made in the fiscal fourth quarter alone. And at around 12 times fiscal 2026 earnings, investors aren't paying as if this level of profit will last anyway.
Could a strike hurt the stock? A long one at Taichung could. But I still think a deal is the more likely outcome, and I don't see the vote as a reason to sell. If Taichung's union goes to a strike vote after its Oct. 22 meeting, though, I'd take the risk of lost output much more seriously.
Eli Lilly: Ve studii fáze 3 dosáhlo klinické remise po 52 týdnech 50 % dětských pacientů s ulcerózní kolitidou, kteří reagovali na léčbu přípravkem Omvoh. Společnost Lilly plánuje požádat regulační orgány o rozšíření indikace.
Building on Omvoh's approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label expansion for pediatric ulcerative colitis
More than 80% of patients responded to Omvoh induction, and half of responders, ages 6 to 17, were in clinical remission at one year in Phase 3 SHINE-2 study
In key secondary outcomes, 71.2% of patients who responded to Omvoh induction achieved symptomatic remission and 50% achieved corticosteroid-free clinical remission at one year without surgery
, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive late-breaking one-year results from the Phase 3 SHINE-2 study of Omvoh (mirikizumab-mrkz) in pediatric patients ages 6 to 17 with moderately to severely active ulcerative colitis (UC), including clinical, symptomatic and endoscopic outcomes. In the single-arm, open-label study, 81% of patients achieved clinical response to Omvoh induction at Week 12. Among responders, 50% achieved clinical remission at Week 52, meeting the study's primary endpoint.* Omvoh is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric UC. These results were presented as a late-breaking oral presentation at United European Gastroenterology (UEG) Week 2026.1
Omvoh is currently approved for adults with moderately to severely active UC. The safety and effectiveness of Omvoh in pediatric patients are currently being evaluated in clinical studies. Lilly plans to submit these data to global regulators to support a potential label expansion. If approved, Omvoh would be the first IL-23p19 inhibitor indicated for pediatric UC.
"For children and adolescents, the persistent bowel urgency, abdominal pain and unpredictability of ulcerative colitis can make a normal childhood feel out of reach, especially when symptoms return after previous treatments," said Mark Genovese, M.D., senior vice president of Lilly Immunology development. "Already approved for adults with ulcerative colitis, Omvoh is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis. We look forward to working with regulators to potentially make Omvoh available to children and adolescents living with this disease, who continue to face substantial disease burden and ongoing unmet needs."
Unmet need in pediatric ulcerative colitis
UC affects more than 26,000 children and adolescents in the U.S.3 Although relatively uncommon, pediatric-onset UC is often more extensive and severe than disease that begins in adulthood.4 Up to half of children treated with corticosteroids become dependent on them, and up to one-third require surgery within a year.4
SHINE-2 evaluated Omvoh in a pediatric population with high disease burden and significant unmet need, including 54% of enrolled patients who had previously experienced biologic treatment failure. Half entered the study with severe disease activity as measured by the Pediatric Ulcerative Colitis Activity Index.1
"For children with ulcerative colitis, every year spent relying on corticosteroids or facing the possibility of surgery can have important implications for growth, development and quality of life," said Marla C. Dubinsky, M.D., Professor of Pediatrics and Medicine at the Icahn School of Medicine at Mount Sinai, Chief of Pediatric Gastroenterology and Nutrition at Mount Sinai Kravis Children's Hospital. "Considering these challenges, the finding that half of the pediatric patients who responded to Omvoh achieved corticosteroid-free clinical remission without surgery at one year is particularly meaningful, especially in a population where many patients had previously experienced treatment failure with advanced therapies."
One-year results from SHINE-2 in children and adolescents with ulcerative colitis
Of the patients enrolled in SHINE-2, 81% achieved clinical response at Week 12. Among responders, ages 6 to 17, efficacy was sustained across multiple clinical, symptomatic and endoscopic outcomes at Week 52, including:
50% clinical remission (primary endpoint)* 50% corticosteroid-free clinical remission without surgery† 73.1% clinical response‡ 71.2% symptomatic remission¶ 53.8% endoscopic improvement# 44.2% endoscopic remission** The pediatric Week 52 clinical remission rate was similar to that observed among adult Week 12 responders treated with Omvoh in LUCENT-2 (50.7%).1 This descriptive observation was separate from the primary endpoint analysis and should not be interpreted as a direct comparison between studies.
These one-year findings build on the early clinical, symptomatic and endoscopic improvements observed at Week 12, which were presented as a late-breaking oral presentation at the American College of Gastroenterology 2026 Annual Scientific Meeting.5
Safety findings from SHINE-2
Through Week 52 in SHINE-2, the safety profile of Omvoh in children and adolescents was consistent with its established safety profile in adults, with no new safety signals identified. The most common treatment-emergent adverse events in SHINE-2 were upper respiratory tract infection, injection site reaction, UC, headache, nasopharyngitis and anemia. Most treatment-emergent adverse events were mild to moderate in severity. Through Week 52, four patients (6.3%) experienced a serious adverse event; none was considered related to study treatment. Two patients (3.2%) discontinued treatment because of UC flare. No deaths, malignancies, opportunistic infections or growth-related safety concerns were reported through Week 52.1
Omvoh has received regulatory approvals for the treatment of moderately to severely active UC and moderately to severely active Crohn's disease in adults and has been approved in 47 countries around the world. In UC, Omvoh is also approved as a single-injection maintenance regimen in several countries around the world including the U.S., EU, Canada and Japan.
Lilly continues to study mirikizumab in pediatric inflammatory bowel disease, including a long-term extension study in UC and Crohn's disease (NCT04844606) and an ongoing Phase 3 study in pediatric Crohn's disease (NCT05509777). Lilly is also evaluating mirikizumab through combination approaches and novel mechanisms aimed at delivering breakthrough induction efficacy while maintaining long-term remission and safety. These include studies in UC with eltrekibart (NCT06598943), a monoclonal antibody that targets neutrophil-driven inflammation, and with zotemtegrast (NCT07186101), an oral α4β7 integrin inhibitor. In Crohn's disease, Lilly is studying mirikizumab in combination with an FXR agonist (NCT07483099). The COMMIT-UC (NCT06937086) and COMMIT-CD (NCT06937099) trials are investigating the concomitant use of mirikizumab and an incretin-based therapy in adults with UC or Crohn's disease and obesity or overweight with at least one additional weight-related comorbid condition.
Disclosure: Dr. Dubinsky is a paid consultant for Lilly. She has not been compensated for any media work.
About SHINE-2
SHINE-2 is a Phase 3, multicenter, single-arm, open-label study evaluating mirikizumab in pediatric patients with moderately to severely active UC. A total of 63 participants, ages 4 to 17, were enrolled and received weight-based intravenous induction every four weeks for three doses (300 mg for patients >40 kg; 5 mg/kg for patients ≤40 kg). At Week 12, 52 patients entered the maintenance period as clinical responders and received weight-based subcutaneous mirikizumab every four weeks through Week 52. The primary endpoint was evaluated against a pre-specified benchmark derived from the adult placebo remission rate in the Phase 3 LUCENT-2 study.* The Week 52 efficacy results are reported for the Week 12 responder population (N=52; ages 6 to 17); safety results are based on all enrolled patients (N=63).
Patients completing SHINE-2 may be eligible to continue in SHINE-ON, an ongoing long-term extension study evaluating mirikizumab in pediatric patients with UC or Crohn's disease.
About Omvoh
Omvoh (mirikizumab-mrkz) is an interleukin-23p19 (IL-23p19) antagonist indicated for the treatment of moderately to severely active ulcerative colitis and Crohn's disease in adults. Omvoh selectively targets the p19 subunit of IL-23 and inhibits the IL-23 pathway. Inflammation due to over-activation of the IL-23 pathway plays a critical role in the pathogenesis of inflammatory bowel disease.2 The safety and effectiveness of Omvoh have not been established in pediatric patients.
Omvoh and its delivery device base are trademarks owned by Eli Lilly and Company.
Endnotes and References
*Clinical remission was defined as stool frequency (SF) subscore=0 or 1, rectal bleeding (RB) subscore=0 and endoscopic subscore (ES)=0 or 1 (excluding friability). The primary endpoint was met by exceeding a pre-specified benchmark based on the placebo remission rate in adults from the Phase 3 LUCENT-2 study. The lower bound of the 80% credible interval for the Week 52 pediatric remission rate among Week 12 responders (42.8%) exceeded the upper bound of the 90% credible interval for the adult placebo remission rate in LUCENT-2 (32.6%). Week 52 efficacy was assessed among the 52 patients who entered the maintenance period as Week 12 clinical responders, based on response status recorded by study sites.
†Corticosteroid-free clinical remission without surgery: clinical remission at Week 52 without surgery, and no corticosteroid use for at least 12 weeks prior to Week 52.
‡Clinical response: a decrease in the MMS of ≥2 points and ≥30% decrease from induction baseline plus a decrease of ≥1 point in the RB subscore from induction baseline or an RB subscore of 0 or 1.
¶Symptomatic remission: SF=0, or SF=1 with ≥1-point decrease from baseline and RB=0.
#Endoscopic improvement: ES=0 or 1, excluding friability.
**Endoscopic remission: ES=0.
1Turner D, et al. Mirikizumab, the first IL-23p19 inhibitor to demonstrate sustained efficacy through 1 year in pediatric moderately-to-severely active ulcerative colitis: efficacy and safety findings from SHINE-2. United European Gastroenterology Week 2026; October 19, 2026; Barcelona, Spain.
2Omvoh. Prescribing Information. Lilly USA, LLC.
3Kappelman MD, Brensinger C, Parlett LE, Hurtado-Lorenzo A, Lewis JD. Prevalence of pediatric inflammatory bowel disease in the United States: pooled estimates from three administrative claims data sources. Gastroenterology. 2025;168(5):980-982.e2. doi:10.1053/j.gastro.2024.11.004
4Wine E, Aloi M, Van Biervliet S, et al. Management of paediatric ulcerative colitis, part 1: Ambulatory care— an updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation. J Pediatr Gastroenterol Nutr. 2025;81(3):765-815. doi:0.1002/jpn3.70097
5Dubinsky M, et al. Mirikizumab induction therapy achieves early clinical, endoscopic, and biomarker improvement in children and adolescents with moderately to severely active ulcerative colitis: Week 12 results from the SHINE-2 study. American College of Gastroenterology 2026 Annual Scientific Meeting; October 14, 2026; Nashville, TN.
Indications and Usage for Omvoh® (mirikizumab-mrkz) (in the United States)
Omvoh is an interleukin-23 antagonist indicated for adults with:
Moderately to severely active ulcerative colitis Moderately to severely active Crohn's disease Important Safety Information for Omvoh (mirikizumab-mrkz)
CONTRAINDICATIONS
Omvoh is contraindicated in patients with a history of serious hypersensitivity reaction to mirikizumab-mrkz or any of the excipients.
WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylaxis during intravenous infusion, have been reported with Omvoh administration. Infusion-related hypersensitivity reactions, including mucocutaneous erythema and pruritus, were reported during induction. If a severe hypersensitivity reaction occurs, discontinue Omvoh immediately and initiate appropriate treatment.
Infections
Omvoh may increase the risk of infection. Do not initiate treatment with Omvoh in patients with a clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing Omvoh. Instruct patients to seek medical advice if signs or symptoms of clinically important acute or chronic infection occur. If a serious infection develops or an infection is not responding to standard therapy, monitor the patient closely and do not administer Omvoh until the infection resolves.
Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Omvoh. Do not administer Omvoh to patients with active TB infection. Initiate treatment of latent TB prior to administering Omvoh. Consider anti-TB therapy prior to initiation of Omvoh in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after Omvoh treatment. In clinical trials, subjects were excluded if they had evidence of active TB, a history of active TB, or were diagnosed with latent TB at screening.
Hepatotoxicity
Drug-induced liver injury in conjunction with pruritus was reported in a clinical trial subject following a longer than recommended induction regimen. Omvoh was discontinued. Liver test abnormalities eventually returned to baseline. Evaluate liver enzymes and bilirubin at baseline and for at least 24 weeks of treatment. Monitor thereafter according to routine patient management. Consider other treatment options in patients with evidence of liver cirrhosis. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. Interrupt treatment if drug-induced liver injury is suspected, until this diagnosis is excluded. Instruct patients to seek immediate medical attention if they experience symptoms suggestive of hepatic dysfunction.
Immunizations
Avoid use of live vaccines in patients treated with Omvoh. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating therapy, complete all age-appropriate vaccinations according to current immunization guidelines. No data are available on the response to live or non-live vaccines in patients treated with Omvoh.
ADVERSE REACTIONS
Most common adverse reactions associated with Omvoh (≥2% of subjects and at a higher frequency than placebo) in ulcerative colitis treatment are upper respiratory tract infections and arthralgia during the induction study (UC-1), and upper respiratory tract infections, injection site reactions, arthralgia, rash, headache, and herpes viral infection during the maintenance study (UC-2). Most common adverse reactions associated with Omvoh in the Crohn's disease study (CD-1) (≥5% of subjects and at a higher frequency than placebo) are upper respiratory tract infections, injection site reactions, headache, arthralgia, and elevated liver tests.
Omvoh injection is available as a 300 mg/15 mL solution in a single-dose vial for intravenous infusion, and as a 100 mg/mL solution or a 200 mg/2 mL solution in a single dose prefilled pen or prefilled syringe for subcutaneous injection. Refer to the Prescribing Information for dosing information.
MR HCP ISI CD APP
Click to access provided Prescribing Information and Medication Guide. See Instructions for Use provided with the device.
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY
Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Omvoh (mirikizumab-mrkz) as a treatment for people with moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Among other things, there is no guarantee that future study results will be consistent with the results to date, or that Lilly will execute its strategies as planned. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.
IFP Advisors Inc grew its stake in shares of Texas Instruments Incorporated (NASDAQ:TXN – Free Report) by 32.9% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 21,256 shares of the semiconductor company’s stock after purchasing an additional 5,263 shares during the quarter. IFP Advisors Inc’s holdings in Texas Instruments were worth $5,954,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in TXN. HBW Advisory Services LLC increased its position in shares of Texas Instruments by 2.2% in the 1st quarter. HBW Advisory Services LLC now owns 1,730 shares of the semiconductor company’s stock valued at $336,000 after purchasing an additional 37 shares during the last quarter. Montz Harcus Wealth Management LLC raised its holdings in shares of Texas Instruments by 2.9% in the 1st quarter. Montz Harcus Wealth Management LLC now owns 1,338 shares of the semiconductor company’s stock valued at $260,000 after purchasing an additional 38 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt lifted its position in shares of Texas Instruments by 0.6% during the 1st quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 5,960 shares of the semiconductor company’s stock worth $1,157,000 after purchasing an additional 38 shares during the last quarter. Moody National Bank Trust Division lifted its position in shares of Texas Instruments by 0.6% during the 3rd quarter. Moody National Bank Trust Division now owns 6,063 shares of the semiconductor company’s stock worth $1,698,000 after purchasing an additional 39 shares during the last quarter. Finally, McGlone Suttner Wealth Management Inc. lifted its position in shares of Texas Instruments by 3.3% during the 3rd quarter. McGlone Suttner Wealth Management Inc. now owns 1,299 shares of the semiconductor company’s stock worth $364,000 after purchasing an additional 41 shares during the last quarter. Institutional investors own 84.99% of the company’s stock.
Wall Street Analysts Forecast Growth
TXN has been the subject of a number of analyst reports. Zacks Research downgraded shares of Texas Instruments from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 21st. Mizuho raised their price target on Texas Instruments from $300.00 to $305.00 and gave the company a “neutral” rating in a research note on Thursday, July 23rd. UBS Group reaffirmed a “buy” rating and set a $380.00 price target (up from $350.00) on shares of Texas Instruments in a report on Thursday, July 23rd. Stifel Nicolaus upped their price objective on Texas Instruments from $340.00 to $360.00 and gave the stock a “buy” rating in a research report on Wednesday, June 24th. Finally, TD Cowen lowered their price objective on Texas Instruments from $360.00 to $340.00 and set a “buy” rating for the company in a research report on Thursday, July 23rd. Sixteen investment analysts have rated the stock with a Buy rating, ten have issued a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $304.26.
View Our Latest Report on Texas Instruments
Insider Activity
In related news, VP Tsedeniya Abraham sold 7,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 27th. The stock was sold at an average price of $264.63, for a total transaction of $1,852,410.00. Following the transaction, the vice president owned 23,181 shares in the company, valued at $6,134,388.03. This trade represents a 23.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 0.60% of the stock is currently owned by company insiders.
Key Headlines Impacting Texas Instruments
Here are the key news stories impacting Texas Instruments this week:
Positive Sentiment: Texas Instruments’ history of exceeding earnings expectations, combined with favorable current earnings-estimate trends, has increased the possibility of another quarterly beat. Investors are also watching operating metrics beyond revenue and earnings per share for evidence of sustained demand. Will Texas Instruments Beat Estimates Again in Its Next Earnings Report?
Positive Sentiment: Analysts expect strength in Texas Instruments’ analog and embedded-processing businesses to support third-quarter results, reflecting demand from industrial, automotive and data-center markets. TXN to Report Q3 Earnings: Should You Buy, Hold or Sell the Stock?
Positive Sentiment: The board declared a fourth-quarter cash dividend of $1.52 per share, payable Nov. 10 to shareholders of record Oct. 30. The announcement reinforces TXN’s shareholder-return profile and may provide some support for income-focused investors. Texas Instruments Board Declares Fourth Quarter 2026 Quarterly Dividend
Positive Sentiment: Exchange-traded funds purchased approximately $113.2 million of TXN stock on Oct. 13, indicating institutional or index-related buying interest. ETFs Bought $113.2 Million of Texas Instruments
Neutral Sentiment: Wall Street’s third-quarter preview emphasizes key indicators such as segment performance, margins and demand trends. These metrics could be more important for TXN’s valuation than simply meeting consensus revenue and EPS estimates. Texas Instruments Q3 Earnings Key Metrics
Negative Sentiment: Geopolitical tensions remain a risk to semiconductor supply chains and international demand. In addition, TXN’s elevated valuation leaves less room for disappointment if its earnings outlook or margins fall short of expectations. TXN Q3 Earnings Investment Outlook
Texas Instruments Price Performance
Shares of TXN opened at $276.48 on Monday. The company has a debt-to-equity ratio of 0.72, a current ratio of 4.86 and a quick ratio of 3.44. Texas Instruments Incorporated has a 1-year low of $152.73 and a 1-year high of $334.03. The stock has a market cap of $252.50 billion, a PE ratio of 42.08, a price-to-earnings-growth ratio of 1.54 and a beta of 1.35. The firm has a fifty day moving average price of $271.75 and a 200 day moving average price of $277.05.
Texas Instruments (NASDAQ:TXN – Get Free Report) last issued its quarterly earnings data on Wednesday, July 22nd. The semiconductor company reported $2.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.91 by $0.23. Texas Instruments had a return on equity of 35.77% and a net margin of 31.11%. The company had revenue of $5.46 billion for the quarter, compared to analyst estimates of $5.26 billion. During the same quarter last year, the company posted $1.41 earnings per share. The business’s quarterly revenue was up 22.8% compared to the same quarter last year. Texas Instruments has set its Q3 2026 guidance at 2.230-2.570 EPS. As a group, sell-side analysts anticipate that Texas Instruments Incorporated will post 8.48 EPS for the current year.
Texas Instruments Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Tuesday, November 10th. Investors of record on Friday, October 30th will be given a $1.52 dividend. This is a boost from Texas Instruments’s previous quarterly dividend of $1.42. The ex-dividend date of this dividend is Friday, October 30th. This represents a $6.08 dividend on an annualized basis and a dividend yield of 2.2%. Texas Instruments’s payout ratio is currently 86.45%.
Texas Instruments Profile
(Free Report)
Texas Instruments Incorporated (NASDAQ:TXN) designs and manufactures analog and embedded semiconductor products used in industrial, automotive, personal electronics, communications equipment, and enterprise systems. Its analog products help manage power, sense and measure real-world signals, and support signal processing, while its embedded processing products provide computing and control functions within electronic systems.
The company offers a broad portfolio of semiconductors, including power-management devices, amplifiers, data converters, microcontrollers, processors, and connectivity products.
Recommended Stories
Five stocks we like better than Texas Instruments
These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington
Meta Claims Frontier-Class AI Status With New Muse Wonder Models
Berkshire Just Backed This Little-Known Stock—Should You Chase It?
Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom
Want to see what other hedge funds are holding TXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Texas Instruments Incorporated (NASDAQ:TXN – Free Report).
Receive News & Ratings for Texas Instruments Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Texas Instruments and related companies with MarketBeat.com's FREE daily email newsletter.
Cyndeo Wealth Partners ve třetím čtvrtletí snížila svůj podíl ve společnosti Intuit o 88,2 % prodejem 7 913 akcií; ponechala si 1 061 akcií v hodnotě 293 000 USD.
Cyndeo Wealth Partners LLC lessened its stake in Intuit Inc. (NASDAQ:INTU – Free Report) by 88.2% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,061 shares of the software maker’s stock after selling 7,913 shares during the period. Cyndeo Wealth Partners LLC’s holdings in Intuit were worth $293,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other institutional investors and hedge funds also recently added to or reduced their stakes in INTU. Fiduciary Financial Advisors purchased a new stake in shares of Intuit during the second quarter valued at about $25,000. Sankala Group LLC purchased a new position in shares of Intuit in the 4th quarter worth approximately $40,000. Whipplewood Advisors LLC purchased a new position in shares of Intuit in the 1st quarter worth approximately $30,000. HHM Wealth Advisors LLC grew its position in shares of Intuit by 75.0% in the 1st quarter. HHM Wealth Advisors LLC now owns 70 shares of the software maker’s stock worth $30,000 after buying an additional 30 shares during the last quarter. Finally, CrossGen Wealth LLC bought a new position in shares of Intuit during the 1st quarter worth approximately $32,000. Hedge funds and other institutional investors own 83.66% of the company’s stock.
Wall Street Analyst Weigh In INTU has been the subject of a number of analyst reports. JPMorgan Chase & Co. cut shares of Intuit from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $605.00 to $331.00 in a research report on Wednesday, August 26th. Citigroup lowered their target price on shares of Intuit from $591.00 to $457.00 and set a “buy” rating for the company in a research note on Thursday, August 13th. UBS Group reaffirmed a “neutral” rating on shares of Intuit in a report on Friday, September 18th. The Goldman Sachs Group reaffirmed a “sell” rating on shares of Intuit in a research report on Thursday, September 24th. Finally, Wolfe Research lowered Intuit from an “outperform” rating to a “peer perform” rating in a report on Wednesday, August 26th. Sixteen research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the stock. According to data from MarketBeat, Intuit presently has a consensus rating of “Hold” and a consensus price target of $431.55.
View Our Latest Stock Report on Intuit Intuit Price Performance Shares of NASDAQ INTU opened at $325.15 on Monday. Intuit Inc. has a fifty-two week low of $252.84 and a fifty-two week high of $689.17. The company has a market cap of $86.89 billion, a PE ratio of 19.71, a P/E/G ratio of 0.95 and a beta of 1.01. The company has a debt-to-equity ratio of 0.34, a quick ratio of 1.51 and a current ratio of 1.51. The business has a 50-day simple moving average of $321.16 and a two-hundred day simple moving average of $327.91.
Intuit (NASDAQ:INTU – Get Free Report) last posted its quarterly earnings data on Tuesday, August 25th. The software maker reported $4.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.58 by $0.45. The firm had revenue of $4.35 billion for the quarter, compared to the consensus estimate of $4.27 billion. Intuit had a net margin of 21.29% and a return on equity of 25.97%. The company’s revenue for the quarter was up 13.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.75 earnings per share. Intuit has set its Q1 2027 guidance at 2.440-2.480 EPS and its FY 2027 guidance at 22.880-23.120 EPS. As a group, equities analysts expect that Intuit Inc. will post 23.02 EPS for the current fiscal year.
Intuit Increases Dividend The business also recently declared a quarterly dividend, which was paid on Friday, October 16th. Shareholders of record on Thursday, October 8th were paid a dividend of $1.38 per share. This represents a $5.52 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date was Thursday, October 8th. This is a positive change from Intuit’s previous quarterly dividend of $1.20. Intuit’s dividend payout ratio (DPR) is currently 33.45%.
Trending Headlines about Intuit Here are the key news stories impacting Intuit this week:
Positive Sentiment: Sequence acquisition expands AI and mid-market capabilities. Intuit agreed to acquire Sequence, a Series A company whose platform automates complex quote-to-revenue workflows, including pricing, contracts, invoicing, collections and revenue recognition. Investors viewed the transaction as a strategic expansion of Intuit Enterprise Suite and QuickBooks Online Advanced into larger and more sophisticated businesses. Financial terms were not disclosed. Intuit to Acquire AI-Native Revenue Management Platform Sequence Positive Sentiment: Intuit Intelligence is now available internationally. The wider rollout of Intuit’s AI platform across international markets could increase adoption of its unified ecosystem, including QuickBooks, TurboTax, Credit Karma, Mailchimp and Intuit Enterprise Suite. The announcement reinforces management’s broader effort to use AI to drive customer productivity and cross-selling. Intuit Intelligence Now Available Internationally Positive Sentiment: Fundamentals provide support. Intuit’s latest reported quarter exceeded revenue and earnings expectations, with revenue increasing 13.7% year over year. The company also issued fiscal 2027 EPS guidance of $22.88–$23.12, helping underpin the longer-term growth narrative. Neutral Sentiment: Investor attention is high, but the Zacks reports add little new information. Multiple articles primarily note that INTU is among the most-searched stocks, suggesting elevated interest following the Sequence announcement rather than identifying a separate fundamental catalyst. Intuit Is Attracting Investor Attention Negative Sentiment: Volatility and mixed ownership signals remain risks. The stock has suffered a substantial 12-month decline, while reported institutional activity shows both large purchases and sizable reductions. Recent insider trading has also been weighted toward sales, potentially limiting enthusiasm after the acquisition-driven rally. Insider Buying and Selling In other Intuit news, Director Richard Dalzell sold 285 shares of the company’s stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $325.36, for a total transaction of $92,727.60. Following the transaction, the director owned 11,531 shares in the company, valued at approximately $3,751,726.16. This represents a 2.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Lauren Hotz sold 907 shares of the firm’s stock in a transaction on Thursday, August 27th. The stock was sold at an average price of $346.54, for a total transaction of $314,311.78. Following the completion of the transaction, the chief accounting officer directly owned 1,628 shares of the company’s stock, valued at approximately $564,167.12. This represents a 35.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 2.49% of the company’s stock.
About Intuit (Free Report)
Intuit Inc is a global financial technology and business software company that develops products designed to help consumers, small businesses and accounting professionals manage finances, taxes and marketing. Its ecosystem combines financial management, tax preparation, accounting, payments and customer relationship tools.
The company’s principal products include TurboTax for tax preparation, QuickBooks for accounting, invoicing, payroll and payments, Credit Karma for personal financial services, and Mailchimp for marketing automation and customer engagement.
Featured Stories Five stocks we like better than Intuit These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington Meta Claims Frontier-Class AI Status With New Muse Wonder Models Berkshire Just Backed This Little-Known Stock—Should You Chase It? Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom
Receive News & Ratings for Intuit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intuit and related companies with MarketBeat.com's FREE daily email newsletter.
Robertson Stephens Wealth Management ve třetím čtvrtletí zvýšila svůj podíl ve společnosti Cummins Inc. o 512 % na 4 217 akcií v hodnotě 2,178 mil. USD.
Robertson Stephens Wealth Management LLC increased its stake in Cummins Inc. (NYSE:CMI – Free Report) by 512.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,217 shares of the company’s stock after acquiring an additional 3,528 shares during the quarter. Robertson Stephens Wealth Management LLC’s holdings in Cummins were worth $2,178,000 at the end of the most recent reporting period.
Several other institutional investors have also added to or reduced their stakes in CMI. Persistent Asset Partners Ltd bought a new position in Cummins during the 2nd quarter worth approximately $26,000. Elevation Wealth Partners LLC lifted its position in shares of Cummins by 91.7% in the 2nd quarter. Elevation Wealth Partners LLC now owns 46 shares of the company’s stock worth $33,000 after purchasing an additional 22 shares during the period. Cedar Mountain Advisors LLC boosted its stake in shares of Cummins by 1,500.0% in the 1st quarter. Cedar Mountain Advisors LLC now owns 48 shares of the company’s stock valued at $26,000 after purchasing an additional 45 shares during the last quarter. Key Financial Inc boosted its stake in shares of Cummins by 62.5% in the 1st quarter. Key Financial Inc now owns 52 shares of the company’s stock valued at $28,000 after purchasing an additional 20 shares during the last quarter. Finally, Cornerstone Financial Management LLC boosted its stake in shares of Cummins by 65.8% in the 2nd quarter. Cornerstone Financial Management LLC now owns 63 shares of the company’s stock valued at $45,000 after purchasing an additional 25 shares during the last quarter. 83.46% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
CMI has been the subject of several recent analyst reports. JPMorgan Chase & Co. decreased their price objective on shares of Cummins from $690.00 to $600.00 and set a “neutral” rating for the company in a research report on Wednesday, September 23rd. Weiss Ratings lowered shares of Cummins from a “buy (b)” rating to a “buy (b-)” rating in a report on Monday, August 31st. Morgan Stanley upped their price target on shares of Cummins from $752.00 to $761.00 and gave the company an “overweight” rating in a research report on Friday, July 17th. DA Davidson increased their price target on Cummins from $605.00 to $750.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Truist Financial lowered their price objective on Cummins from $894.00 to $779.00 and set a “buy” rating for the company in a research report on Monday, October 5th. Thirteen investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, Cummins presently has a consensus rating of “Moderate Buy” and a consensus target price of $708.18.
Get Our Latest Stock Report on Cummins
Insider Activity
In other Cummins news, VP Earl Newsome sold 698 shares of the business’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $572.22, for a total transaction of $399,409.56. Following the completion of the sale, the vice president owned 4,479 shares in the company, valued at approximately $2,562,973.38. The trade was a 13.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 0.30% of the stock is currently owned by corporate insiders.
Cummins Stock Down 0.1%
CMI stock opened at $530.72 on Monday. The stock’s 50 day simple moving average is $555.86 and its 200 day simple moving average is $620.62. Cummins Inc. has a fifty-two week low of $405.82 and a fifty-two week high of $737.76. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.13 and a current ratio of 1.73. The company has a market cap of $73.06 billion, a P/E ratio of 27.12, a price-to-earnings-growth ratio of 1.40 and a beta of 1.24.
Cummins (NYSE:CMI – Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $6.73 EPS for the quarter, missing analysts’ consensus estimates of $7.21 by ($0.48). The firm had revenue of $9.46 billion during the quarter, compared to analyst estimates of $9.33 billion. Cummins had a net margin of 7.82% and a return on equity of 25.29%. The company’s revenue was up 9.4% on a year-over-year basis. During the same period last year, the business posted $6.43 EPS. On average, research analysts expect that Cummins Inc. will post 29.98 earnings per share for the current fiscal year.
Cummins Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Investors of record on Friday, November 20th will be issued a $2.20 dividend. This represents a $8.80 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date is Friday, November 20th. Cummins’s dividend payout ratio (DPR) is currently 44.97%.
Cummins Company Profile
(Free Report)
Cummins Inc is a global power technology company headquartered in Columbus, Indiana. Founded in 1919, the company designs, manufactures, sells and services engines and power systems for commercial vehicles, industrial equipment, mining, construction, agriculture, marine applications and other markets.
Cummins’ product portfolio includes diesel and natural gas engines, generators and other power-generation equipment, as well as fuel systems, filtration products, emissions-control systems, turbochargers and drivetrain components.
Read More
Five stocks we like better than Cummins
These 3 Green Stocks Have a Growth Story That Goes Far Beyond Washington
Meta Claims Frontier-Class AI Status With New Muse Wonder Models
Berkshire Just Backed This Little-Known Stock—Should You Chase It?
Broadcom’s CEO Sees Years of AI Demand But Warns of a Bigger Threat to the Boom
Want to see what other hedge funds are holding CMI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cummins Inc. (NYSE:CMI – Free Report).
Receive News & Ratings for Cummins Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cummins and related companies with MarketBeat.com's FREE daily email newsletter.
Berkshire Hathaway od července 2024 prodala více než 549 milionů akcií Bank of America, ale růst sazeb a ocenění s 30% prémií k účetní hodnotě mohou další odprodeje omezit.
For the first time in well over half a century, Berkshire Hathaway (BRKA +1.08%)(BRKB +1.21%) entered the year in uncharted territory. On Dec. 31, Warren Buffett retired as CEO, paving the way for his protégé, Greg Abel, to oversee the company's day-to-day operations and its closely watched $363 billion investment portfolio.
Abel didn't waste much time making his mark. He disposed of 16 stocks in the first quarter and pared down six others, including one of the Oracle of Omaha's core holdings, Bank of America (BAC -0.91%)(also known as BofA).
Warren Buffett has officially passed the baton to Greg Abel. Image source: Getty Images.
In the six quarters leading up to Buffett's retirement, he was a persistent seller of BofA stock. This pattern has continued through Abel's first two quarters as CEO, with Buffett and Abel collectively selling more than 549 million shares since July 2024, or 53% of what had been a 1.03-billion-share position.
The writing looked to be on the wall that Bank of America would get the heave-ho -- but that may not be the case any longer.
Buffett and Abel collectively sold over 549 million shares of Bank of AmericaAs recently as a few months ago, there were three reasons to believe that BofA's time as a prominent Berkshire Hathaway holding would come to an end.
BAC Bank of America$51.23-$0.47 (-0.91%)
NYSE · As of 4:00 PM ET 10/16/26
Firstly, Buffett and Abel have always been sticklers for value. When the Oracle of Omaha first invested in BofA's preferred stock in August 2011, its common stock was trading at a 62% discount to book value. As recently as August, BofA peaked at a 65% premium to book value.
Secondly, Bank of America is the most interest-sensitive of the country's money-center banks. With the Federal Reserve lowering rates six times between September 2024 and December 2025, no large bank was at greater risk of its net interest income shrinking than BofA.
Third and finally, Greg Abel's first annual letter to shareholders excluded Bank of America in his discussion of companies that can compound over multiple decades.
The writing looked to be on the wall that Bank of America would soon get the heave-ho.
Image source: Getty Images.
Greg Abel's tune on Bank of America may have changedWhile additional selling is possible, several catalysts that had made Bank of America stock less attractive have reversed course.
For example, Bank of America's ongoing profitability and prudent lending have allowed its book value per share to steadily rise. When coupled with the recent pullback in BofA's share price, the company's stock is now trading at only a 30% premium to book value following its third-quarter operating results. BofA may not be a screaming bargain like it was in August 2011, but it remains attractive at just a 30% premium to book.
BAC Price to Book Value data by YCharts.
Additionally, the central bank kicked off only its fourth rate-hiking cycle of the century on Sept. 16. According to the CME Group's (CME +1.52%) FedWatch Tool, the odds are incredibly high that the Fed will implement several rate hikes over the next year. As the most interest-sensitive large U.S. bank, BofA's net interest income should benefit.
The narrative surrounding Bank of America appears to be changing, making it less likely that Warren Buffett's successor sends it to the chopping block.
Berkshire Hathaway drží rekordních 369 miliard USD v hotovosti, protože akcie velkých společností se obchodují 10 až 19 % nad svými historickými průměry ocenění.
Greg Abel finally broke a 14-quarter streak for Berkshire Hathaway (BRKA +1.08%) (BRKB +1.21%) last quarter, when he purchased more stocks for the company's marketable equity portfolio than he sold. Before Abel took over as CEO, Warren Buffett spent the last three years trimming and selling off huge positions in Berkshire's portfolio, ultimately leaving Abel with a record $369 billion in cash available to deploy.
There's a good reason Buffett struggled to find good investments. There just wasn't a lot of value in the market available to him. Even today, Abel struggles to find ways to deploy a significant portion of Berkshire's cash. While he's made a splash by adding tens of billions to the Alphabet position Buffett initiated last year, other investments have remained relatively small.
A single table explains exactly why Berkshire has struggled to find attractive opportunities in today's market, but it also highlights the opportunity for investors like you and me to find great value.
Image source: Getty Images.
This table explains exactly where to find value in today's market
The following table shows the P/E ratio of various segments of the market relative to their 20-year historic P/E ratios.
ValueBlendGrowthLarge-Cap119%115.8%110%Mid-Cap96.7%96.9%119.9%Small-Cap91%103.6%134.8%
Data source: J.P.Morgan Asset Management.
The table above shows that large-cap stocks trade at an average premium of 10% to 19% relative to their historical valuations. Value stocks have become the most overvalued relative to their historic trading range. That's a problem for a value investor like Buffett, Abel, or Berkshire Hathaway's other investment manager, Ted Weschler. Large-cap stocks are practically the only way for Berkshire to deploy significant capital. And if the average stock is trading above its historic average, there aren't going to be very many stocks trading at an attractive value.
Buffett summed up the problem in a single sentence in his 2023 letter to shareholders. "There remain only a handful of companies in this country capable of truly moving the needle at Berkshire, and they have been endlessly picked over by us and by others." Not only is Berkshire's investable universe small, but it's also well-followed, which makes it less likely that Berkshire will discover anything the market has overlooked.
$532.02+$6.34 (+1.21%)
NYSE · As of 4:00 PM ET 10/16/26
But if you look further down the table on the left side, you'll find that small- and mid-cap value stocks are trading below their historic valuations. That's exactly where you should be looking for attractive value stocks. Large institutional investors are effectively unable to invest in smaller stocks because it's simply not worth the time to analyze a company just to invest a few million dollars for them when they're managing billions. But small retail investors can probably invest as much as they want in any publicly traded stock.
How to find great value stocks
Focusing on the portion of the market that much larger institutional investors often ignore can help find more mispriced companies and better values.
Investors can easily screen for businesses with consistent profits, growing free cash flow, and manageable debt levels trading at an attractive valuation. Take the top names and do your due diligence to determine whether a company has a durable competitive moat and if there's a reason the market is offering a discount on the stock.
If you don't understand exactly how a business makes money, there's no shame in putting it in the "too hard" pile. As Buffett said, "Investors should remember that their scorecard is not computed using Olympic-diving methods: Degree-of-difficulty doesn't count."
Investors who don't want to do the homework can buy an ETF that invests in the attractive market segment. For those focused exclusively on small-cap value stocks, the Avantis US Small Cap Value ETF (AVUV -0.30%) is a favorite. It doesn't just filter by valuation; it also uses profitability metrics and book value as additional checks to weed out value traps.
AVUV American Century ETF Trust - Avantis U.s. Small Cap Value ETF$120.08-$0.36 (-0.30%)
NYSEMKT · As of 4:00 PM ET 10/16/26
The Dimensional US Targeted Value ETF (DFAT -0.17%) includes both small- and mid-cap value stocks. It also avoids companies with poor profitability to keep value traps out of the portfolio. As an actively managed ETF, it also empowers its traders to substitute stocks within its investable universe for one another to reduce transaction costs and potential tax consequences.
Either is a great option for investors looking to add exposure to the historically undervalued portion of the market, where big investors like Berkshire Hathaway don't spend much time.
New York, New York--(Newsfile Corp. - October 19, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Hims & Hers Health, Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) on behalf of investors that purchased or otherwise acquired Hims & Hers securities between August 4, 2025 and July 29, 2026 (the "Class Period").
CLICK HERE TO JOIN THE CASE
If you are an investor in Hims & Hers and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (646) 315-9003.
DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than November 2, 2026 for an opportunity to be lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery.
On July 29, 2026, the Federal Trade Commission ("FTC"), the People of the State of California through Los Angeles County Counsel and the Utah Division of Consumer Protection sued Hims & Hers in the Northern District of California. According to the FTC, the action alleges that Hims & Hers fails to clearly disclose that it charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them." The FTC also alleges that the company has made it difficult for consumers to cancel subscriptions and misled consumers about keeping their health information private. The FTC alleges that Hims shared consumers' health information with Meta, Snap and other third parties.
Following this news, the price of Hims & Hers stock fell $4.32 per share, or 14.73%, to close at $25.00 per share on July 29, 2026.
Based on the FTC allegations, the complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts to investors, including that (1) the Company shared consumers' health information with third-party advertising platforms; (2) the Company charges consumers for prescriptions almost immediately after they submit an intake form, despite telling consumers that they will be able to consult with a medical provider to find a treatment that is "right for them;" (3) the foregoing conduct subjected the Company to regulatory scrutiny; (4) as a result of the foregoing, the Company was reasonably likely to incur fees and penalties; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
CLICK HERE TO LEARN MORE
WHY CONTACT KAPLAN FOX?
Kaplan Fox & Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.
Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in In re Bank of America-the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act-$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in ATRS v. Allianz Global Investors, and a $475 million settlement in In re Merrill Lynch.
For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.
If you have any questions about this Notice, your rights, or your interests, please contact:
Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
Akcie Nebius v říjnu klesly o 30 %, přesto firma musí ve druhém pololetí dosáhnout tržeb ve výši zhruba 2 mld. USD, aby splnila dolní hranici celoročního výhledu.
On June 18, Nebius Group (NBIS -12.18%) stock ended the day at $286.69, a record. Right now, shares trade around $165 -- about 40% lower. Most of that drop is recent, with the stock falling about 30% in October alone.
Sure, it's still been a great year for anybody who bought the artificial intelligence (AI) cloud provider's stock in January. Even after the slide, the stock has nearly doubled this year.
But the stock arguably isn't cheap enough yet. Nebius is calling for a sharp gain in revenue in the next two quarters, and I think the price already assumes it gets there.
Image source: The Motley Fool.
No company news explains the dropNebius itself hasn't given investors much new to worry about. Its October announcements included a small software acquisition and a developer-training program. And the company hasn't changed its forecast since it reaffirmed its 2026 guidance with its second-quarter report in August.
Instead, the selling looks broader. Fellow AI cloud provider CoreWeave has dropped about as much as Nebius in October, as investors seem to have soured on companies that rent out AI computing power. I can't pin down a single reason.
Put another way, the price has changed far more than the business has over the last few weeks.
Can the second half deliver?Nebius' growth has been remarkable. Revenue climbed from around $228 million in the last three months of 2025 to $399 million in the first quarter of 2026, then $582 million in the second quarter, up 454% year over year. Compared to the previous quarter, growth slowed from 75% to 46%. But every quarter still added over $170 million in revenue. Annualized run-rate revenue (the last month of the quarter's AI cloud revenue, times 12) rose from $1.9 billion in March to $3.0 billion in June.
Management, though, is calling for a much steeper climb. Nebius expects revenue of $3.0 billion to $3.4 billion for 2026, and year-end annualized run-rate revenue of $7 billion to $9 billion.
With $981 million of revenue in the first half, reaching even the bottom of that range means taking in around $2 billion in the second half, more than twice the first half's total. Put differently, Nebius has to average about $1 billion a quarter, or about 75% more than it took in during the second quarter.
If it just kept adding revenue at its second-quarter rate, full-year revenue might be closer to $2.7 billion.
Management expects new capacity to bridge that gap. On the August earnings call, chief financial officer Dado Alonso said Nebius expects "capacity deployed late in Q2 to begin contributing to revenue in Q3."
The third-quarter report should show if it does.
Meanwhile, building that capacity is expensive. Capital expenditures were around $5.7 billion in the second quarter alone. And Nebius swung to a net loss from continuing operations of around $190 million, since a big investment gain from a year earlier didn't repeat.
The price still assumes a lotNebius often points to more than $40 billion in customer commitments. The amount in its financial statements is a little lower. Remaining performance obligations (signed contract revenue it hasn't recognized yet) were around $37.5 billion on June 30, and Nebius expects just 36% of that to become revenue over the two years through June 2028. That total was up from about $33.6 billion at the end of March.
Plus, revenue is concentrated. Three customers made up 24%, 21%, and 14% of second-quarter revenue, or 59% combined, though Nebius labels them just by letter. The only investment-grade clients it names, Microsoft and Meta Platforms, have each signed deals worth over $10 billion.
At around $47 billion, Nebius trades at about 15 times the sales it expects this year, using the midpoint of its forecast. At the June peak, it was closer to 24 times sales.
NBIS Nebius Group$165.47-$22.94 (-12.18%)
NASDAQ · As of 4:00 PM ET 10/16/26
True, that multiple has fallen a lot. But around 15 times sales is still pricey for a company that lost money in the second quarter and is spending heavily to add capacity.
Is a 40% drop enough to make Nebius a buy? Not yet, in my view. The company is growing exceptionally fast. But at this price, I'd want to see the second-half ramp show up in the results before buying.
What would change my mind is a third-quarter report showing revenue heading toward $1 billion a quarter, plus backlog growth from customers besides Microsoft and Meta. A lower stock price would help, too.
Natera představí na kongresu ESMO 20 abstraktů; její test Signatera Genome dosáhl analytického limitu detekce nižšího než jedna částice na milion a detekce byla pozorována výrazně pod jednou částicí na 10 milionů.
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 20 abstracts featuring its technology will be presented at the 2026 European Society for Medical Oncology (ESMO) Annual Congress, taking place October 23–26 in Madrid, Spain.
New evidence highlights the power of Natera’s latest ultrasensitive molecular residual disease (MRD) technology, Signatera Genome with Phased and Structural Variants, which has demonstrated an industry-leading analytical limit of detection (LOD95) below 1 part per million (ppm), and detection observed significantly below 1 part per 10 million.1
Spanning tumor types and treatment modalities, multiple ESMO presentations will show that serial ctDNA testing provides meaningful clinical benefit:
ICONIC trial in gastroesophageal cancer (abstract 2901P): Among patients treated with perioperative chemotherapy and immunotherapy, MRD clearance during neoadjuvant therapy was strongly associated with a lower risk of recurrence and a favorable pathologic response. Signatera Genome with Phased and Structural Variants detected all evaluable recurrences during surveillance, with a >7.3 month median lead time over standard imaging.SAGITTARIUS trial in colon cancer (abstract 808P): In this phase III trial, post-operative patients were randomized to a physician-choice adjuvant treatment plan prior to receiving MRD results to assess impact. The analysis showed that Signatera results influenced a change to providers’ pre-planned treatment for one in three patients, of which 87% were treatment de-escalated based on MRD negativity.Colorectal/Breast cancer (abstract 4258P): In a retrospective analysis of surveillance monitoring of stage I-III breast and colorectal cancer survivors, serial Signatera negativity was associated with an extremely low 2-year recurrence risk, which may help refine risk stratification and inform eligibility for solid organ transplant earlier than current methodologies.Breast cancer (abstract 1770RO): In HER2+ metastatic breast cancer, an analysis of exceptional responders on anti-HER2 therapy showed 81% with sustained MRD-negativity during serial monitoring, supporting the potential for Signatera-guided de-escalation.MDT-Bridge trial in non-small cell lung cancer (NSCLC) (abstract LBA62): This phase II trial evaluated MRD clearance from baseline to pre-surgery/pre-CRT using the Clarity™ assay with phased variant technology.MRD-guided reflex to liquid CGP drives actionable treatment decisions (abstract 4260P): In a cohort of 50 patients across 10 tumor types, Signatera, complemented by reflex to blood-based comprehensive genomic profiling (liquid CGP), identified clinically relevant biomarkers in 18 patients, including ESR1, BRAF, FGFR3, and BRCA2.“We are pleased to share data at ESMO that highlights our expanding diagnostics portfolio, which includes the newest version of our ultrasensitive Signatera Genome test,” said Minetta Liu, M.D., chief medical officer, oncology and early cancer detection, Natera. “The incorporation of phased and structural variants results in the ability to detect ctDNA significantly below 1 part per 10 million and takes MRD sensitivity into a range we haven’t seen before.”
The 2026 ESMO program featuring Natera’s technologies includes:
October 23, 2026, 15:15 CET | Abstract 4258P
Presenter: Hideaki Bando, M.D., Ph.D.
Poster: Circulating tumor DNA (ctDNA)-informed risk prediction in breast (BC) and colorectal cancer (CRC) patients (pts): implications for solid organ transplant (SOT)
October 23, 2026, 15:15 CET | Abstract 4265P
Presenter: Luca Lazzari, Ph.D.
Poster: Genomic alterations and association with post-surgery circulating tumor DNA status in early-stage colon cancer
October 23, 2026, 15:15 CET | Abstract 4764P
Presenter: Yousef Zakharia, M.D.
Poster: Outcomes in patients with muscle-invasive bladder cancer with divergent differentiation or histologic subtypes from NIAGARA
October 23, 2026, 15:15 CET | Abstract 3633P
Presenter: Nicholas Bingham, BS
Poster: Utility of circulating tumor DNA in patients with renal cell carcinoma at increased risk of recurrence after resection
October 23, 2026, 16:15 CET | Abstract 542RO
Presenter: Yukinori Ozaki, M.D., Ph.D.
Rapid Oral: Prognostic impact of postoperative ctDNA surveillance on relapse-free survival and molecular lead time in high-risk breast cancer: JCOG1204A1
October 23, 2026, 15:15 CET | Abstract 4462P
Presenter: Benjamin O. Herzberg, M.D.
Poster: Genomic landscape of the SKI Complex in a large multi-cancer cohort of 260,000 tumors
October 23, 2026, 15:15 CET | Abstract 4276P
Presenter: Nicholas Hornstein, M.D., Ph.D.
Poster: Quantification of circulating tumor DNA (ctDNA) in patients using a multi-cancer, methylation-based assay for tissue-free treatment response monitoring (tf-TRM)
October 23, 2026, 15:15 CET | Abstract 4260P
Presenter: Jason A. Mouabbi, M.D.
Poster: Clinical utility of reflex liquid comprehensive genomic profiling (LCGP) to complement tumor-informed circulating tumor DNA (ctDNA) monitoring in solid tumors
October 23, 2026, 15:15 CET | Abstract 4417P
Presenter: Fizza Mughal, Ph.D.
Poster: Plasma whole-exome sequencing (pWES) reveals somatic landscape and clonal dynamics in metastatic urothelial carcinoma
October 24, 2026, 10:15 CET | Abstract 4741RO
Presenter: Matthew D. Galsky, M.D.
Rapid Oral: Exploratory analysis of molecular subtypes and association with treatment outcomes in patients (pts) with muscle-invasive bladder cancer (MIBC) from NIAGARA
October 24, 2026, 12:00 CET | Abstract 574P
Presenter: Adrianne L. Rolfes, M.D.
Poster: Neoadjuvant anti-PD1 without chemotherapy in early-stage luminal B breast cancer
October 24, 2026, 12:00 CET | Abstract 583P
Presenter: Teck Long King
Poster: ≥4 positive nodes identify a population enriched for ctDNA-guided adjuvant treatment escalation in ER+/HER2- early breast cancer
October 25, 2026, 12:00 CET | Abstract 808P
Presenter: Vicente Alonso-Orduna, M.D.
Poster: ctDNA negativity influences adjuvant treatment decisions: a paired counterfactual analysis from the SAGITTARIUS trial
October 25, 2026 | Abstract 870eP
Presenter: Carlo Federici, Ph.D.
e-Poster: Cost-effectiveness of a dynamic ctDNA-guided adjuvant strategy in stage II-III colon cancer, A SAGITTARIUS model-based analysis
October 25, 2026, 12:00 CET | Abstract 810P
Presenter: Stefano Tamberi, M.D., Ph.D.
Poster: ctDNA-guided adjuvant trials may miss the molecular residual disease (MRD) window: evidence of early attrition during trial allocation
October 25, 2026, 12:00 CET | Abstract 820P
Presenter: Benjamin Weinberg, M.D.
Poster: Leronlimab (LRM) in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) in metastatic colorectal cancer (mCRC): The phase 2 CLOVER study
October 25, 2026, 12:00 CET | Abstract 3542P
Presenter: Torben Van Zijp
Poster: Organ preservation in rectal cancer after neoadjuvant radiotherapy, bevacizumab and atezolizumab: Translational analysis from the TARZAN study
October 25, 2026, 12:00 CET | Abstract 2901P
Presenter: Marco Gerlinger, M.D., FRCP
Poster: Clinical performance of the Signatera Genome assay in patients with localized gastroesophageal adenocarcinomas (GEA) treated with peri-operative FLOT and immunotherapy: ICONIC trial
October 26, 2026, 10:15 CET | Abstract 1770RO
Presenter: Kazuki Nozawa, M.D.
Rapid Oral: Ultra-sensitive MRD assessment in long-term complete responders to anti-HER2 therapy in HER2-positive metastatic breast cancer: Initial results from HER2-CR study
October 26, 2026, 10:15 CET | Abstract LBA62
Presenter: Jonathan Spicer, M.D., Ph.D.
Rapid Oral: ctDNA clearance (CL) during neoadjuvant treatment (neoadj Tx) and its association with outcomes in patients (pts) with resectable/borderline resectable stage IIB–IIIB NSCLC from MDT-BRIDGE
References
William B, Galanina N, Iqbal M, et al. ctDNA-Based MRD as a Dynamic Biomarker for Monitoring Treatment Response and Relapse in Lymphoma. SOHO 2026 Annual Meeting, Houston, TX, September 9-12, 2026.About Natera
Natera is a global leader in cell-free DNA and precision medicine, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard-of-care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are supported by more than 400 peer-reviewed publications that demonstrate excellent performance. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California, and through Foresight Diagnostics, its subsidiary, operates an ISO 27001-certified and CAP-accredited laboratory certified under CLIA in Boulder, Colorado. For more information, visit www.natera.com.
Forward-Looking Statements
All statements other than statements of historical facts contained in this press release are forward-looking statements and are not a representation that Natera’s plans, estimates, or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update the forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and commercialize new product offerings, whether the results of clinical or other studies will support the use of our product offerings, the impact of results of such studies, our expectations of the reliability, accuracy, and performance of our tests, or of the benefits of our tests and product offerings to patients, providers, and payers. Additional risks and uncertainties are discussed in greater detail in "Risk Factors" in Natera’s recent filings on Forms 10-K and 10-Q, and in other filings Natera makes with the SEC from time to time. These documents are available at www.natera.com/investors and www.sec.gov.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261018851261/en/
It's nearly Amazon's (AMZN -1.87%) turn to step up to the earnings podium. The e-commerce and cloud computing mega-giant is scheduled to report third-quarter earnings on Oct. 29, and I think investors have plenty of reasons to be optimistic.
Amazon spent much of 2026 defending its massive investments in artificial intelligence (AI) infrastructure, with capital expenditures expected to reach approximately $220 billion this year. That's an enormous amount of money, even for a company of Amazon's size.
However, the market isn't necessarily impressed by big spending announcements anymore. I've argued that Wall Street is in the "show-me" phase of AI, where investors want evidence that those investments are generating meaningful returns.
Image source: Amazon.
Amazon delivered some of that evidence in July, when its cloud computing business reported outstanding growth and Amazon stock jumped 12% in a single day. If that momentum continues into Q3, I think Amazon stock could soar once again following its upcoming earnings report.
Amazon is giving Wall Street what it wants
Amazon Web Services (AWS) is unquestionably the company's most important generator of profits, even though its online retail operations account for a much larger share of revenue. AWS revenue increased 37% from a year ago to $42.2 billion in the second quarter, its fastest growth in 18 quarters. Operating income jumped to $16.6 billion from $10.2 billion a year earlier.
That's particularly impressive when compared with Amazon's retail operations. Its North America segment generated $116.2 billion in revenue, but only $9.1 billion in operating income.
AWS also reported an annualized revenue run rate exceeding $25 billion for its AI business, while its custom chips business, which includes the Trainium AI processor, reached a similar annualized pace.
Those figures demonstrate that Amazon is doing more than building expensive data centers and hoping customers eventually show up. Companies are already paying for the computing capacity and AI services that AWS provides.
The demand isn't limited to one customer or application. Amazon has announced agreements involving companies such as OpenAI, Anthropic, Pinterest, and Uber Technologies.
That's the kind of evidence investors should be looking for during the show-me phase of AI.
Anthropic gives Amazon another advantage
Amazon's relationship with Anthropic, the developer of the Claude family of AI models, provides another interesting opportunity.
Amazon has invested $13 billion in Anthropic, and the companies have an extensive cloud computing relationship. Anthropic uses AWS infrastructure and Amazon's custom AI chips to support its growing computing requirements.
That arrangement gives Amazon two potential ways to benefit from Anthropic's expansion. First, AWS can generate revenue by supplying computing capacity to Anthropic. Second, Amazon could benefit from an appreciation in the value of its investment in the AI company.
In fact, Amazon's Q2 results included $53.4 billion in non-operating pretax income, primarily attributable to its Anthropic investment. That's an impressive gain, but there's an important distinction. Investment-related accounting gains aren't the same as recurring profits generated by AWS operations.
For that reason, I'll be paying much closer attention to AWS revenue and operating income than to any additional gains associated with Anthropic's valuation. Amazon doesn't need another enormous paper gain to demonstrate that its AI strategy is working. Continued growth in its cloud business would be much more meaningful.
AMZN Amazon$250.00-$4.76 (-1.87%)
NASDAQ · As of 4:00 PM ET 10/16/26
The $220 billion question
Amazon's spending comes with a substantial financial cost. It reported negative free cash flow of $7.6 billion for the 12 months ending June 30, compared with positive free cash flow of $18.2 billion during the preceding 12-month period.
Amazon attributed much of that deterioration to increased spending on property and equipment, primarily related to AI investments.
I think there's a huge difference between spending aggressively without meaningful customer demand and spending aggressively while your most profitable business is expanding at its fastest pace in years. Amazon appears to be in the latter category.
The Q3 report should provide another opportunity to evaluate that argument. Investors will want to see continued AWS revenue growth, healthy operating income, and evidence that demand for AI computing remains strong.
Another strong AWS quarter could go a long way toward addressing those concerns -- and provide the catalyst for a substantial post-earnings rally that I think Amazon will deliver after Oct. 29.
Berkshire Hathaway ve 2. čtvrtletí nakoupila akcie za 23,5 miliardy USD a prodala akcie za 3,7 miliardy USD, čímž se po třech a půl letech stala čistým nákupcem akcií.
In general, I've always found it better to follow someone's actions than their words, and the same holds true with investing. Interestingly, this rule can now be applied to legendary investor Warren Buffett and Berkshire Hathaway (BRKA +1.08%) (BRKB +1.21%).
In an early-May interview with CNBC, when asked whether stock prices were too high, Buffett responded, "Yeah." He said prices for a "lot of things will look very silly," and that he's never seen more people in a gambling mood than now.
Warren Buffett. Image source: Getty Images.
Fast forward five and a half months later, and the S&P 500 index (^GSPC -1.09%) is up 7% between May 1 (7,230.12) and Oct. 15 (7,744.06) since Buffett's interview. However, during that time, despite Buffett's call that the market was overvalued and risk levels were elevated, Berkshire has become more aggressive.
Berkshire and Buffett in a buying mood
In Q2, Berkshire became a net buyer of stocks for the first time in three and a half years. The insurance conglomerate bought roughly $23.5 billion in stocks while selling only around $3.7 billion. Prior to that, the company had been aggressively pairing down several of its top holdings, including Apple and Bank of America.
BRKB Berkshire Hathaway$532.02+$6.34 (+1.21%)
NYSE · As of 4:00 PM ET 10/16/26
At the same time, Berkshire bought back $4.5 billion worth of its own stock in the quarter. Prior to a modest $235 million share repurchase in Q1, it was the first time Berkshire had bought back any stock since 2024.
Berkshire has traditionally only bought back stock when it believes its assets are trading below their intrinsic value. In the past, it used price-to-book (P/B) ratios of 1.1x and 1.2x as guidelines for repurchasing shares, but it eliminated those thresholds in 2018. Berkshire stock currently has a P/B ratio over 1.5x, although it dipped below 1.4x in Q2 when it was buying shares.
Meanwhile, some of the stocks that Berkshire has been buying are also interesting. As of early October, over a quarter of the stocks in the S&P 500 were 40% or more off their highs. However, instead of hunting for bargains among these names, Berkshire has made investments in Alphabet (GOOGL -2.47%) (GOOG -2.32%) and the recent IPO Bending Spoons (BSP -15.60%). Under Buffett, Berkshire took a position in Alphabet toward the end of last year and then added to it significantly in a private placement this year to help fund the company's artificial intelligence (AI) infrastructure investments. Alphabet is now Berkshire's third-largest holding, representing nearly 13% of its equity portfolio.
More recently, the company has taken a stake in Italian company Bending Spoons. Berkshire bought $600 million worth of shares at its IPO in July, and then made another $330 million investment this month during a private placement. Bending Spoons is a leveraged digital technology holding company that buys beaten-down tech companies and works to improve their businesses by cutting costs, improving their technology, and raising prices. The stock trades at a 29-times forward price-to-earnings (P/E) ratio based on 2027 estimates and will carry plenty of debt, so it is not exactly a screaming "bargain" in any traditional sense.
Index
S&P 500 IndexToday's Change
(
-1.09
%)
-84.62
Index Level
7,659.44
Is now a good time to invest?
Whether you're looking to invest in Berkshire stock or the broader market with an S&P 500 exchange-traded fund (ETF), such as the Vanguard S&P 500 ETF (VOO -1.10%), you'll have some pretty heavy exposure to megacap tech. Apple and Alphabet make up nearly 35% of Berkshire's equity portfolio, while large-cap tech stocks account for about 40% of the S&P 500.
Although there is some fear of an AI bubble and some potential red flags (certain backward-looking valuation metrics like the CAPE ratio and funding concerns), there are also signs that the AI boom is still in the early innings (cumulative spending to GDP vs. past historical innovation booms). And valuations based on projected future earnings growth look low (the S&P 500 has one of its lowest PEG (price/earnings-to-growth) ratios ever).
Ultimately, it's nearly impossible to time the market, and time in the market is generally the better path to building wealth. As such, I'd continue to invest and dollar-cost average into stocks and ETFs, without letting valuation fears get in the way. In a way, that is what Berkshire has started to do this year.
SummaryCisco is downgraded to Hold as shares approach fair value after a 46% YTD rally.AI-driven order momentum and robust FY 2026 results underpin strong revenue and earnings guidance into FY 2027.Valuation is no longer compelling, with margin risks from hardware mix and elevated price-to-sales ratios.Technical support near $100-105 offers a potential swing-trade entry; fundamentals suggest patience for long-term investors.Pixelbizz/iStock Editorial via Getty Images
AI winners continue to come off the boil. Shares of Cisco (CSCO) are now down 18% from their June 4 high of $130. Earnings don't hit until mid-November, so price action hinges on what AI hyperscalers report and
9.84K Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
Rahul G. Patel reported a sale of 2,276 shares of Synaptics Incorporated (SYNA -0.32%) in an SEC Form 4 filing.
Transaction summaryMetricValueTransaction value$213,557Shares sold2,276Post-transaction shares (directly held)186,515Post-transaction value$17.8 millionTransaction value based on SEC Form 4 weighted average sale price ($93.83); post-transaction value based on Sept. 21 market close ($95.36).
Company OverviewMetricValueShare Price (as of Sept. 21 market close)$95.36Market Capitalization$3.6 billionRevenue (TTM)$1.2 billionNet Loss (TTM)-$490.8 millionCompany SnapshotSynaptics, established in 1986 and headquartered in San Jose, California, is a global semiconductor solutions provider with approximately 1,700 employees.
Synaptics develops and markets semiconductor product solutions, including AudioSmart for advanced sound and voice processing, ConnectSmart for high-speed multimedia connectivity, and DisplayLink for compressed video transmission, generating revenue across audio, video, and connectivity solutions.The company operates a fabless semiconductor business model, designing specialized chips for human-machine interface and multimedia connectivity applications.Synaptics serves original equipment manufacturers and system integrators in consumer electronics, computing, and mobile device markets, with primary customers including major PC, smartphone, and IoT device manufacturers.What this transaction means for investorsInvestors tend to get their haunches up when they see a key insider, like the CEO, dispose of shares. In this case, Patel was one of several insiders to sell shares at the same time. Aside from CEO Patel, VP/Controller Esther Song, and SVP/Chief Legal Officer Lisa Bodensteiner also sold stock.
However, investors shouldn’t read anything into the transactions. That’s because they sold shares under 10b5-1 plans. These trading plans are set up ahead of time between insiders (e.g., directors and officers) with access to key information. They set terms like the timing and number of shares.
Designed to avoid the appearance of insider trading on material, nonpublic information, which means investors can’t glean any information from these transactions.
Shareholders have been rewarded for owning Synaptics’ stock. This year, the stock gained 58.3% through Oct. 16. That easily beat the tech-heavy Nasdaq Composite’s total return of 13%.
Source: SEC Form 4 filing for SYNA | Filed: Sept. 21
Lawrence Rothman, CFA has no position in any of the stocks mentioned. The Motley Fool recommends Synaptics. The Motley Fool has a disclosure policy.
Největším rizikem pro AMD je ocenění: ukazatele P/E 139 a forward P/E 72 výrazně převyšují úrovně konkurence, přestože datová centra tvořila v posledním čtvrtletí 58 % tržeb.
Advanced Micro Devices (AMD -5.96%) has sold off in recent trading sessions. Amid an artificial intelligence (AI) chip shortage, it has thrived, as the leading AI chip company, Nvidia (NVDA -1.43%), is unable to meet all of the demand.
Admittedly, if the AI industry slowed and Nvidia could serve all interested customers, investors might have less reason to buy from AMD. But in that case, one overlooked factor could have the most effect on investors.
Image source: The Motley Fool.
The supreme threat to AMD stock Right now, the most pressing risk to AMD shareholders is the stock's valuation.
Currently, its price-to-earnings (P/E) ratio stands at 139. That is several times higher than the earnings multiples of Nvidia, Broadcom, and Taiwan Semiconductor. Additionally, AMD's forward P/E ratio of 72 appears to confirm the overvaluation.
CompanyP/E RatioAMD141Nvidia27Broadcom43Taiwan Semiconductor27 Data source: YCharts.
Worse, that valuation is probably based on its future as an AI chip producer. Indeed, if more customers turn back to Nvidia, investor interest in AMD stock could plummet. Moreover, if AMD's P/E ratio falls to Nvidia's current level, the stock could lose close to 80% of its value, a factor that may cause some investors to rethink their positions.
AMD Advanced Micro Devices$528.75-$33.48 (-5.96%)
NASDAQ · As of 4:00 PM ET 10/16/26
AMD the stock vs. AMD the company The silver lining here is that the valuation is more of a threat to the stock than to the company.
For one thing, AMD's data center business, which designs AI chips, accounted for 58% of the company's revenue in the latest quarter. While that is a lot, investors should remember that the company also operates gaming, client, and embedded segments, providing some diversification. In comparison, the data center segment made up almost 93% of Nvidia's revenue, making it close to an all-in play on AI chips.
Secondly, even in a downturn, it would likely be a mistake to write off AMD's AI chips. For one, many customers have built systems around them, which will likely make them reluctant to switch away from AMD. Also, agentic AI, a technology that can operate with minimal supervision, could propel the chipmaker to new heights under the right circumstances.
Additionally, AMD's AI accelerators have typically sold at lower prices than Nvidia's. This probably means that even in a plausible worst-case scenario, it will likely maintain a following among more budget-conscious customers.
Moving forward with AMD stock In the end, AMD investors should worry more about the chip stock's valuation than about the future of its AI chip business.
The stock's high valuation and a desire for diversification motivated me to reduce my AMD holdings. However, I am also a long-term investor and chose to maintain a substantial position in AMD stock. Despite my concerns about valuation and the possibility of an AI bust, I believe the need for chips will likely increase in the long term.
The company has established itself as a major player in the industries in which it operates. Over time, I expect its growth to catch up to its valuation.
Výnos dluhopisů CoreWeave se splatností v roce 2032 dosáhl 15 %, což signalizuje rostoucí riziko platební neschopnosti a může zatížit růst i finanční situaci společnosti Nvidia.
Even if you don't hold any bonds in your portfolio, paying attention to the market can offer some very valuable insights about your stock portfolio. Some investors may have found that out the hard way recently.
CoreWeave (CRWV -11.91%), the leading neocloud company backed by Nvidia (NVDA -1.43%), saw its stock pummeled after venture capitalist Chamath Palihapitiya shared a chart on social media showing its recently issued bonds set to expire in 2032 touched a 15% yield. CoreWeave issued the bonds with a 9.625% coupon in June. Reuters later reported that the 9.75% notes CoreWeave issued in April due in 2031 topped a yield of 16%.
The rising yields on CoreWeave's debt indicate the market believes CoreWeave's risk of default is increasing. Doubts are starting to creep in about whether the neocloud company can generate returns on its invested capital that exceed the cost of capital, especially amid a rising interest rate environment. Other neocloud companies such as Nebius (NBIS -12.18%) face similar pressures.
That's bad news for Nvidia and its investors.
Image source: Nvidia.
Nvidia's future is tied to CoreWeave and the neoclouds Nvidia's biggest customers may be the big investment-grade tech companies building out robust platforms and their own AI stacks, but the neoclouds present one of its biggest sources of growth going forward. Nvidia made efforts to ensure that when it made strategic investments in CoreWeave and Nebius earlier this year. The chipmaker invested $2 billion in each of the neoclouds. As such, any decline in their stock prices has an immediate impact on Nvidia's balance sheet.
Nvidia also signed an agreement with CoreWeave last year to buy any unused capacity from CoreWeave through 2032. While Nvidia CEO Jensen Huang says he doesn't think the company will have to step in, it's still a liability that hangs over the company. CoreWeave cites its $104 billion backlog of contracted revenue as a defense against the need for a backstop. Management says that's more than enough to cover its debt obligations.
CRWV CoreWeave$61.39-$8.30 (-11.91%)
NASDAQ · As of 4:00 PM ET 10/16/26
Most importantly for Nvidia, the neocloud companies are dedicated to building with Nvidia. Nvidia's strategic investments and willingness to help finance purchases are key reasons. But if the rising cost of capital catches up with the neoclouds before they can deliver returns, a key driver of Nvidia's sales growth could become a massive drag.
While the hyperscalers have much deeper pockets, they're all looking to add more of their own custom-designed AI accelerators, or XPUs, to their data centers instead of Nvidia GPUs. Amazon CEO Andy Jassy has said that using its Trainium chips saves it tens of billions in capital expenditures every year. Alphabet's Google Cloud CEO noted that the payback period for its custom TPUs is less than half that of its average server. Microsoft recently indicated plans to expand the use of its Maia chips for inference starting next year. In short, Nvidia can't rely on its largest customers to drive sales growth, even as they spend more on building AI data centers.
What it means for Nvidia investors Nvidia is unlikely to let CoreWeave or its other neocloud partners fail. But any signs of failure for the businesses will put pressure on its finances and growth.
Nvidia could end up lending CoreWeave more money through its financing arm. However, Nvidia's plans to finance up to $500 billion in AI build-outs have faced objections from its banking partners over the residual value of its GPUs. The chips Nvidia sells to its partners are used as collateral for the debt, so if they retain less value than Nvidia claims, Nvidia will have to cover more of the default risk itself.
NVDA Nvidia$214.13-$3.10 (-1.43%)
NASDAQ · As of 4:00 PM ET 10/16/26
The chipmaker is reportedly in talks with insurance companies about offloading some of the liability. Either way, it's a drag on Nvidia's finances in order to keep growing its sales. What's more, the bond market is saying those loans may be riskier than Nvidia originally thought.
That risk will fall to Nvidia by extension. The good news for investors is that the market already appears to be pricing in the risk of such financial pressure. Investors currently pay just 23 times forward earnings expectations for the stock, which is a low price for a company that just grew its bottom line by 126% year over year. The bond market just showed exactly why investors probably shouldn't be willing to pay more than that, though.
Adam Levy has positions in Alphabet, Amazon, and Microsoft. The Motley Fool has positions in and recommends Alphabet, Amazon, Microsoft, and Nvidia. The Motley Fool has a disclosure policy.
Nvidia (NVDA -1.43%) has made investors significantly richer over the past four years, turning a $10,000 investment into nearly $179,000 as of this writing.
This massive surge in Nvidia's shares has been fueled by the advent of artificial intelligence (AI). When OpenAI's ChatGPT, introduced publicly in November 2022, became a big hit, companies lined up to buy Nvidia's graphics processing units (GPUs) after it emerged that the semiconductor giant's chips played an instrumental role in training the chatbot.
The AI economy and Nvidia have come a long way since then. AI is now finding its way into several industries, boosting productivity and economic growth. The good news for Nvidia investors is that AI adoption isn't showing any signs of slowing, which explains why the company continues to deliver robust growth even after becoming significantly larger over the past four years.
We will take a closer look at the company's prospects in this article and assess whether investing $10,000 in Nvidia stock over the next five years could be a profitable move.
Image source: Nvidia.
Nvidia is the world's largest company, but it can become even biggerNvidia's AI-driven surge has made it the world's largest company with a market cap of $5.2 trillion. So, expecting another 20x jump in Nvidia's stock price over the next five years would be quite absurd, as it would put its market cap past $100 trillion. However, that doesn't mean Nvidia stock can't climb higher over the next five years.
NVDA Nvidia$214.13-$3.10 (-1.43%)
NASDAQ · As of 4:00 PM ET 10/16/26
After all, the company is still growing at an impressive pace despite the scale it has achieved. Nvidia's revenue in the first six months of fiscal 2027 (which will end in January 2027) increased by 96% over the same period last year to $177.8 billion. The company expects fiscal Q3 revenue of $108 billion, an 89% jump from the year-ago period.
Analysts expect a 91% spike in Nvidia's revenue for fiscal 2027 to $411.6 billion. Meanwhile, earnings per share are expected to almost double in fiscal 2027 to $9.31. Importantly, Nvidia CEO Jensen Huang is confident that the company's growth will continue unabated next year. He recently noted at a conference that the number of chips the company sells will double in 2027, according to CNBC.
Huang added that continued investments in AI infrastructure will drive this incredible growth, as companies and governments look to make the most of the technology's benefits. For example, the World Economic Forum noted earlier this year that AI could increase labor productivity by 1.5% to 3% over the next decade, citing the chief economist of consulting giant EY.
Moreover, investors will do well to note that AI is moving beyond data centers into real-world applications, such as robots and cars. Known as physical AI, Nvidia is pushing into this niche where machines can make complex decisions on their own. From performing precision-related tasks such as threading needles in surgical wards to operating on a conveyor belt, Nvidia is moving into a new frontier that could supercharge its long-term growth.
Nvidia's physical AI offerings are already being used by the likes of Amazon and Japan's national AI venture, and I won't be surprised to see the tech giant pulling in more customers. That's because the physical AI market's revenue is expected to grow to 430 billion euros by 2030, suggesting this niche could move the needle significantly for Nvidia over the next five years.
Throw in the $3 trillion to $4 trillion revenue opportunity that Nvidia sees in the AI infrastructure market in 2030, and it is easy to see why analysts have become extremely bullish about its growth prospects through fiscal 2029 (which will end in January 2029).
NVDA Revenue Estimates for Current Fiscal Year data by YCharts
According to the above chart, Nvidia's revenue could increase by 68% in fiscal 2028, which is almost in line with the company's guidance of 70% growth. That's expected to be followed by a 30% increase in fiscal 2029 to $900 billion. There is a solid chance Nvidia will maintain strong growth in fiscal years 2030 and 2031 as well, which could set the stock up for further gains.
The stock can still deliver impressive gainsLet's assume Nvidia's top line increases by even 10% in fiscal 2030 and 2031 (which will end in January 2031), its top line could reach $1.09 trillion in 2030 (given that fiscal 2031 will coincide with the majority of calendar 2030).
Now, this AI stock trades at 18 times sales. Assuming Nvidia trades at half of this sales multiple after five years, its market cap could jump to $9.8 trillion (based on the $1.09 trillion revenue estimate). That implies a potential upside of 88% from current levels. So, a $10,000 investment in this semiconductor stock will be worth more than $18,800 by 2030.
However, that could be a conservative estimate, as Nvidia could grow faster and command a premium valuation after five years. That's why investors can still consider buying this AI bellwether, as it has the potential to make investors richer owing to emerging niches within the AI ecosystem.
SummaryPalantir Technologies is rated Strong Buy due to accelerating revenue growth, expanding margins, and a durable AI-as-a-service moat.PLTR's model should benefit when AI infrastructure costs fall; its margins are already widening while peers’ compress, backed by deep government and commercial client entrenchment.Quarterly revenue grew 93% YoY, U.S. commercial revenue surged 149%, and adjusted operating margin expanded to 62%, outperforming software peers.Despite high multiples (115x earnings, 53x sales), PLTR's premium is justified by compounding growth, proven execution, and significant forward contract value.JasonDoiy/iStock Unreleased via Getty Images
Palantir Technologies Inc. (PLTR) has had one of the strangest years in the market. Its revenue grew 93% last quarter, its earnings more than doubled, and management raised its full-year guidance for the third time. The stock has gone
88 Followers
Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
On its third quarter of 2026 earnings call, held on Oct. 15, 2026, Interactive Brokers (IBKR -3.88%) announced record pre-tax profit and an annual dividend increase to $0.60 per share. The automated brokerage platform generated a 78% pre-tax margin while customer accounts grew over 30% worldwide. That operating leverage lets the business convert rising trading activity directly into shareholder cash. Three key takeaways from management highlight how the business continues to compound.
1. Record Profit Margin Powers Higher Dividend PayoutsInteractive Brokers converted revenue growth into expanding earnings, keeping its pre-tax margin, the share of revenue remaining before taxes, above 70% for eight consecutive quarters. Management used that extra cash to raise its annual dividend from $0.35 to $0.60 per share.
Pretax profit was a record, and our 78% pre-tax margin marked the eighth consecutive quarter with margins above 70%.
-- Milan Galik, President and CEO2. Artificial Intelligence Tools Accelerate Platform Automation and TradingManagement expanded its artificial intelligence tools by rolling out autonomous trading features. The updates let clients connect software through the model context protocol, a technical standard for software tools, to run automated trading strategies.
Our AI connector remains one of the fastest-adopted features we have ever introduced.
-- Milan Galik, President and CEO3. Wealth Management Offerings Target Displaced Financial AdvisorsInteractive Brokers is expanding its service for registered investment advisors, professional financial managers who direct client funds, by introducing tax-aware trading strategies. It's positioning its automated margin and lending infrastructure to win independent advisors seeking a new custodian.
Tax-aware accounts that use margin, short selling, and securities lending are a good fit for us.
-- Milan Galik, President and CEOLooking AheadCustomer accounts and total assets continue to expand across global markets, and management isn't hiding its satisfaction with the underlying momentum. The company holds structural advantages through its single global platform, low-cost margin lending infrastructure, and automated clearing capabilities. Management is watching regulatory expansion in local markets alongside client adoption of automated trading tools.
In conclusion, this was another financially strong quarter, reflecting our continued ability to grow our customer base and deliver on our core value proposition to customers, while simultaneously scaling the business.
-- Paul Jonathan Brody, CFOBy scaling software automation across account onboarding and customer service, Interactive Brokers expands its cost advantage as trading volumes grow. The firm's continuous platform upgrades position it to capture market share from traditional wealth custodians.
Our business strategy continues to be effective automating as much of the brokerage business as possible, continuously improving while expanding through new product introductions what we offer while minimizing what we charge.
-- Paul Jonathan Brody, CFOThe Motley Fool has positions in and recommends Interactive Brokers Group. The Motley Fool recommends the following options: long January 2027 $43.75 calls on Interactive Brokers Group and short January 2027 $46.25 calls on Interactive Brokers Group. The Motley Fool has a disclosure policy.
Rosen Law Firm podala hromadnou žalobu proti společnosti The Ensign Group (ENSG), kterou obviňuje z klamání investorů a zatajování zanedbávání péče o pacienty i podvodů v programech Medicaid a Medicare.
New York, New York--(Newsfile Corp. - October 18, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of securities of The Ensign Group, Inc. (NASDAQ: ENSG) between February 10, 2022 and June 18, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 7, 2026 in the securities class action first filed by the Firm.
SO WHAT: If you purchased Ensign securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Ensign class action, go to https://rosenlegal.com/cases/the-ensign-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 7, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered billions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.
DETAILS OF THE CASE: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Ensign's business model depends on the systematic and widespread neglect of elderly people who live in its facilities, including those with needs for high levels of care; (2) Ensign's abuse and neglect includes not giving residents enough food, medical attention, or even basic toiletries as well as failing to respond to residents in clear distress, which has resulted in resident deaths; (3) Ensign uses self-reporting measures as a way to cover up that it systematically neglects patients; (4) Ensign defrauds Medicaid and Medicare by taking federal funds to help patients who need high levels of care, and then neglecting those same patients; (5) Ensign falsifies the number of hours that Certified Nursing Assistants spend with residents; (6) Ensign engages in an illegal scheme to rent the licenses of Administrators who are not generally present at, nor actually managing, its facilities; (7) Ensign materially understated the reputational and litigation exposure that comes with a dangerous, abhorrent, and illegal business model; and (8) as a result, defendants' statements about Ensign's business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
To join the Ensign class action, go to https://rosenlegal.com/cases/the-ensign-group-inc/join or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.
No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.
Attorney Advertising. Prior results do not guarantee a similar outcome.
-------------------------------
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/319514
Source: The Rosen Law Firm PA
Ready to Announce with Confidence?
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
